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ABSTRACT
Albumins Redhill, Warwick-1 and Carlisle are
monomeric slow albumin variants discovered in sera
obtained from patients in unrelated families resident
in the U.K.
Albumin Redhill had previously been studied in this
laboratory and was here purified by fast protein liquid
chromatrography (FPLC) and was subsequently submitted for
amino acid sequencing by the solid-phase Edman process.
It was found that Albumin Redhill has an extra N-terminal
arginine residue, and this places it into a new class
of albumin variants.
The binding of nickel and copper was studied in
greater depth than previously, and the binding of these
metal ions at the primary N-terminal site confirmed these
as being significantly inhibited due to the inclusion of
the extra basic amino acid residue. The binding of warfarin
to Albumin Redhill is reduced compared to normal albumin.
Albumin Carlisle, a heat-stable variant, was found
in three members of a family of English origin from
Carlisle. The binding of a range of dyes and the
electrophoretic mobility on a series of media were assessed.
The variant Albumin Carlisle was purified to homogeneity
by FPLC chromatofocusing and was shown to be antigenically
indistinguishable from albumin A, although it does have
a more basic isoelectric point (5.74 compared to 5.63 for
normal albumin). The evidence from both electrophoretic
and chromatographic procedures are consistent with an
acid + neutral amino acid mutation, and studies of the
CNBr fragments of the variant suggest that the site of
mutation is in the region 329-548 residues.
Reverse-phase HPLC has been used to pinpoint a
difference in the profile of the tryptic digest of the
variant albumin from the normal, and it may be that this
technique could be utilised to obtain molecular data on
the mutation.
The ligand binding properties of metal ions,
bilirubin, palmitate and warfarin were assessed and it
was shown that Albumin Carlisle has increased warfarin
binding but decreased bilirubin affinity, although
the binding of metal ions and palmitate was unaffected.
(1)
( 2)
( 3)
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CHAPTER ONE
INTRODUCTION
1.1 HUMAN SERUM ALBUMIN
1.1.1 Occurrence
Serum albumin has been one of the most
studied proteins; it is ubiquitous in mammals and
birds and is found in several classes of reptiles.
Albumin (derived from albus, the Latin for white,
i.e., egg-white) was first used to describe the
soluble fraction of slightly acidified serum, more
rigorous definitions having successively been devised
as the physical properties that characterise the
protein have been elucidated. One of the best
definitions was proposed by Peters (1970) who
suggested the following five criteria:
(a) high solubility - even in half saturated
2 M ammonium sulphate, 23°C, pH 6.0;
high net negative charge, -19 at neutral pH,
albumin is the most anodic of the major
proteins of serum;
a molecular weight = 66,000 daltons;
lacking any carbohydrate substituents, by
customary tests (recently normal albumin has
been shown to be at least 10% glycosylated
(Shaklai, 1984».
(b)
(c)
(d)
(e) the major protein component of serum.
The most unambiguous definition of albumin
.is its amino acid sequence which has subsequently been
discovered.
Albumin comprises more than 50% of the total
protein content of serum (usually = 43 giL); its
ability to bind reversibly many different ligands
makes it unique in both biological and medical uses.
Albumin provides 70% of the colloidal osmotic pressure
of the blood, it is important for the maintenance of
circulation and its high affinity for long chain fatty
acids makes it an ideal transporter of fatty acids in
the blood, increasing their effective solubility by
several orders of magnitude as it carries them from
their site of absorption in the intestine to the liver.
Albumin also binds bilirubin very strongly and
removes this potentially toxic metabolite from the blood,
so protecting the newborn from kernicterus and the
possibility of brain damage, due to the accumulation
of bilirubin in its tissues. Albumin acts as an
overflow carrier of steroid and thyroid hormones,
binds divalent heavy metal ions, and is of great
interest to pharmacologists due to its wide range of
hydrophobic drug and dye binding, playing an
important role in the pharmacodynamics of drug
treatment. Albumin can act as a nutritional reserve,
its catabolism providing amino acids for the peripheral
tissues; albumin concentration has been used as a
3marker for malnutrition and cellular damage, as it
drops markedly after surgery or fasting. Albumin has
been used as a diagnostic marker of vascular and
renal integrity and its rate of synthesis as a measure
of liver function. Albumin has been used as a standard
protein in many assays and biochemical measurements and is
also used by immunologists as a model antigen. It has
often been used to protect valuable macromolecules from
possible degradation and is added to many immobilisation
reactions to block excess reactive sites.
In the light of its many uses, and its great
abundance in serum, it is surprising to discover that
the amino acid sequences of the serum albumins were
only determined comparatively recently.
1.1.2 Primary Structure
Human serum albumin (RSA) is a protein of
65,000 molecular weight, with a total of 17 disulphide
bridges and 35 cysteine residues in total. The length
of the albumin peptide chain (585 amino acids in a
continuous single polypeptide) has long discouraged
efforts to elucidate its complete sequence. The N-
and C-terminal amino acids were discovered in 1960
(Ikenaka, 1960) and some proteolytic studies were
made using trypsin, chymotrypsin, cathepsin or
pepsin. However, the tryptic digest alone should give
rise to 82 pept1des and the sequencing and alignment
of such a number of fragments was not achieved until
the more modern protein sequencing techniques of the
1970's were available. Some peptides were sequenced
earlier, such as that around the free SH group
(Witter and Tuppy, 1960) and the N-terminal peptic
fragment (Bradshaw and Peters, 1969).
In the early 1970's several groups worked
independently on the sequencing of human albumin,
using gram quantities of protein and different
methodologies. Brown, et a~., published the first
full sequence of human serum albumin in 1975 (Behrens, et a~.,
1975), having purified both chymotry.ptic and tryptic
fragments,and by comparison of the results obtained
a complete sequence which agreed with existing data
(see Fig. 1.1)",'
At the same time Meloun, et a~. (1975)
published a complete amino acid sequence; however,
their approach had been different in that they had
first cleaved albumin with cyanogen bromide and
then proteolytically digested the resultant large
fragments. The two sequences were in 93% general
agreement.
In 1982 the mRNA derived cDNA clone was
sequenced by Ougaiczyk, et aZ. (1982) using in vit~o
methods to express the liver mRNA (Fig. 1.2). As
well as encodin9~the·~aequence of albumin itself,
the 2078 nucleotidemRNA included additional bases which
.'
confirmed the presence of an amino acid propeptide
and a further 18 amino acid prepropeptide whose
Fig. 1.1 The complete amino acid sequence of human
serum albumin showing disulphide bridges
and domain structure (from Dugaiczyk, et aZ. ,
1982).
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Fig. 1.2 The complete nucleotide sequence of human
serum albumin rnRNA as determined from cloned
eDNA, showing the presence of the pro- and
prepro-peptides (from Dugaiczyk, et aZ., 1982).
7existence had already been suggested by previous
workers (see Section 1.1.6).
1.1.3 Secondary Structure
Once the amino acid sequence was known,
predictions of the secondary structure were soon
made. Both teams responsible for sequencing HSA
noticed the regular occurrence of adjacent cys-cys
residues~ these form the basis of the postulated
repeating loop structure (see Fig. 1.3). The nine
loops held together by these disulphide bridges give
rise to three domains, each with characteristic binding
properties. There is some 50-55% a helix by circular
dichroic measurements and 15-18% a sheet (Peters,
1975) which are in good agreement with the values of
46% a helix and 16% a sheet predicted from the
structure of bovine serum albumin (BSA). From
predictions based on the methods of Chou and Fasman
(1978) the long loops appear to be helical with some
a sheet in loops one, three, six and seven. In the
shorter tight loops the a helical content is less,
due to the steric restrictions imposed by the
disulphide bridges. Eight of the tips of the loops
have e turns, seven with cystine residues and one with
the free thiol of cys-34.
Brown (1977) has proposed a structure with
six uniform helical regions; each consisting of a
long and a short loop. The final structure (see Fig. 1.4)
can be viewed as consisting of three domains of the
repeated unit (large loop)-(small loop)-(connecting
segment)-(large loop) which can be broken down into
three sub-domains. This structure with its strong
disulphide bridges, explains the stability of albumin
to denaturing conditions such as acid, base, heat
and 6 M urea. Each segment is held in close proximity
by the S-S bridges and so secondary structure readily
forms. Even after fragmentation serum albumin retains
helical structure in those fragments which contain
disulphide bonds. However, the stability of the
conformation is not due entirely to disulphide
bridges as after complete reduction of these bonds
the fragments and even the whole protein will slowly
refold to restore its antigenic, circular dichroic
and fatty acid binding properties.
1.1.4 Tertiary Structure
Albumin has been shown to exist in four
interchangeable conformations, dependent upon pH.
aFoster (1960) showed the existence of A norma1 (N)form at
atpH 5-7 and .8' fast migrating form~,(F), pH 3-4, which
appears to be due to expansion of the molecule and
results in increased anodic mobility on electrophoresis.
Below pH 3 a further conformational change occurs,
resulting in the expanded form, exposing many of the
hydrophobic residues to the solvent. Above pH 7
several other conformations exist; a slow transitiQn
I.}
to the A form occurs above pH 8, resulting in a slower
migration on electrophoresis (pI = 5.45 cf. 5.2 for
normal form). This transformation appears to involve
the rearrangement of some disulphide bonds, since
it is suppressed by alkylating agents, yet accelerated
by thiol compounds. Wallevik (1976) has shown that the
A form is broken down more rapidly in vivo than the
normal. Transformation to the A form becomes
irreversible around pH 10. Between pH 7 and 8 a
second slow form can exist especially in the presence
of calcium ions. This B form also appears to involve
the free thiol group and a slight loss of helical
content has been noted (Zurawski and Foster (1974)
(Fig. 1.5)•)
Fig. 1. 3 Distribution of secondary structure in BSA
(Peters and Reed, 1917).
Key: ~ a-helix
·IDaI B-pleated sheet
::.'.:.-.B-turns
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Fig. 1.4 structural organisation of HSA showingsubdomain and loop structures (from
Brown, et al., 1979).
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Fig. 1.5 The conformations of serum albumins at
differing pH values.
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The free thiol group of albumin, cysteine-34,
has aroused much interest in that in vivo it appears to
be partially blocked by thiol-containing ligands such
as glutathione or cysteine. The mercapto and non-mercapt-
albumins have been extensively studied and there appears
to be ~ 0.6 mole free thiol group/mole albumin, although
this can be restored to one mole by addition of
reducing agents. Albumin has been proposed to exist
to some degree as a dimer in serum,and partial blocking
of the thiol residue aids the peptic digestion of the
protein.
The three dimensional structure of albumin
is thought to be an ellipsoid molecule approximately
141 x 42 R (Wright and Thompson, 1975). Other studies
suggest that there are three globular subunits of
diameters 38, 53 and 38 R (Bloomfield, 1966) and this
gains some support from 1,amino-8-naphthalene sulphonic
acid (ANS) binding studies (Fig. 1.6). The N-terminus
appears to be more compact than the C-terminus and
undergoes a lesser degree of unfolding during N + F
transformations, indeed when isolated the N-terminal
fragment 1-385 of BSA does not undergo the N + F
transition (Kahn and Salahuddin, 1984). Sakata and
Atassi (1980) have demonstrated five antigenic sites
on human albumin.
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Fig. 1.6 Three dimensional models of serum albumin
(Peters, 1970).
(a) Four domain model of peters,
(b) Three sphere model (Bloomfield, 1966),
(c) Ellipsoid structure (Squire, et al., 1968).
1.1.5 Domain Homology
The three domains are not only similar
in conformation but have regions of homologous sequence.
The cysteine residues appear invariant in all
mammalian albumins and this indicates that they all
share a similar domain type structure. There is
internal homology between all three domains; 48
residues are identical in domains one and two
(25% identity), the longest continuous homologous
sequence being four amino acids. Domains two and
three have 41 positions the same (21% identity) and
one and three have 35 positions (18% identity),
demonstrating that domains one and two are more
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similar to each other than either is to domain three
(Brown, 1976). This similarity has led Brown to
propose that albumin originated as a single domain
(residues 504-81) which underwent gene duplication
and subsequent deletion several times to arrive at
et atthe present structure (Br~wn, 1979). The degree of
domain homology is similar to that seen between
myoglobin and haemoglobin or the immunoglobin light
and heavy chains. Human and bovine albumins have
20-23% difference in amino acid sequence. Brown
maintains that the proposed 'primordial domain'
residues 504-581, has some homology with sperm whale
myoglobin in sequence and structure; however,McLachlan
and ~ialker (1977)I although confirming the intramolecular
homology did not find homology between HSA and myoglobin,
as although some regions did show good matches they
were all typical surface helices, with one side exposed
to the aqueous environment and the other buried in
the protein.
1.1.6 Albumin Synthesis and Degradation
Serum albumin is synthesised in the liver,
where it can comprise up to 50% of the total protein
produced by that organ. The complex balance of
synthesis and degradation has been reviewed by
Rothschild and Oratz (1977). DNA directed mRNA
synthesis in the hepatocyte nuclei is followed by
cytoplasmic translation of the mRNA attached to the
14-
ribosomes of the endoplasmic reticulum. Synthesis
commences on the 40S ribosome subunit attached to
the mRNA and the peptide chain is inserted through
the 60S subunit into the endoplasmic reticulum,
extending as each amino acyl tRNA donates its amino
acid in the order specified in the mRNA, one mRNA
accommodating as many as 20 ribosomes. Albumin
passes through the endoplasmic reticulum to the Golgi apparatus ana
from there in vesicles to the cell membrane for
secretion. Using labelled amino acids it has been shown that
from theirincorporation to location in the endoplasmic
reticulum requires 3-6 minutes and the label reaches
the Golgi apparatus in 15-20 minutes.
Urban, et aZ. (1974) showed the presence of
a propeptide at the N-terminus of albumin isolated
from hepatocyte microsomes and the sequence of this
hexapeptide (Russell and GeUer, 1975) is given in
Fig. 1.7. This was confirmed by Quinn, et aZ. (1975)
who showed that the propeptide could be excised
in vitro using trypsin to give normal albumin.
Edwards, et aZ. (1976) traced the course of the
proalbumin and showed that it was the predominant
form in the endoplasmic reticulum, but that it
constituted only 45% of the albumin in the Golgi
and that in the secretory vesicles the serum form
only was observed. Strauss, et aZ. (1977) expressed
rat liver mRNA in vitro to show the presence of the
additional 18 amino acid 'prepropeptide, and obtained
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part of its sequence which consisted of at least
38% hydrophobic residues and was similar in length,
half-life, intracellular localisation and possibly
function to sequences in parathyroid hormone and
proinsulin. Subsequently, Dugaiczyk (1982) demonstrated
that the human propeptide was also similar with a high
percentage of hydrophobic residues.
The probable function of the prepropeptide is
to enable the protein to enter the endoplasmic
reticulum on synthesis, the hydrophobic section acting
as a signal peptide passing through the non-polar membrane.
The signal sequence is excised and it is thought that the
propeptide acts in an analogous manner directing the
albumin through the endoplasmic reticulum and to the
Golgi for incorporation into secretory vesicles. It is at
this stage that it too is proteolytically cleaved,
leaving the serum form of albumin to be exported from
the cell.
Albumin has been found in the liver at as
little as 32 days gestation; howeve~ it would seem that
in the foetus a-foetoprotein performs the major role
in ligand transport (Herve, et aZ., 1984). Albumin
synthesis rises soon after birth and continues to
increase,attaining a plateau value in adulthood of
around 130-200 mg/kqlday. The level of albumin is
slightly higher in men than women, = 40 ± 5 gIL.
I
Between thirty and forty percent of the exchangeable
.albumin pool occurs in the plasma, the rest being
16
Rat Preproalbumin
~ prepropeptide ------- .....
NH2-met-lys-trp-val-thr-phe-leu-leu-leu-leu-
phe~e-ser-gly-ser-ala-phe-ser-
E propeptide >
arg-gly-val-phe-arg-arg-
albumin
glu-ala
Possible Rat Proalbumin Varia~ (Urban, et aL., 1974)
~ propeptide > albumin
NH2-gly-val-phe-ser-arg-glu-ala
Human Preproalbumin (Dugaiczyk, et aL., 1982)
~ -- -prepropeptide--------------------
NH2-met-lys-trp-val-thr-phe-ile-ser-Ieu-Ieu-phe-leu-
phe-ser-ser-ala-tyr-ser-
< propeptide >
arg-gly-val-phe-arg-arg-
albumin
asp-ala
Fig. 1.7 Pro- and Prepro-peptides from Human and
Rat Serum Albumins
located in the extravascular tissue such as muscle
and skin. The latter contains 30-40% of the extra-
vascular pool although only being 6% of the total
body weight. The two pools are in equilibrium with
around 75% of the albumin exchanging every two days.
Albumin is present in all secretions and excretions
that have been tested and is the major constituent in
oedema.
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Albumin synthesis is stimulated by both
thyroid hormone and cortisone, but the most important
factor for its control is the nutritional state.
In starvation,albumin synthesis is rapidly decreased
and remains depressed until the deficiency state
is corrected. The level of albumin in the extra-
vascular pool is depleted, and degradative rates also
decrease in order to conserve it.
Albumin breakdown is a randcrnprocess, it is
poorly understood but proceeds at a high rate,presumably
due to pinocytosis and subsequent digestion in the
lysosomes. No single orga~ can be defined as
predominantly responsible for albumin degradation.
Muscle must account for a major part due to its
relative abundance, and though the kidneys and intestine
both degrade albumin in disease states neither play
a si.gnificantrole in healthy patients.
1.2 LIGAND BINDING
Many studies have been carried out into the
ability of albumin to bind a wide range of ligands
both of physiological importance and of pharmacological
interest. Several excellent reviews have been written
(Bro~ and Shockley (1982), Vallner (1977), Sellers and
,", ~.~,- .
Koch-Weser(1977) and Kragh Hansen (1981».
Each of the three domains of albumin is
specialised to bind a particular type of ligand.
!8
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Fig. 1.8 Two representations of the ligand binding
sites on HSA.
(a) Brown and Shockley (1982)
(b) Peters and Reed (1977)
A summary of these sites is shown in Fig. 1.8. Each
domain has been split by Brown and Shockley (1982)
into three subdomains; howeve~ other reviews consider
the binding of each ligand type individually, as will
be done here (see Table 1.1).
1.2.1 Metal Ions
The amino terminus of the albumin molecule has
a primary site for the binding of divalent metal ions
such as Cull and NiII, in a 1:1 molar ratio to albumin
(Sarkar, 1981). The binding affinities decline in the
order cu2+ > Ni2+ > zn2+ with Ka values from 9 x 106
to 5.7 x 102 M-I. Other metal ions have been shown
to bind to albumin including Cd2+ and AI3+; howeve~
this may occur at less specific secondary sites. Copper
is an important trace element in mammals and although
caeruloplasmin acts as the primary carrier, the binding
of Cull by albumin does appear to be of physiological
importance. NiII has not been shown to have any
physiological role in man and may well be toxic
(MCNeely, et al., 1972); the high affinity of albumin
for it may well playa role in the removal of toxic
amounts from the body and this is possibly true to a lesser extent
for Cd2+ also. Zinc is bound to HSA and a deficiency
of ZnII results in impairment of growth, and in
skin disorders (acrodermatitis enteropathica).
Glennon and Sarkar (1982) have studied the
divalent metal site using a model tripeptide,
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TABLE 1.1 LIGAND BINDING TO HUMAN SERUM ALBUMIN*
Ligand -1 -1 Temperature °cnl Ka M n2 Ka M
Bilirubin 1 1.4x 108 2 5 x 105 37
Haemin 1 1.1x lOB 24
Palmitate 2 6.0 x 107 5 3.0 x 106 23
Linoleate 2 1.3x 107 5 2.5 x 106 23
Oleate 2 1.1x 108 5 4.0 x 106 23
L-Tryptophan 1 1.6x 104 2
L-Thyroxine 1 1.6x 106 3 6 x 104 24
Progesterone 1 3.6 x 105 B 6 x 103 4
1 4 25Testosterone 2.38 x 10
Estradiol 1 1.0x 105 5
Cortisol 2 5.0 x 103 37
Warfarin 2 8.9 x 104 4 6.7 x 103 27
Salicylate 1 2.2 x 105 5 1.6x 103 37
Phenylbutazone 1 2.3 x 105 4 5.6 x 103 37
Digitoxin 6.9 x 104 20
Clofibrate 2 2.5 x 104 8 4.7 x 102 ca 20+
Sulfaethidole 1 1.Sx 105 3 1.6x 103 25
Diazepam 1 4.9 x 105 22
O-methyl Red 1 5 371.99 x 10
Methyl Orange 2 2.8 x 103 37
Bromocresol
106 4Green 1 1.0x 4 2.1 x 10 37
*Adapted from Kragh Hansen (1981) and Bowmer and Lindup (1980)
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L· asp-L-ala-L-his N-methylamide,corresponding to the
first three amino acids of HSA. They proposed that
the binding geanetryfor copperions was square planar
and involved the a-amino nitrogen group, two deprotonated
peptide nitrogens and the imidazole nitrogen (see
Fig. 1.9). Laussac and Sarkar (1984) have since
given support to this model from n.m.r. studies of
the isolated 1-24 peptide residue of HSA. In their
model they suggest that the carboxylate group of the
aspartate residue stabilises the binding from above
the plane of the ring. The penta-coordinated copper
seems unusual and there may be further stabilisation
from a water molecule beneath to attain the 6-coordinate
state.
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";. ! c-un 1"~)
/lY'1lL._.~l/
I" 'Ala/
Glu AI
Aleu_""'" a-ly" Ph.-
ly.-....,
Ph.X': A"
(
Val Val H;. A,n JV
, "-,,/ 'Glu Cly
Ala '-Clu_.......
leu
~PROTeIN CHAINAAAMAAAAA
, 'f Y , 'f Y Y l' V '-COO·
Fig.l.9 Proposed copper t l l i transport site of human a l burai n ,
Callan and Sunderman (1973) presented data
for the binding of NiII to several mammalian albumins
(summarised in Table 1.2). This emphasises the need
for histidine at the third amino acid residue,as the
affinity for Nill of canine and porcine albumins which
lack histidine at residue three is significantly lower
than those which possess it. This gives further
evidence to Sarkar's model, and dogs and possibly pigs
are more susceptible to nickel and copper poisoning
than the other mammals in the table, as they can only
bind metal ions at the weaker secondary sites.
1.2.2 Bilirubin
Bilirubin, the breakdown product of haem,
is tightly bound by albumin, and thus rendered less
toxic as already mentioned. The location of the
primary binding site has been studied using covalently
attached affinity labels and also from the properties
of fragments from proteolytic digestion. Peptides
1-386, and 49-307 residues, both bind bilirubin
similarly to intact HSA (Geisow and Beaven, 1977b).
Using affinity labelling both lys 220 and lys 240
have been shown to be involved, as is the region desi~nated
subdomain 2AB in Brown's model (Brown and Shockley,
1982); residues 186-306 have been suggested to contain
the primary binding site. Using 3H-bilirubin,
Hutchinson and Mutopo (1979) interpreted the labelling
of the 1-124 CNBr fragment of HSA as being the primary
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binding site, with a secondary site in residues
125-217; however, Gitzelmann - Cumarasamy etal. (1976)
using similar methods had found the label in residues
129-297 and 446-547. This inconsistency may be due
to the labelling of other reactive groups not associated
with bilirubin binding, or of secondary bilirubin
sites only.
The binding of bilirubin to its primary site
may be influenced by fatty acids. The addition of two
molar laurate increases the affinity for bilirub,in and
the binding sites for the first two moles of long
chain fatty acids and bilirubin are distinct (Berde,
et al., 1979). However, the third mole of long chain
fatty acid binds nearer to the bilirubin site and at concentra-
tions of fatty acid > 5 M there is competition at or
near the bilirubin primary site and bilirubin is
et al.displaced. Hsia (1982) have shown the presence of
one high affinity and two lower affinity stereo-
specific binding sites for bilirubin together with
a series of non-stereospecific sites of low affinity.
The primary binding site has a high Ka
value in the region 5.5 x 107 to 1 x 108 M-1 and the
6 -1secondary sites approximately 10 M , indicative of the
importance of bilirubin in the body. Other ligands do
bind at or near the bilirubin site and these include
warfarin, salicylate, bromocresol green, bromophenol
blue and phenol red; these may be responsible for
displacing bilirubin when present in high concentrations.
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1. 2.3
1.2.3.1
Fatty Acid Binding
Introduction
Fatty acids bind to albumin with an
affinity only exceeded by that of bilirubin; albumin is
normally the only plasma protein to bind appreciable
amounts of fatty acid and so plays an important
role in their utilisation by the body_ Fatty acids are
released from the intestine complexed to albumin;
being poorly soluble in aqueous media,binding to
albumin increases their effective solubility and
prevents the dimerisation of the C14-18 chain fatty
acids as only the monomeric anion will bind. Albumin
transports fatty acids to the liver and also from
the liver to peripheral muscles, heart and other
organs enhancing their uptake by reducing the
d~ffusion distance, so increasing their relative con-
centration at cell membranes. Fatty acids can be
grouped into two classes, long chain fatty acids
CI2-18 and short chain CIO and less; albumin appears
to have distinct sites for each class.
1.2.3.2 Short Chain Fatty Acids (SCFA)
There appears to be a primary binding site
for SCFA up to decanoate in the subdomain 3AB, no binding
occurring to any extent elsewhere until this is
saturated (Brown and Shockley, 1982). The site is
linked to residues Trp 214 and Lys 220 and there is
a strong preference for SCFA reflected in the K
a
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values, although this may also be a secondary site for long
chain fatty acids. A secondary site for SCFA
occurs at subdomain 2AB near Trp 214, and Lys 220 is
involved as it is protected from modification by
octanoate. The site is probably identical to the
bilirubin primary binding site and again although long
chain fatty acids will bind there is a preference for
SCFA.
Long Chain Fatty Acids (LCFA)
Long chain fatty acids bind to at least three
sites on albumin. The primary site (Ka ~ 107 M-I) is
1.2.3.3
near loop 7 residues T377-505 (subdomain 3C) and no other
ligands compete at this site. Secondary sites still
6 -1with high affinity (Ka :::10 M ) occur in subdomains
IC and 2Ci although when isolated these fragments do
1
not show palmitate binding this is probably due to a
loss of the structural stability of the sites in
aqueous solution. Spin label studies reveal that palmitate
binds to a tight hydrophobic cleft and that the carboxyl
group is relatively immobile, suggesting an electrostatic
bond to a positively charged residue such as lysine.
Models of the primary fatty acid binding site
have been constructed with six helices positioned so
as to create a hydrophobic pocket in the centre ideal
for the binding of the lipophilic carbon chain of long
chain fatty acids (Brown and Shockley, 1982). It 1s
known that the hydrophobic forces are the major
driving force in binding fatty acids although the
27
electrostatic charge does make a contribution.
The binding of long chain fatty acids requires
a multiple site model with at least six high affinity
sites and three or four weaker ones with as many as
twenty low affinity binding sites also occurring. The
association constants decrease in sequence from
Kal = 91.4 x 107 M-I to KnS = 2.2 x 107 M-I for
palmitate (Spector and Fletcher, 1977). The Scatchard
approximation of binding does not allow for the
creation of new sites or for co-operativity between
sites and so the generalised equation of Spector and
Fletcher (1977) is preferred. The presence of a
first double bond in the hydro-carbon chain increases
binding, but the second double bond reduces it to below
that of the saturated fatty acid, for example C lS:l >
C 1S:0 > C 18:2.
At physiological levels of fatty acid (0.3-
1.2 mM) the binding of two moles of long chain fatty
acid has no effect on other ligand binding; however,
the distribution of fatty acids between albumin
molecules is not homogenous. At a 1:1 molar ratio of
stearate:albumin only 43% of the fatty acid is in
a 1:1 complex, with 43% being bound to albumins at a
2:1 ratio and 12% at a 3:1 stearate:albumin ratio.
T-his trend is similar for other physiological long chain-,
fatty aCids suggesting that the lower affinity sites may
be occupied even at low molar ratios in a percentage
of albumin molecules.
\
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Fatty acids can compete with other ligands
for binding to albumin due to their many secondary
sites. L-tryptophan can be displaced by quite low
levels of oleate (McMenamy, 1965) and this may play
a role in the control of tryptophan and hence over
etat.serotonin levels in the brain tCurzon 1973). Thyroxine
is also significantly displaced byhiqh levels of fatty
acids, although this is not physiologically important
due to its binding primarily to more specific globulins.
The only ligands known to displace fatty acids from
albumin are salicylates in high concentration and
Clofibrate (an anti-cholesterolemic drug), probably acting
via a conformational change (Spector, 1975).
1. 2.4 Other Physiological Ligands
Indole Derivatives1.2.4.1
The primary indole binding site seems to be
located near an active tyrosine residue as it can be
inhibited by the nitration of tyrosine; the site
may be composed of several distinct regions of the
molecule brought into close proximity (Brown and
Shockley, 1982). Geisow and Beaven (1977b)showed
the primary site to be located in residues 307-86
and this is consistent with the findings of Reed,
et at. (1976), but Sjodin, et at. (1977) and Garnbhir
and MCMenamy (1973) have placed the site nearer the
N-terrninus. Gerig and Klinkenborg (1980) found
evidence for two sites by n.m.r. and from the peptic
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fragments of King (1973) it would appear that a primary
site occurs in the 3AB region with secondary binding near
the N-terminus, incorporating his 146.
L-tryptophan is bound with one hundred times
4 -1the affinity of the D form (1.6 x 10 M ) and can be
displaced by fatty acids, the site seeming to be
associated with that for thyroxine and a secondary
salicylate site.
1.2.4.2 Thyroid Hormone
Albumin binds thyroxine only as a secondary
carrier, however it may be of physiological importance
at high levels of the hormone. There is a primary site
6 -1of high affinity (1.6 x 10 M ) and a number of
secondary sites (Steiner, et aL., 1966, Cheng, et aL.,
1981). The primary site is thought to occur in
subdomain 2AB.
1.2.4.3 Steroid Hormones
Steroid hormones are primarily carried by a
specific a-globulin but can also bind to albumin,
which has a higher capacity though of lower affinity.
A primary site has been assigned to the subdomain
2C (residues 307-85) by Pearlman and,Fong (1972).
This site also binds bilirubi~ and Soltys and Hsia
(1978) have shown competition between nine steroids
and bilirubin for this site.
1.2.4.4 Haemin
Haemin, a breakdown product of haemoglobin,
binds to albumin with a high association constant
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and is not displaced even by a 10:1 oleate:HSA level
(Adams and Berman, 1980). The location is not
exactly known but appears to be in the sequence
124-298 residues, although it seems that the c-
terminus of the molecule is required for the total
binding affinity (Hrkal, et al., 1978). The binding
of haemin is presumably instrumental to its
catabolism.
1.2.5
1.2.5.1
Drug Binding
Introduction
Pharmacological interest in albumin is due
mainly to its ability to tightly bind a large range of
drugs. These drugs can be placed into two categories:
those that are negatively charged organic acids or
with electronegative centres,and bind mainly by non-
covalent hydrophobic interactions, and those which
bind irreversibly due to the formation of amide or
similar linkages. Excellent reviews of drug binding
to albumin have been written by Vallner (1977) and
Sellers and Koch-Weser (1977) and more recently, by
Kragh-Hansen (1981). Most drugs form only weak ionic
interactions with albumin and so their hydrophobic
interactions are the driving force for binding,
although electrostatic interactions help to strengthen
the binding.
Albumin acts as a reservoir for unbound drugs,
the free form is usually the only active one.
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However, binding to albumin ensures that the drug is
carried throughout the vascular system and so decreases
the effective dose and concentration and the rate of
elimination (see Fig. 1.10). The distribution of the
drug is dependent upon the degree to which it binds
to albumin and this may vary from one tissue to another.
Many experiments have examined the binding of drugs to
albumin but their results are only valid where near
physiological conditions have applied. Kragh-Hansen
(1981) defines three major binding sites for drugs;
the benzodiazepines which bind to the indole site,
other drugs such as warfarin and Phenylbutazone which
bind to the bilirubin site, and others which appeared
to occupy an independent site. The anti-rheumatoid
pain relievers Ibuprofen and Naproxen seem to bind
to subdomain 3AB as does Clofibrate.
The kidneys remove drugs which bind to albumin
and their metabolites. If the drug is tightly bound
then it~ elimination from the body is a slow process,
the drug-albumin complex will not diffuse through the
glomerulus and only the free drug is eliminated;
however, turnover is quicker in the kidney tubules.
1.2.5.2 Warfarin
Warfarin is used with other coumarin
derivatives as an anticoagulant and it is > 99% bound
to albumin at physiological concentrations. Over
95% of the bound drug is associated with the one or
two primary sites (Ka
5 -1~ 10 M ), the rest is spread
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Fig~ 1.10 The effect of drug-albumin binding on
drug metabolism (Sellers and Koch-
lVeser'1977 )
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over the three or four secondary ones (Ka ~ 5 x 103'M-I)
L-------~tr-------~
(Oester, et a l ; , 1976, Maes, et aL. 1982). Warfarin
is bound primarily as the anion, and binding is dependent
upon fatty acid concentration. Binding of long chain
fatty acids up to a 3:1 molar ratio enhance warfarin
binding by causing conformational changes to the albuminbut at
molar ratios> 3:1 fatty acid:albumin they decrease
warfarin binding, presumably by direct competition
(Sebille, et al., , 1984).
The albumin molecule must be intact for
high affinity warfarin binding, as binding to isolated
subdomains is only one-tenth that of the whole
molecule. The warfarin binding site is primarily
hydrophobic; however, hydrogen binding is important
as the hydroxy form of warfarin is bound poorly.
Feshke, et al. (1979) have shown the warfarin primary
binding site to include Trp 214. Warfarin can be
displaced by Clofibrate, Phenylbutazone and salicylate.
However, differences in the type of binding between
warfarin and salicylate imply that they do not
simply compete for the same site (Oester, et al.,
1976) •
1.2.5.3 Benzodiazepines
The benzodiazepines, widely used tranquilisers
and anti-depressants, bind to albumin with Ka ~ 105-106 M-I
(Sjodin, et al., 1976). Electronegative and halogen
substituents increase the binding and positive groups
inhibit it. Wanwimolruk, et al. (1983) have shown
the binding site to be a hydrophobic cleft 16 R deep
by 8 R wide with a cationic group near the surface.
The site could possibly be identical with the short
chain fatty acid binding site, Sudlow, et al. (1976)
defining benzodiazepine binding requirements as being
a hydrophobic molecule such as an aromatic
carboxylic acid with a negatively charged group
distinct from the hydrophobic region.
1.2.5.4 Salicylate
The binding of salicylate may be to a
separate site as Kragh-Hansen (1981) can fit it into
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none of the five sites he describes. The secondary
site is most likely identical to the high affinity
thyroxine site. Vallner (1977) suggests four primary
sites with Ka = 2 x 105 M-I, and its high degree of
binding may implicate it in influencing the binding of
1.2.5.5
other drugs administered simultaneously.
Acetylsalicyclic Acid (Aspirin)
Hawkins, et aZ. (1968) showed that acetyl-
salicylic acid acetylates albumin, and this was pin-
pOinted by Walker (1976) to the £-amino of lysine 199
(Fig. 1.11).
/
COOH
Cr°" +
Fig. 1.11 The acetylation of albumin by
acetyl-salicylic acid.
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structures of some ligands which bind to albumin:
I)Phenylbutazone, 2} Cephalexin, 3) thyroxine,
4) Ibuprofen,S) Indole, 6) Phenytoin,
7) Tolbutamide, 8) Chloral hydrate, 9) Cephalothin,
10) Diazepam, 11) salicylic Acid, 12) Naproxen,
13) ~arfarin, 14) acetyl-salicylic acid,
15) Clofibrate.
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Fig. 1.12 Continued. 16). Sulphathidole, 17) Cephal-
oridine, 18) Pent:cillin N, 19) Cephalosporin
C.
/
Fig. 1.13 The acetylation of HSAby pen-j.cd Lf.Ln,
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1.2.5.6 Antibiotics
Sulphonamides bind with a fairly high
affinity (Ra = 102-103 M-I) to albumin (Hsu, et al.,
1974) at two or three main sites. Phillips et al. 1973
described a hydrophobic cleft for the primary binding
site of penicillins; he noted that binding was due to a
covalent attachment to a lysine residue which brought
about a conformational change on binding four molar
equivalents of penicillin. Hsu, et al. (1974'
estimated the association constant as K ~ 3 x 103 M-Ia
and showed that halogen, methyl, benzene and methoxy
substituents increased binding but amino groups inhibited
it. Several penicillins have been shown to acetylate
an E-amino lysine residue and this destroys the 8-lactam
ring (Bundgaard,1977) (Fig. 1.13).
Cephalosporins appear to bind at a hydrophobic
site and again a cationic amino acid has been implicated,
3 -1binding constants are ~ 10 M • Bruderlein, et al.
(1981) have shown a similar acylation of a lysine
residue, resulting in loss of the e-lactam ring in a
series of ·antibiotics ..
1.2.5.7 Implications of Drug Binding to HSA
Due to the wide range of ligands binding
to albumin there is inevitably competition. Bilirubin
can be displaced by sulphonamides and so potentiate$
its toxicity especially in the neonate where many
drugs are only poorly bound and so effective drug
concentrations may vary. An important factor
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when considering drug competition is the amount of drug
bound by albumin. A 1% displacement of a drug only 50%
bound has little effect, but if a drug is 99% bound
there is an effective doubling of the free drug
concentration. This can have serious consequences:
warfarin can be displaced by phenylbutazone or
Clofibrate to cause hyperprothrambinemia and spontaneous
haemorrhages due to the raised level of the anti-
coagulant. Bone marrow toxicity may result if metho-
trexate is displaced by salicylates and sulphonamides.
The volume in which the drug is contained is an im:x>rtantfactorin
therise in effective drug concentration: the level of
albumin synthesis is also important - in hypoalbuminemia
(low albumin concentration) the percentage free drug
is increased and so in liver disease or kidney failure
the albumin binding of drugs is reduced and thus the
effective free drug concentration is increased to
possibly toxic levels. For example, the effective level
of Phenytoin (an anti-convulsant) can rise by 30% in viral
hepatitis. Drug treatment in hypoalbuminemia and
combinations of drugs in therapy should be dictated by
the free drug concentrations in the individual patients.
1.2.6 Dye Binding
Peters (1970) describes dye binding to
albumin as being weaker than for fatty acids or
bilirubin, with a number of sites which vary for
different dyes. Possibly the most studied class of
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dyes binding to albumin are the sulphophthaleins with
Ka ~ 106 M-I, such as phenolsulphonephthalein (phenol
red), bromophenol blue, and bromosulphophthalein.
Other dyes which are tightly bound include Evans Blue,
Trypan Blue, Congo Red, and azobenzoates such as
methyl red. Dye binding causes a configurational
change in albumin, protecting it from denaturation
and proteolysis. l-Anilino-naphthalene-8-sulphonic
acid (ANS) also binds to albumin in a funnel shaped
primary site in subdomain Ie and at four other sites on
the inner aspects of the three domains of albumin, and
this dye has been used as a probe to follow fragmenta-
tion studies.
Bowmer and Lindup (1980) have calculated
association constants for methyl orange, o-methyl red, and
bromocresol green (see Table 1.1); Kragh-Hansen
(1981) has shown that phenol red and bromophenol
blue bind to the primary bilirubin site, and that
they displaced each other and bromocresol green and
bilirubin from this binding site. Sulphonobromophthalein
binds to a different site,possibly at the secondary
bilirubin site (Kawisaka, et aZ., 1974) and it is
feasible for a region to bind one molecule of
Trypan Blue but two of ANS.
The binding of immobilised Cibacron Blue F3GA
to albumin has been used in affinity purification of the
protein from serum and appears to bind at the primary
bilirubin binding site, and a more general conformational
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change may occur (Lagercrantz and Larsson, 1983). The
binding of bromocresol green has been incorporated
into an albumin concentration assay (Do'Ljmas,eta t . ,
1971) although the complexation must be studied
immediately to avoid interactions with other serum proteins.
The concentration of albumin may be under-estimated due
to the presence of Phenylbutazone and Clofibrate or in
uremic patients (Cah~o et aL, 1985). An improved
assay using bromocresol purple has recently come into
use.
1.3 VARIANTS OF SERUM PROTEINS
1.3.1 Introduction
Several blood proteins have been shown to
have genetically inherited variant forms, some causing
pathological deficiencies (see Table 1.3). Three
such proteins will be considered here as examples of
the nature of such mutations and their effect on
function.
1.3.2 a ..proteaseInhibitor (a-Antitrypsin)-1 1
The third most abundant class of plasma
proteins by weight are the protease inhibitors and
the best characterised of these is ~-protease
inhibitor (~-antitrypsin). Serum protease inhibitors
control a variety of events associated with
connective tissue turnover, coagulation, fibrinolysis,
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Table 1.3 Some serum protein variants and
their effects.
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complement activation and inflammatory reactions.
As the name suggests, a1antitrypsin was first noticed
due to its inhibitory effect on trypsin. However, it is
effective against a range of serum proteases, its
greatest inhibitory effect being on neutrophil elastase.
It has for this reason been renamed ~-protease inhibitor
(a1-PI)•
a1~rotease inhibitor is a single polypeptide
of 53,000 molecular weight, with 10-15% carbohydrate
content. At least twenty variant forms are known, the
common form being called M and the phenotype PIMM'
Variants are detected as slow or fast migrating components
on electrophoresis and the slowest known variant P1zz
was discovered by Laurell and Erichsson (1963) and
occurs in 1-2% of North Europeans but has a higher
frequency in Maoris (8.2%) and Iranians (2.2%).
Another variant is the S form and both these have been
shown to cause reduced ~-PI concentration in serum.
There is a variant PIt--) which is very rare with
only twenty known cases, a~d which results in no
~ ~I synthesi s. Tjle'1.;?Iconeentrations for the
various genotypes are: PIMM 100%, PISS 54%, PIMS 80%,
PIM- 50%, PIMZ 60%, PIsz 33%, P1zz 12% and PI__ 0%.
In patients with less than 35% aIPI' the
occurrence of emphysema is very high and is thought to
be caused by a lack of active inhibitor in serum; neutrophil
elastase, being free to digest connective tissue,
causes damage to the alveoli which appear to be
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especially susceptible to elastolytic attack. In
FIzz individuals the probability of developing
emphysema is twenty times that of normal individuals and
amongst those FIzZ individuals who smoke, the
mortality rate is 70% by the age of 50 years, due to
the further inhibitory effect of the oxidants in
cigarette smoke upon the small amount of active alPI.
Large amounts of ayFI are found in the hepatocytes
of PIZZ individuals and it would appear that a point
mutation in the protein sequence, the substitution of
lysine for glutamate (a C + T transition) at residue
53/prevents 85% of the protein from obtaining the
correct conformation and instead it aggregates to
form inclusion bodies in the hepatocytes. In the
PISS variant a glutamate to valine substitution at
residue 131 occurs due to a T + A transversion in the mRNA.
However, the reduction in serum levels of active inhibitors
is less severe in this case.
Twenty per cent of PIzz individuals also
develop hepatitis, possibly due to the intracellular
levels of non-functional Z variant alPI, and rheumatoid
arthritis may also result from this condition. The
heterozyqousindividuals do not suffer any ill effects
as the level of alPI in the serum is not as drastically
reduced.
1.3. 3 Transferrin
Transferrin is the primary carrier of free
ferric ions in serum, and is responsible for their
transport from the site of haemoglobin catabolism to
the bone marrow and to storage organs such as the
liver, so providing an efficient turnover of metabolic
iron and preventing iron toxicity. Transferrin,
previously termed siderophilin, has a molecular weight
of around 77,000 daltons and is a single polypeptide
chain with two binding sites for ferric ions, one
at the N-terminal domain and one at the C-terminal domain,
which appear to function independently. Transferrin
is synthesised by the liver and has a plasma concentration
of ~ 2.5 giL. Variants of transferrin have been
detected in at least twenty cases, those with charge
differences being disclosed as fast or slow migrating
bands in the a-globulin region on electrophoresis.
The variants are fairly equally divided between fast
forms (TfB) and slow ones (TfD)' compared to the
common type (TfC). Several transferrin variants have
been sequenced, the variant TfD has two glycine
~
residues which have been converted to aspartate and
asparagine respectively, and TfD' another slow variant,
results from an arginine to lysine mutation (Putnam,
1975). No mutant form has yet been associated with
a pathological condition although Evans, et aL. (1982)
found a variant with a defective C-terminal iron binding
site. The isolated C-terminus appeared to be less
stable than the normal and to have only one-tenth the
association constant for FellI, though not influencing
the N-terminal binding (Evans, et al., 1984). This
variant may function as a monoferric transferrin but
no pathological effects have yet been ascribed to
this condition.
Atransferrinemia, the congenital absence of
transferrin, has only rarely been reported. Heilmeyer,
eta l., (1961) detailed such a case with severe anaemia,
frequent infections, impaired growth and the absence
of immunologically detectable transferrin. Radio-
labelled 59Fe was cleared from plasma abnormally
quickly and became localised in the liver, little
being used for haemoglobin synthesis. Death resulted
from hemosiderosis of heart muscle and visceral
organs. Hypotransferrinemia may be found with other
clinical conditions, for example, extreme proteinuria,
but no genetic basis has as yet been postulated.
Haemoglobin
Introduction
Haemoglobin is not a plasma protein, being
incorporated into the erythrocytes. However,
1.3.4
1.3.4.1
haemoglobin variants have probably been the most
studied of all variant proteins with over 300 types
characterised. Consequently, the methodology used
in the studies of these variants is of great use in
considering other variant proteins, and they can provide
a great deal of information about the types of mutation
which can occur.
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Haemoglobin is a tetrarner consisting of
monomeric globular polypeptides, around 140 amino
acids in length with a subunit molecular weight of
16,000 daltons. Adult haemoglobin is made from two
a and two a-subunits although other monomer subunits
exist, the ~ and E chains being formed in the early
foetus and the y chain in later development and in
the neonate. The a and ~-chains have seven and
eight helices respectively, lettered A to H; the iron
containing haem ring is positioned between the E and
F helices, and one molecule of oxygen binds to each
subunit haem group. Allosteric effects between the
subunits result in sigmoidal binding affinity,
releasing oxygen at low pressure in the tissues and
binding it tightly in the relatively greater oxygen
pressure of the lungs. There are several classes of
haemoglobin mutation which result in altered physiological
state and these are called haemoglobinopathies
(Smith and HIIJ'I 1983) •
Haemoglob:tns with Altered Solubility
Sickle cell anaemia is probably the best
documented disease caused by an alteration to the
haemoglobin (Hbl molecule. The sickle cell haemoglobin
1.3.4.2
(_HbS),which contains a glu + val transformation at the
sixth residue of the 'B-'chain,'aggregates on deOXygenation,
resul~lng 1n the deformi~y,of the red cells known as sick-
ling, .and rendering them' susceptible to lYSiS, .resul ting,
in a haemolytic anaemia. The aggregation is thought
to be due to the generation of a hydrophobic region
'\,:' ..
at the site of mutation which then adheres to a
complementary hydrophobic region, residues 78-88, of
the 8-chain and results in clumping of the chains.
Several other variants of this type are known. The
heterozygote for HbS,having 50% normal haemoglobin,
is not seriously anaemic but does have a degree of
resistance to the malarial parasite, PLaamodium
faZaipapum, which cannot survive in the sickled cells
of the patient's sera.
1.3.4.3 Inclusion Body Haemolytic Anaemia
The formation of amorphous intra-cellular
aggregates which deform the cells and predispose
them to lysis can occur in haemoglobin variants such
as Hb . h. The aggregates, termed ~nclusio~ orHammersm~t
Heinz' bodies are caused due to the destabilisation
of the oxyhaemoglobin state, resulting in reduced
.oxygen affinity and opening of the haem binding pocket
with loss of the porphyrin group and subsequent
aggregation of the free globin chains. This is
termed inclusion body haemolytic ana~mia,and in the
I
above-mentioned variant is due to a :~he + ser mutation
at the a-chain 42nd residue.
1.3.4.4 Haemoglobins with Altered Oxygen Affinity
Haemoglobin variants exhibiting abnormally
high oxygen affinity cause an absolute increase in
the mass of red cells, termed polycythemia. This
condition is due to the destab1lisat1on of the
deoxy~Hb for.m by disruption of .the inter-subunit
., . .
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interaction, for example in Hb aspB99 isKempsey'
replaced by a.snand this prevents formation of a
stabilising hydrogen bond between residue 99 and _tyra42
in the a chain. Similarly, destabilisation of the
oxy-Hbstate results in reduced oxygen affinity and
cyanosis - a bluish discolouration due to the
depletion of the oxygen supply in skin and peripheral
tissues.
Five abnormal haemoglobins result in methaemo-
globinemia where high concentrations of MetHb,which can
no longer bind oxygen,are formed. Mutation of the
distal or proximal histidines (aSS and aS7) to tyrosine
in HbML t and HbM1 t results in this condition-~os on wa e
where the oxygen coordination site is blocked by a
water or hydroxyl group. The homozygous state is
unknown and is presumably fatal.
a Chain
140
A Th, Se, Lvs Tvr Arg Term
ACC UCC AAA UAC CGU UAA -
ConstantSpring Th, . Ser . t.vs . Tvr AIg .. Gin. Ala Gly Ala ~ Val Ala
UCU AAA UAC CGU CAA GCU GGA Gee ueG GUA Gel!
Ser Asn Thr Val Lvs Leu Glu Pro AIg Term
uce AAU ACG GUU I\AG eUG GAG eGU eGG UAG
Fig. 1.14 Chain elongation in Hbc t t S ions an pr ngdue to a mutation in the termination
codon (residue 142).
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1.3.4.5 Types of Mutation
Variant proteins such as those causing
the haemoglobinopathies can be the result of several
types of error; deletion of the S141 residue, for
example, results in the variant HbC toven ry Addition
or removal of amino acids from the globin chain can
be the result of a point mutation converting a
termination codon into one specifying an amino acid
and viae versa. In Hbconstant Spring the termination codon
UAA is converted to CAA coding for glutamine and the
chain is extended by 16 residues (Fig. 1.14). Several extended
variants are listed in Table 1.4. Deletion of a
single nucleotide can result in a "frame shift" mutation
which again can result in different amino acid chains
being constructed as in HbW (see Table 1.4). Inayne
HbG d duplication of part of the reading framera y
results in a tripeptide insertion in the sequence.
Fusion of the different genes for Hb can occur due
to unequal crossing-over and this can give rise to
variants such as HbLepore where the first third
of the sequence is that of Hb a-chain and the rest is
like the S-chain (Winslow and Andersson, 1983).
The hereditary anaemias a and B-thalassemia
are caused by defective chain synthesis due to
deletions in the globin genes. In a-thalassemia deletions
in both the a-genes encoded on a chromosome are
common and a homozygote will usually die in infancy
so
Residue Name
0142-172 Consranr
Spring
Glu-Ala-Gly-Ala-Ser
Val-Ala- Val-Pro-Pro-
Ala-Arg-T rp-Ala-Ser-
Gln-Arg-Ala-Leu-Leu-Pro-
Ser- Leu -H is-Arg- Pro-
Phe-Leu- Val- Phe-Glu
Gly-Thr-Phe repeated
Asn-Thr- Val-Lys-Leu-
Glu-Pro-Arg
0115-118
o1J9-146
Grady
\'(Iavne
Table 1.4 Some extended haemoglobin variants.
due to lack of a functional a-globin subunit. In
a-thalassemiaII only one a-gene is usually affected
and the condition is less severe (Hbconstant Spring is
of this type). a-Thalassemia, resulting from deletions
in the a-globin gene, is widespread in the Middle
East, Mediterranean, Africa and Asia, and although
the heterozygote is assymptomatic the homozygous
condition is usually fatal if regular transfusions are
not received and iron toxicity and secondary complications
are also a problem. A milder form of a-thalassemia
can occur where both a and a-thalassemias are cO-inherited
or where the foetal globins are still synthesised in
adult life (WaiKan, 1983).
Consideration of the types of mutation known
to occur in haemoglobins may be of assistance in
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understanding variation in other plasma proteins.
1.4 VARIANTS OF HUMAN SERUM ALBUMIN
1.4. 1 Introduction
Variants of serum albumin were first demonstrated
by SCheurlen (1955) who noticed that the electrophoretic
pattern of a Swiss German patient with unstable diabetes
contained two albumin bands during periods of coma and
precoma', though these coalesced on return to normal health.
Knedel (1957) described this condition of two albumins
in the serum as "Bisalbuminemia" and he showed it to be an
hereditary condition and described two 'slow' variants
(Knedel, 1958). Albumin variants, as with several other
plasma proteins are classified by their mobility on
electrophoresis compared to the normal band;hence a
more anodic band is termed 'fast' and a more cathodic
band, 'slow'. Nennstiel and Becht (1957) reported
the first fast albumin variant. ~vuhrmann (1959) re-
examined Scheurlen's patient and found that this variant was now
a permanent characteristic of her serum,and was also
present in her father, brother and son. The early
transient nature of the band was probably due to the
inadequate separations obtained on filter paper
electrophoresis, the double albumin being more
apparent in the acidosis which accompanied the comatous
state.
Ear le, eta 1-. (1959) described another slow
variant bisalbumin in a Norwegian/American family;
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they isolated the variant and performed peptide mapping,
concluding that an acidic residue, aspartate or glutamate
had been replaced by a basic one, probably lysine;
the decrease in net negative charge giving rise to a
cathodic variant (D. Gitlin, et aZ., 1961). During
the following few years other cases were discovered
in families of various European nationalities, most
being slow variants similar to that discovered by
Earle. However, two.fast variants were found,
Albumin Reading (Tarnoky and Lestas, 1964) in an
English/Welsh family and Albumin Gent in a Belgian
one (Wieme, 1960). These variants were all at
low frequency in the population (one in several
thousand). However, in 1966 Melartin and Blumberg
(1966a)reported a fast variant albumin among American
Indians which was present in a higher frequency. The
variant was originally found in Naskapi Indians and
so was named Albumin Naskapi. The tribe was small and
inbred and homozygous individuals, possessing only
the variant albumin, were found for the first time.
~
The term bisalbuminemia was no longer appropriate
and Melartin (1967) proposed the name alloalbuminemia
to describe the condition and this has subsequently
replaced the previous terms, bisalbumin, para-albumin
and double or split albumin, which were really only
accurate in the heterozygous state. A second poly-
morphic variant, this time of the slow variety, was
discovered in Mexican Indians (Melartin and Blumberg,
S3
1966~ and was also shown to occur in the homozygous
state.
1.4.2 Albumin Variant Classification
There are over eighty known albumin variants
in the literature and an exhaustive account of their
discovery and properties will not be attempted here,
the field being reviewed excellently already by
Schell and Blumberg (1977) and Tarnoky (1980). A
systematic nomenclature has been proposed, the common
form of albumin being called Albumin A and the slow
varLant;of Earle ef al (1959)being given the name
Albumin B. Other variants are named after their ethnic,
geographic or laboratory origin using the standard
nomenclature used in several other serum protein
variants, for example, Albumin Stirling and Albumin Gent.
In other cases, the genotype is expressed as a
superscript,for example, an albumin Naskapi heterozygote
would be termed AlAAINa• The many Italian variants
use the location of the laboratory making the discovery
and the family's place of origin, with the lettering
system of Italian car number plates, for example
AI.SO/BS for Albumin Sondrio/Brescia.
The qualitative terminology 'very slow, slow,
normal, fast and very fast' first used to describe the migration
of variants, soon became inadequate and Weitkamp, et aL.
(1973) devised a starch gel electrophoretic procedure
for characterising variant forms;at three pH ranges;
sodium acetate/EDTA pH 5, Tris/lithium/succinate/
citrate pH 6 and Tris/EDTA/borate pH 6.9. Some of the
later variants differ in mobility in only one of the
three systems, and it would seem that fast variants
separate better at pH 5 and slow ones at higher pH,
migration distance being with respect to the origin
or an artificially enhanced transferrin peak.
1.4.3 Genetics of Alloalbumins
More recently T~rnoky (Curnow, et al., 1978)
has proposed a dye-binding procedure which .utilises
six ligands in several media: this allows for the
detection of variants differing only in their dye
binding affinities and has now been used to more fully
characterise a number of variants (Fig. 1.15).
From those variants where it has been possible
to trace ancestries it has been shown that alloalbuminemia
is a co-dominant autosomal trait, inherited in a simple
Mendelian manner with unreduced expression of both
genes, resulting in 50:50 ratios of variant to normal
in most heterozygotes. The only exceptions known are
Albumin Luarca which falls to 29% on freezing (Izquierdo,
et al., 1971), some dimeric mutants, where the percentage
of variant to normal can vary and Albumin Vancouver
(Frohlich, et al., 1978) where the ratio AI~Alva is
35:65. Linkage studies performed on albumin indicate
that only the Group specific component (Gc) is
r-r
..)J
Br Br
O~C~OHB~MBr
~~Na
U
Br
OH
bromophenol blue bromocresol green
S03Na HO
Na03S~N==N~N==N
Ponceau S
NH2 NH2
'-':::: N=N-O--O-N=N~
y0
S03Na S03Na
Congo Red
bilirubin
Fig.1.15 Classification of variants by dye binding: structures
of the RBH test dyes.
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co-inherited to any degree.
1.4. 4 Immuno~
Most experiments to determine the anti-
genicity of albumin variants have shown them to be
identical to the normal form, using double immuno-
diffusion, immunoelectrophoresis and two-dimensional
immunoelectrophoresis with mono-specific antihuman albumin
antibody from a number of mammals. The only
contradictory report is that of Robbins, et al.
(1963), who reported antigenic identity at a 1:1
ratio antibody:albumin, but two separate arcs if
the serum was diluted 1 to 3~ However, this may be
an artefact due to excess antibod~ (Payne and
Dickinson, 1967). In addition, Margni, et al.
(1970) found slightly different antigenic properties
in two alloalbuminemic forms.
More recently Lapresle and Doyen (1983) have
raised monoclonal antibodies to a proteolytically derived
6,000 dalton fragment of albumin, comprising the
last small loop (residues 558-67), the disulphide
bridge 514-59 and residue 570. Using this antibody
they have shown that it was necessary to add 120 times
the amount of albumin B compared to albumin A to obtain
50% inhibition of labelled-albumin detection, indicating
that residue 570,which is different in albumin B, is
important in the monoclonal antibody binding site. It
therefore seems that monoclonal antibodies may be
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able to distinguish between normal and variant albumins.
1.4.5
1.4.5.1 Amerindian Variants
Genetic polymorphism is the simultaneous
occurrence in the same habitat of two or more discontin-
uous forms of a species in such proportions that the
rarest of them cannot be maintained merely by recurrent
mutation (Ford, 1965). Albumin variants are classed
as polymorphic if they have a frequency> 1% in a
population. There are four albumin variants which can
be regarded as polymorphic, Albumins MexiCO, Naskapi,
Makiritare and Yanomama-2. These four variants occur
almost exclusively in the American continents and
represent two types of polymorphism:
(a) Yanomama-2 and Makiritare reach polymorphic
frequencies only in the ethnic groups in which they
occur and are thus termed restricted variants.
Albumins Naskapi and Mexico are classed as
dispersed variants as they occur in frequencies above
1% in several ethnic populations over a wide geographical
area (Schell and Blumberg, 1977). Albumin Naskapi is
found predominantly in Northern Amerindians, occurring
at high frequencies among the Naskapi and Montagnais
Indians of Quebec, also among some Albertan and Alaskan
TABLE 1.5
sa
Some albumin variants and their distribution
(Adapted from Sellers and Koch-Weser (1977)
and Tarnoky (1980)
Name of Variant Ethnic Origin Properties
Ann Arbor European
B European
Birmingham Indian
Christchurch New Zealand
Gainesville European
CU.S.A.)
Gent European
Kashmir Indian
Lille French
Luarca Spanish
Makiritaire S. American
Indian
Mexico N. American
Indi.an
Mi/Fg Italian
Naskapi N. American
I'ndian
Oliphant European
Parklands New Zealand
Pollibauer European
Reading European
Stirling Scottish
Warao S. American
Indi.an
Yanomama S. American
Indian
Slow migrating. Mutation
located
Slow, may have subtypes
Slow, similar to Kashmir
Slow, proalbumin variant
Slow, identical to
Christchurch
Fast migrating
Slow, identical to
Afghanistan
Slow, proalbumin variant
Slow, unstable to freeze-
thawing
Slow, dimeric
Slow, polymorphic,
mutation pinpointed
Fast, homozygote
Fast, polymorphic
Slow, identical to
Ann Arbor
Slow, mutation located
Slow, identical to
Lille
Fast,migrating
Slow, ratio in serum
variable
Slow, dimeric
Slow, diemric
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Indian groups and at lower frequencies in several
other Indian tribes in the United States and Canada.
Albumin Mexico is distributed amongst the Middle
American and South Western United States Indians,
although occurring in other tribes at lower frequencies.
Albumins Naskapi and Hexico are both found in some
southwestern tribes such as the Apache and Navajo
Indians.
These variants have been studied extensively
in order to elucidate the anthropological origins of
the tribes and the findings are consistent with archaelogical
evidence for the relat~onships between the tribes.
Franklin, et aZ. (1980b) have shown that Albumin Naskapi
is identical to a variant found in a community of
Eti Turks in Asia Minor; this variant was !?reviously called
Albumin Mersin. In view of the limited distribution
of Albumin Naskapi,which has not been found to occur
in other racial groups the suggestion is made that
these two communities may have descended from a
common ancestral stock; skeletal, morphological and
genetic evidence support the hypothesis that American
Indians may have descended from a Mongoloid population
which entered the New World from Central or Eastern
Asia over the Bering Straits.
Several other Amerindian variants are
known, including Belem I, II and III (I and II slow,
III fast); Belem III however, is indistinguishable
from two other Amerindian albumins, Maku and
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Makiritare-2 (Salazano, et aL, 1974). Helena,
et aZ. (1975) described ten rare Brazillian variants
and compared them to seven known variants, several
showing unique mobilities on electrophoresis.
1.4.5.2 European Variants
The frequency of albumin variants in Europe
is low (1 in 1,000 to 1 in 10,000); however, sLow variants of
the B type occur in several countries, for example,
in the region of Stuttgart where there are slight
differences which are classified as sub-types within
albumin B (Ott, et aZ., 1975). A fast variant,
Albumin Syracuse is d~tectable only on electrophoresis
at pH 5.4. Italy has the highest number of classified
variants in Europe including two homozygotes,
Albumin MI/TN (Milano/Trentq a slow variant, and
Albumin MI/FG (Milano/Foggia) a fast one (Vanzetti,
et a i ; , 1979).
1.4.5.3 Southern Asia
Alloalbuminemia has been found in natives of
Kashmir (Tarnoky& Dowdjng I 1969), Afghanistan, the
Punjab (Dash, et aL., 1982), Vellore (Hill, 1975)
and other parts of India as well as occurring in
Indian, Malayan and Chinese populations in other
countries (Welch and Lie Injo, 1972). Several
Japanes.e variants are known (Nishimukai, et aL, 1982),
the inhabitants of Hiroshima and Nagasaki showing a
frequency fifteen times that in other parts of
Japan. The explanation for this may not be straight-
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forward as no increase in variant albumins is seen
in those exposed to fall-out from nuclear tests in the
Marshall Islands (Neel, et aZ., 1~76). Albumin New
Guinea has the same migration as Albumin Reading.
1.4.5.4 African Variants
Few African variants are known, Albumin
Cayemite, a fast Haitian Negroid variant (Weitkamp,
et aL., 1969) and two or three more being the only
ones recorded. Smith, et aZ. (1976) may have found
a silent variant of African origin.
1. 4.6
1.4.6.1
Structural Properties of Variant Albumins
Assessment of New Variant Albumins
Over 80 albumin variants are known (Schell
and Blumberg, 1977). These are, however, unlikely
to be all unique; the data suffers from ambiguities
such as those variants which have been renamed, those
which are rediscoveries of existing variants, those
which are not given a name or are used in comparative
studies only and are not fully classified individually.
Schell and Blumberg (1977) compared variants, giving
geographical location, synonyms, and ethnic origins.
Weitkamp, et a l, (1973) listed twenty three
types of variant and their population distributions,
all of which were separable using the three buffer
starch gel electrophoretic system. The number of new
types has grown since then, however it is difficult to
assess a new variant without the whole range of known
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variants.
1.4.6.2 Types of Variant Albumin
The majority of variants are monomeric,
probably arising from a single pOint mutation at
a single amino acid. Several dimeric variants do
exist, although the percentage in the dimer form is
usually low, suggesting that the mutation is in a
monomeric variant which subsequently tends to aggregate.
Examples of this are Albumins Makiritare (Warao) and
Yanomama. The molecular weight of variants can be
assessed on SDS-PAGE, some dimeric albumins reverting to
monomer with 0.1 M mercaptoethanol but others being
resistant to such reduction requiring 8 M urea to
dissociate them (Jamieson and Ganguly, 1969). Most
variants occur in a 50:50 ratio and are stable to heating
at 560C and repeated freeze-thawing. The percentage
of dimeric variants often varies under these conditions
and this has been used as a diagnostic test, Albumin
CN/BL (Vacca, et aZ., 1974) constituting only 21% of
the total albumin and Norwegian variant RIH (Chapman,
et at., 1978) occurringin a 64:36 ratio A1bA:AlbR1H•
The Scottish variant Albumin Stirling (Curnow,etal 1978)
varies from 33-41% dependent upon drug treatment
whereas the Fijian variant, Albumin Vancouver (Frohlich,
et al., 1978) occurred in the ratio AlA:Alva 35:65;
differential synthesis has been proposed to explain
this effect.
Izquierdo, et aZ. (1971) has reported a
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Spanish variant, Albumin LuarcR, which is unstable to
freezing,falling from 44 to 27% on prolonged storage
and is also decreased by rapid freeze-thawing. Albumin
Makiritare (Warao) has been shown to constitute 30%
of serum albumin (Arends,et al., 1969), but reverted
to the mobility of normal albumin on heating to 560C
for one to two hours, this suggesting the variant band
was due to dimer.
Electrophoretic techniques characterise only
those variants which have an altered charge from
normal albumin. Nei and Chakraborty (1976) have
postulated that a change in net charge occurs only in
one-quarter to one-third of all substitutions, so that
the number of silent albumin variants, that is, those
not causing any difference in charge, could be two
or three times the number detectable by electrophoresis.
Two possible examples of the silent variants may have
been found by Smith, et al. (1976) and Walsh, et al.
(1983). Smith, et al. reported a family with high
plasma zinc level whose excess zinc was albumin-bound,
possibly due to an electrophoretically silent albumin
variant, as 80% of serum zinc binds to albumin. A
similar result has been reviewed by Tarnoky (1980)
for a raised indocyanine green binding, coupled to
normal binding of bromosulphophthalein described by
Kawasaki, et al., 1973. A variant albumin, IMVS
was reported by Walsh, et at. (1983) solely on the
basis of increased bromocresol green and bromocresol
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purple binding in the presence of excess ~egosperse
detergent and merthiolate. They noticed decreased
HABA binding and found six other patients with similar
findings in 21 months. They isolated the abnormal
dye-binding albumin from a protein with normal binding
on DEAE-Sepharose. Albumin IMVS was not detectable on
gel electrophoresis but was present in several members
of the family.
Sequence Analysis
The albumin B variant of Norwegian/American
origin has been shown by Gitlin, et aZ. (1961) to have
1.4.6.3
an equivalent of two extra protons, which was thought
to be an aspartate/glutamate to lysine mutation.
Winter, et aZ. (1972) followed a similar regime to
obtain sequence data on two B type slow variants,
Albumin Ann Arbor (a Danish variant) and Albumin
Oliphant (of German origin). Variant albumins
were isolated by ion-exchange chromatography and the
abnormal peptides,located by tryptic/ chymotryptic
digestion and peptide mapping, were sequenoslby the
Edman procedure. The abnormal peptide was found to
be Ala-Lys-Glu-Gly-Lys-Lys-Leu compared to Ala-Glu-
Glu-Gly-Lys-Lys-Leu in the normal albumin. This
mutation Glu + Lys has been subsequently located in
the albumin sequence at residue 570. Both albumin
variants showed the same mutation and in view of the
similarity to Earle's variant this has become the
accepted mutation resulting in albumin B.
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Franklin, et a l , {l980a)reported a new slow
albumin variant in a sub-class of Albumin Mexico -
termed Mexico-2. By use of cyanogen bromide fragmenta-
tion and acid-Triton X lOO-urea gel electrophoresis
the mutant fragment was isolated and sequenced. They
found the variant was due to a mutation from aspartate
to glycine at residue 550, part of the long chain
fatty acid binding site.
In the same year Franklin, et aZ. (1980b)
isolated a mutant fragment from the fast variant Albumin
Naskapi, and located the mutant in the region residues
373-89. They also pinpointed the mutation site of a
slow Turkish variant, Albumin Adana, in the region
447-548 and hence distinct from the albumin B
site.
A New Zealand variant, Albumin Christchurch,
was characterised as a slow variant by Brennan and
Carrell (1978). On sequencing the albumin variant they
found the proalbumin hexapeptide sequence was still
intact; but there had been a mutation in the last
residue from JI_rry-(;lY'""Val-Phe-Arry-Argto Arg-Gly-Val-Phe-Arg-Gln.
The hexapeptide, normally excised by an ~xq-AIg specific
protease, possibly Cathepsin B, (Judah and Quinn, 1978)
had not been recognised and removed in Albumin
Christchurch, the proalbumin being secreted into the'
bloodstream. In the heterozygote, equal amounts of
normal and variant albumins were present in blood. Further
support for the proposed theory of propeptide
cleavage deficiency was ~ained when another proalbumin was
discovered by Rousseaux's group (Abdo, et aL., 1981) in
a serum sample from Lille, France. The slow variant
was separated by preparative cellulose acetate
electrophoresis and found on sequencing to have an
N-terminal peptide - Arg-Gly-Val-Phe-His-Arg -
differing from the normal albumin at residue -2, an arginine to
histidine mutation; the arg-arg sequence having changed,
the propeptide remained intact and the proalbumin was
secreted intact into the bloodstream. Limited digestion
with trypsin in vit~o resulted in removal of the
propeptide, using a less specific proteolysis
(Fig.1.16).
a -
234
Asp - Ala - His - Lys -
-6 -5 -4 -3 -2 -I
b - Arg - Cly - V.l - Phe - Arc - Arg - A,p - Ala - Hia - Lys _
c - Arg - Cly - Val - Phe - Hi, - Arg - Asp - Ala - His - Lys -
d - Arc - Cly - V.l - Ph. - Arc - GIn - A.p - Ala - Hi. - Ly.
Fig. 1.16 Comparison of human proalbumin variants.
(a) Nor.mal albumin N-ter.minal sequence.
(b) Sequence of normal human proalbumin
(Dugaiczyk, et aL., 1982).
(c) Sequence of Proalbumin Lille (Abdo,
et a l ; , 1981).
(d) Sequence of Proalbumin Christchurch
(Brennan and Carrell, 1978).
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Subsequent to the discoveries of Albumins
Christchurch and Lille two other variants of
different ethnic origins have been sequenced and shown
to be identical to them. Fine et aZ. (1983) reported
the amino acid sequence of Albumin Gainsville, an
American variant of Irish descent, as being the same
as that of Albumin Christchurch and the slow albumin
variant Pollibauer, of Austrian descent,was identical
to that of Proalbumin Lille CGalliano, et az', 1984).
The same mutation occurring twice in distinct populations
may suggest that some other variants in the list of
Schell and Blumberg may be identical also.
More recently, P. Iadorola, et a l, (1984)
isolated a mutant peptide from the serum of a patient
with the Italian variant Mi/Fg (Vanzetti, et aZ., 1979).
Sequencing of the variant revealed a mutation of Lys -+
Glu at residue 573, resulting in an increase in net
negative charge and giving rise to a more anodic fast
variant (Iadarola, et aZ., 1985).
During the compilation of this review a new
variant has been reported in the literature. Brennan
(1985) has isolated a slow varian~Albumin Parklands, from
a 77 year old male Caucasian heterozygote by chromatography
on DEAE-Sephadex eluting with a pH gradient from 5.2
to 4.5. After tryptic digestion of the S-carboxymethylated
albumin and using reverse-phase high performance liquid
chromatography to separate the fragments, Brennan
discovered a variant peptide consisting of residues
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360-72, which had a histidine substituted for
aspartate at residue 365. This mutation was not
shown to cause any ill effects in the patient but
did show resistance to partial acid hydrolysis due
to loss of the susceptible asp-pro sequence.
In Table 1.6, the point mutations of known
variant albumins are presented with the nucleotide
transformations in each case. In each of these
assignments the mutation requiring a single base
change has been assumed to be the one which has
occurred. All but Albumin Park lands are thought
to be the result of transitions, G ~ A in all the slow
variants, and A ~ G in the fast Mi/Fg variant.
Albumin Parklands is thp.only case of a transversion
yet discovered,from G ~ C. Whether this trend is
significant cannot be determined until further data
on albumin mutants can be obtained.
Abnormal :Propertiesof Albumin Variants
Disease States
No disease or clinical condition has been
linked to the possession of a variant albumin, even
1. 4.7
1.4.7.1
in the homozygous state. Variants are often found
initiallv during hospitalisation or treatment for
some medical problem. However, these are not restricted
only to those possessing a variant albumin, for example,
a hand defect found in two bisalbuminemic members
of a family was also found in those members with
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Genetic Mutations In Known Variants
Albumin
Variant
Amino-Acid
Res idue
Amino-Acid
alteration
Codon
alt~n
NQrm!l1 ~ilrlant Normal Variant
B 570 glu ~ Iys GAG~AAG
Ch r ist ch u rc h -I a rg ~ gin CGA----\ CAA
l ille -2 a rg --'I his CGT~CAT
M ifFg 573 Iys ~ glu AAA----4 GAA
Mexico - 2 550 asp~ gly GAT----4GGT
Parkl and s 365 asp~ his GAT~CAT
Table 1.6 Genetic mutation of human variant albumins.
only normal albumin (Franglen, et at., 1960).
Several incomplete accounts of diabetes
mellitus and also raised serum cholesterol levels have
been associated to alloalbuminemia, although chance
association cannot be excluded. Tarnoky (1980) referred
to a platelet defect in an Australian family which
segregated in the same members as a slow alloalbumin
with raised thyroxine binding and decreased binding
of bromophenol blue (Clancy and Firkin, 1974). This
is unlikely to be due to chance, but whether the condi-
tions are genetically linked or actually caused one
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by the other is not clear.
1.4.7.2 Differences in Ligand Binding
1.4.7.2.1 Metal Ions
Defects in the N-terminus of albumin
have been shown to result in Cull and NiII binding
deficiencies. Brennan and Carrell have shown that
this primary binding site is missing in Proalbumin
Christchurch and Fine, et al. (1983) showed that
Albumins Gainesville and Pollibauer have defective
b' d' f 63N,1.n1.ng0 1.. This defect in the divalent metal
ion site is not seen in any other alloalbumin type
other than proalbumins and so it would seem that the
elongation of the N-terminus blocks metal ion binding
at the primary site.
1.4.7.2.2 Drugs
Wilding, et al. (1977) have shown that
the binding of warfarin to heterozygote and homozygote
patients, in both sera and isolated protein, was
greater for albumin B than albumin A but less for both
Albumins Naskapi and Mexico. The differences were
sufficient to have a pharmacological effect and care
is needed in the administration of drugs to such patients.
Schell and Blumberg (1977) suggest that the reduced
binding of warfarin to albumin variants may have been
an advantage in prolonged exposure to hallucinogens
over generations.
Blumberg (1969) has suggested that neonatal
kernicterus might be a problem in those patients with
albumin variants; several dye binding studies
Royal Berkshire Hospital (Curnow et al1~78)
after the TarnokY~RBH schedule have been performed on various
variantssome proteins showing slight differences. The
quantitative work of Loreyet at.(1984)onYanomama-2 showed these
Indians to have decreased binding capacity for bili"rubin
and hence increased likelihood of bilirubin toxicity.
Sarcione and Aungst (1962) found an albumin variant
which bound high levels of 131I-thyroxine in all those
affected by it; Tarnoky and Lestas (1964) have also
found Albumin Reading to bind more thyroxine than
albumin A. Barbaree and Decker (1971) showed that
normal albumin bound more thyroxine than theirvariant .
Albumins Naskapi and Mexico bind thyroxine in a manner
which closely resembles that of normal albumin.
THYlIOXJNE BINDINC OF ALBUMIN BAtlOS IN BlSAUI.'MINEMIC Sav.·
Albumins Thyroxine binding
Slow Al. A
A. Reading
A. \'askapi
Mexico. A
A. fast :\.1
Slow •.6J. A
Slow Al. ,\
Vancouver, A
S only
A < Re
A ..Na
Me .. A
A> F
5 .. A
S .. A
Va ..A
~ -. The results are taken from published paperl on studies where test conditions may differ.
Cathodic (slow) albumins are printed to the left. r.. 1 \'uianU to the right. of albumin A.
TABLE 1.7 Thyroxine binding: properties of some
variant albumins.
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Competition for albUMin sites
has already been referred to as important in drug
therapy. However, the effects of variants on drug
therapy requires further stud~ although it may well
be significant especiallyfur polymorphic variants.
1.4.7.2.3 Dye Binding
The binding of dyes to albumin has been
used extensively to characterise variant types. The
ligands of the Royal Berkshire Hospital (RBH) test
include; Ponceau S, bromocresol green, RABA,
bromophenol blue, congo red and bilirubin, and the
qualitative binding of these drugs provides a more
effective method of classifying variant types than
electrophoretic mobilities alone, the binding of these
ligands indicating the relative affinities of the
different binding sites. Tarnoky has proposed that
bromophenol blue binds less to slow variants and more
to fast variants than to the normal albumin, however,
Wieme, et at. (1975) has criticised these findings
as being an artefact of the streaming of bromophenol
blue to the anode. The binding of a ligand to
variant albumins may vary in different media and pH
values and so direct comparison of results must be
made cautiously. However, some variants have been shown
to have differing dye affinities to albumin A.
1.4.7.3 Metabolic Studies
,:
B~anchi, et at. (1974) perfo~simultaneous
metabolic turnover studies of the two albumins from a
"3
bisalbuminemic patient, labelling albumin A with 1311
and the albumin variant with 1251. They found that
the turnover of the albumins over eight days was
almost identical for normal and variantfbrms.
1. 4.8
1.4.8.1
Transient Bisalbuminemia
Introduction
In 1964 Gabl and Huber described the case of
an eleven year old boy with ascites who had a fast
migrating albumin variant as well as albumin A.
The fast variant was immunologically albumin and
monomeric but occurred in serum in the ratio AlbA:AlbF
3:1 and in the ascitic fluid as Alb~AlbF 1:2,but did
not occur in the urine. After treatment for the
ascites the fast variant disappeared and was absent in
subsequent checks; the albumin did not occur in any other
members of the family and the cause of this 'transient'
bisalbuminemia was not established.
1.4.8.2 Penicillin Therapy
The binding of some ligands to albumin can
alter the electrophoretic mobility of the albumin band
and the transient band is often present as less than
50% of the total albumin. Several such cases are
known (Tarnoky, 1980) and the best defined is that
for penicillin. Arvan, et aZ. (1968) discovered that
patients receiving high dosages of penicillin G showed
a transient fast albumin band on screening of their
serum; this effect was reproducible in vitro and the
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term 'transient bisalbuminemia~ was used to describe it.
Formation of a fast band in vitro did not occur if
the penicillin was pre-treated with penicillinase,
but the penicillinase had no effect if used after the
albumin complex was formed. It would therefore seem
that the S-lactam ring is necessary for the
interaction with albumin. The condition is not
associated with permanent alloalbuminemia; heterozygous
Naskapi serum when treated gave four bands. The
albumin-bound penicillin is inactive although other
binding properties of the albumin are not affected.#
Porta, et aZ. (1974) standardised the conditions for
in vitro production of penicillin-albumin complexes and
showed timtpenicillinase present as a ratio 1:4
penicillinase:penicillin prevented formation of
the fast band; penicillinase-producing bacteria
have a similar effec~. and the inhibition of albumin-
penicillin complexes has been proposed as an assay
for penicfllinases in pathogens (Porta, et aZ., 1976).
The binding of penicillin is thought to be by
covalent modification of the lysine residue with
simultaneous destruction of the S-lactam ring
(Bundgaarni,1977). Lapresle and Wal (1979) separated
normal and penicillin-induced fast albumin from a
patient and showed that penicilloyl functions occurred
in far greater numbers on the fast variant. The
amount of penicillin involved in such binding is
small and appears to have no serious effect on the
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dosage in the patient.
1.4.8.3 Pancreatitis
The presence of fast albumin has been
reported in cases where plasma amylase is high.
Stoodley and Rowe (1970) described bisalbuminemia
in a patient with hyperamylasemia and pancreatitis
where the fast band was not immunoelectrophoretically
albumin and faded~ the course of treatment.
Tarnoky (1980) rev~ the case of a fast band due
to pancreatitis where the albumin pattern obtained
was consistent to that of tryptic digestio~ and it
may be that the transient albumins detected in such
conditions are the product of proteolytic digestion
of normal albumin by pancreatic enzymes. Rousseaux,
et aZ. (1976) showed differences in the C-terminii of
albumin A and a transient albumin consistent with
proteolytic digestion by elastase or chymotrypsin.
Vaysee, et aZ. (1981) described a case of pancreatitis
in a bisalbuminemic patient giving rise to three
albumin bands, the modified slow band becoming
merged with albumin A.
1.4.8.4 Albumins in Other Diseases
There are several reports of albumin
modification in disease states~ bisalbuminemia
was shown in two patients with immunological
abnormalities, one suffering from myasthesia gravis
and the other from myeloma. Although no definite
explanation of this concurrence could be given,
Ib
proteolytic effects may have caused one or both
abnormal protein bands.
Albumin is not usually heavily glycosylated.
However, CandianQ, et at. (1984) showed extensive
microheterogeneity in diabetic patients due to the
glycosylation of up to twenty amino acids; however, the
degree to which glycosylation occurs normally is a
matter of recent speculation. Gentou and
Plazzonet (1978) studied a slow variant in a 49 year
old man dying with reticulosarcorna, present at 44%
in serum and cerebrospinal fluid. On amino acid
analysis the slow band had ten glu ...lys modifications
and five ala ...pro causing a more cathodic albumin.
This may have been due to inversion of a segment of
cistron (see Fig. 1.17). Borisenko and Troitskii (1984)
have also reported modifications in the albumin of
cancer patients, with reduced numbers of unmodified
tyrosine hydroxyl groups and with alter.ation of
the free thiol residue causing inhibition of polymerisation.
They also found that 50% of the IOOleculeshad a glycosylated
N-terminus~and a modified lysine at the fourth residue
also occurred. In both these reports the changes are
probably not inherited and have most likely been due
to the serious pathological conditions of the patients;
Foster (1977) described albumin
17
microheterogeneity in normal patients and the causes
of this must be determined before an accurate assessment
of the two cases discussed can be made.
1.4.9 Analbuminemia
Analbuminemia, the apparent absence of albumin
from the serum, has been described in only twenty cases since
its discovery by Bennhold, et al. in 1954. This discovery was
in a 31 year old woman who had a genetically inherited absence
ofserum albumin. Most cases have been in the White population
though this may merely reflect differences in the availability
amedical care. The lack of albumin has been partly balanced
by increases in globulins to three or four times their normal
level. High cholesterol and triglyceride levels have been found
and serum calcium is also reduced in some analbuminemics.
In the absence of albumin fatty acids can bind to other
serum proteins with a lower affinity although bilirubin binding
is more difficult to replace.
Some very reduced levels of albumin are de-
tectable by rocket immunoelectrophoresis, being around
150-400 mg/L. _ Analbuminemia can be the result of two
different conditions. Christen and Franglen (1972)
found a patient with only 38 mg/L free albumin.
However, on gel filtration and lyophilisation a large
amount of albumin was found which had been complexed
to macroglobulin and the total level of albumin was
approximately normal, although whether the complexed
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glu
GAA
~ Iys
~AAG
ala ~ pro
~eCGGce
Fig. 1.17 Inversion of ci s tron possibly the cause of
the variant albumin of Gentou and Plazzonet
(1978) •
Intron HI
+ VS'GTAGGTTTCCGCGAG3' S'GTAGCGAG3'
+
S'GTTTCCG3t deleted
Fig. 1.18 Deletion in analbuminemic rat DNA
(Esumi, et a l , 1983).
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albumin was physiologically functional was not known.
This type of masking of albumin may occur in other
cases of analbuminemia but genetically reduced
synthesis of albumin may be the correct explanation of
others. The small amount of free albumin appears to have
a half-life six times tha~ of normal albumin in the
body; if levels are increased to normal by transfusion
reversion to the normal rate of catabolism will occur
in some but not all patients (Gitlin and Gitlin, 1975).
Avery, et al. (1983) have shown that the DNA
of an analbuminernic patient did not differ in its gross
structure from that of normal patients and so no major
deletion of the gene had occurred as in the thalassemias.
Nagase has succeeded in breeding a strain of analbuminemic
rats (NAR) and studies of these have shown there to be
a seven base pair deletion in the intron HI of the
gene for albumin (see Fig. 1.18). This is thought to
block mRNA splicing and prevent expression of the
albumin gene (Esurni,et al., 1983). No similar changes
in the human gene have yet been reported. The condition
is thought to have autosomal recessive inheritance
because of its rarity and consanguinous occurrence. Clinical
symptoms of analbuminemia are surprisingly few and
this has led Cohen (1965) to suggest that albumin is
not an essential protein. The main effect found is
Oedema due to drop in osmotic pressure, and other
symptoms may include fatigue, diarrhoea and fainting
spells. Several patients have had more serious
illnesses but these have been unassociated to the
albumin defect. The skin contains 11% of the total
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body albumin and dermatitis might be expected'and is
,noted as occurring by Tarnoky (1980).
Studies of Nagase analbuminemic rats (NAR)
have also shown no severe pathological effects.
Plasma clearance of bilirubin is increased fourfold
over normal rats, due to a significant reduction in
serum binding capacity (Inoue, et al.., 1985).
Takikawa, et al.. (1985) have shown a marked decrease
in bile acid levels in NAR, the unbound fraction in
serum being ten fold greater than for normal Sprague
Dawley rats (SDR). This also suggests reduced serum
binding in the absence of albumin. Shiraishi, et al ,
(1984) have shown that serum zinc (which is normally 60%
bound to albumin) is unaffected in NAR. Hirate,et al..
(1984) studying the metabolism of 14c-salicyliC acid
showed that the distribution volume was three to four
times greater in NAR and implicated as the cause
the absence of albumin binding to control the free
drug concentration.
These results suggest that further studies
are needed to determine the consequences of analbuminemia
in drug clearance and metabolism of physiological
ligands; although there is no severe pathology apparent,
more subtle changes may be important in the administration
of drug therapies or the possibility of bilirubin toxicity
in the newborn. It is not known how well the NAR
condition reflects human analbuminemia and further studies
of human individuals with the condition is necessary
before a more conclusive understanding of the effects
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of the vastly reduced albumin levels can be attempted.
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CHAPTER TWO
AIMS OF THIS PROJECT
2.1 INTRODUCTION
The occurrence and properties of several
serum albumin variants have been studied in this
laboratory over a number of years. During this time
four albumin variants, all inherited and of the slow
type, have been found, their properties studied and
attempts made to purify the variant forms and specify
the pOints of mutation. Much of the earlier work has
been performed by two previous students and has been
reported in two theses [Au (1982) and Brand (1983)],
and briefly in three papers (Au, et aL., 1984a, bi and
Brand, et aZ., 1984). Details of the variants character-
ised are outlined below.
2.2 ALBUMIN WARWICK-1
Albumin Warwick-1 was found in a family of
Punjabi descent, and was first identified in a young
male with ulcerative colitis. Subsequent stUdies
revealed that another brother, a sister and the mother
of the first case were shown to carry two albumins but
not the father or the two other sisters. Purification
of the variant was carried out and two possible sites
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of mutation indicated by cyanogen bromide (CNBr)
cleavage, thought to be in residues 1-87 and 447-548.
A reduction in the binding of bilirubin was noted and
an isoelectric point (pI) of approximately 0.1 pH
units higher than normal was estimated for the
variant. It is a heat-stable monomeric variant
indistinguishable from albumin A by immunological
tests, with dye-binding properties similar to Albumin
Kashmir by the RBH schedule (Au, 1982).
2.3 ALBUMIN WARWICK-2
Albumin Warwick-2, which is a slow migrating
variant, was found in a heterozygous Indian woman
living in the Warwick locality. It has been shown to
have an amino acid substitution in the N-terminal
region, residues 1-87 but is not a proalbumin.
Albumin Warwick-2 is present in slightly less than 50%
of the total albumin in serum and has a pI value of
~5.01, compared to 4.9 for normal albumin. It has
normal palmitate, Cull and NiII binding but has
reduced bilirubin binding. Its dye binding properties
have also been ascertained. It is a heat stable
monomer.
3.4 ALBUMIN REDHILL
Albumin Redhill was discovered in a
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Caucasian mother and her son from Redhill, Surrey.
Initial evidence suggested that this monomeric
variant might be a proalbumin, as the N-terminal amino acid
was shown to be arginine and not the aspartate of
normal albumin. However, limited tryptic digestion
gave an ambiguous result. The nickel and copper
binding of the variant was reduced and this also
suggested that a mutation had occurred in the N-terminus.
There might also be a mutation near the C-terminus,
in residues 503-585, possibly due to a short insertion
of 10-12 amino aCids which gave an increased molecular
weight on SDS PAGE. The pI value of Albumin Redhill
was shown to be 4.75 compared to ~ 4.9 for normal
albumin and was indistinguishable from albumin A by
immunological tests. It is a heat-stable variant
(Brand, et al., 1984).
2.5 ALBUMIN CARLISLE
This variant was reported to our laboratory in
Spring 1984, having been discovered by Dr. C. Lord
of the Department of Pathology at the Cumberland Infirmary,
Carlisle. Albumin Carlisle was first found in August
1983 in a 36-year old Caucasian woman of British
descent who had presented with slight weakness and
aching in the left leg. Nine months previously she
had a short-lived rash diagnosed as chickenpox
(Variocella) associated with the sudden onset of
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weakness first in the left leg and later in the left
arm; some numbness of the left side of the face, and
reduction of sensation in the left arm and leg were
also noted at that time. These abnormalities had
resolved slowly and no unusual symptoms were noted on
presentation. In the past, she had required emergency
surgery for ruptured ectopic pregnancy. Haematological,
thyroid, renal and liver tests all gave normal results.
However, bisalbuminemia was noted in the serum with
a slow variant, visible after cellulose acetate
electrophoresis of serum.
Familial studies showed that the bisalbuminemia
was present in the youngest daughter (7 years old) and
16 years old son of the index patient but not in the
other two daughters (17 and 11 years old). The
mother and one brother of the index patient also had
bisalbuminemia, although other members of the family
were not studied (see Fig. 2.1). Two of the index
patient's offspring had suffered with childhood
eczema.
2.6 OBJECTIVES OF THIS PROJECT
The objectives of this study are outlined
below.
(a) The establishment of a high yield
purification process forthe isolation of
albumin variants.
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Fig. 2.1 Family tree of the family with
Albumin Carlisle showing inheritance
of the variant through three
generations.
(b) The purification and N-terminal sequence
of Albumin Redhill in order to elucidate
the point of mutation, and further study
the decreased affinity of the Nickel and
copper binding site.
(c) The characterisation of the new albumin variant,
Albumin Carlisle, isolation of the variant
albumin and studies of the possible pOint
of mutation.
(d) The comparative analysis of the binding
to the variant albumin of a number of
ligands.
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2.7 EXPERIMENTAL
The experimental work is divided into several
sections.
(i) The initial classification of Albumin Carlisle,
its isoelectric pOint, thermal and freezing stability
and immunological character were deduced.
(ii) Various methodologies were employed to
isolate the albumins from serum and purify them to
homogeneity in order to obtain pure variant albumin
Carlisle.
(iii) Albumin Redhill was purified from double
albumin in a similar manner to Albumin Carlisle and
the isolated Albumin Redhill was used to obtain an
N-terminal sequence of the variant albumin.
(iv) Peptide mapping was performed by both
proteolytic and chemical methods in order to locate
regions of mutation in Albumin Carlisle.
Cv) Ligand binding studies were performed in
order to qualitatively compare the affinity of normal
and variant albumins to a range of ligands.
Each of these steps will be considered
individually and the results of each section recorded
and conclusions presented from the research performed.
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CHAPTER THREE
THE CHARACTERISATION OF ALBUMIN CARLISLE
3.1 INTRODUCTION
Albumin Carlisle was first discovered in
1984 as previously mentioned and studies commenced
upon it in this laboratory in April of that year. The
initial step was to quantify its electrophoretic
behaviour and dye binding properties and to establish
the other criteria drawn-up for the characterisation
of albumin variants as described in Section 1.4.6.2.
The following is a list of the stages in this
characterisation:
(a) Estimation of the total protein concentration of
the serum.
(b) Estimation of the total albumin concentration of
the serum.
(c) Qualification of the electrophoretic mobility
of the albumin variant on the five media of
RBH schedule.
(d) Estimation of the ligand-binding properties of
the normal and variant albumins using the RBH
schedule.
te) Determination of the relative proportions of
normal to variant albumins in the serum.
(f) Determination of the stability of the variant
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with respect to repeated freeze-thawing.
(g) Determination of the thermal stability of the
variant albumin.
(h) Elucidation of the molecular weight of the
variant albumin.
(i) Identification of any proalbumin variant by
limited tryptic digest.
(j) Calculation of the isoelectric point (pI) of
the variant albumin.
(k) Determination of the inununological identity of
the variant albumin.
The third and fourth criteria were carried
out by Dr. A. L. Tarnoky and Mrs. J. V. Curnow of
the Royal Berkshire Hospital, Reading.
3.2 EXPERIMENTAL
3.2.1 Materials
A list of the special chemicals is given
in Appendix I. All other chemicals were freely obtain-
able and were of the highest quality available and used
without further purification.
3.2.2 Determination of Total Protein in Serum
The total protein content of a known vOlume
of serum was determined by the Biuret method (Gornall,
et at., 1949).
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3.2.2.1 Biuret Reagent
The Biuret reagent consisted of copper
sulphate pentahydrate (1.5 g), sodium potassium
tartrate tetrahydrate (6.0 g), sodium hydroxide
(10% w/v, 300 ml) and potassium iodide (1.0 g) made
up to one litre with double distilled water. A
plastic bottle was used to store the reagent in which
it was stable indefinitely provided no red or black
preCipitate formed.
3.2.2.2 Standard Albumin Solutions
Human serum albumin was used as received and
a concentration of 0-14 mg used to construct a standard
curve, each sample being made up to a final volume of
1 ml in distilled water. Aliquots (4 ml) of the Biuret
reagent were added with vortexing to the range of
standards in duplicate and the absorbances at 540 nrn
were read after leaving the tubes to stand 30 minutes
to allow stabilisation of the colour formation. The 540nm.
absorbance was plotted against known albumin
.
concentration, determined spectrophotometrically from the
1%absorbance at 280 nrnusing E280 nm = 5.31 (Hunter and
McDuffie, 1959).
3.2.2.3 Preparation of the Serum Samples
Sera were defatted essentially by the method
of McFarlane (1942) except that sera (diluted 1:20 in
water) was extracted with ether at room temperature and
then centrifuged, the resultant organic phase being
discarded, and the aqueous phase (l ml) used for the
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Biuret assay, as with the standard solutions above.
3.2.3 Determination of Total Albumin in Serum
The total albumin concentration of serum was
determined by the bromocresol green binding assay
(Doumas, et al., 1971, Gustaffson, 1976). The
reagent dye consisted of bromocresol green (0.15 mM),
sodium succinate (75 mM), 'Brij 35' surfactant (30%
w/v, 4 ml) per litre pH 4.2 ± 0.05 with NaOH. Reagent
(2 ml) was added to serum (l0 u l.) or HSA standard
solutions callibrated by absorbance at 280 rum. The
solution was vortexed briefly and the absorbance read
at 629 nm after 10 seconds and at 10 second intervals
thereafter for 2-3 minutes. From these values the
absorbance at time zero could be extrapolated for
each of a range of albumin concentrations ranging from
1-10 g/dL, and a standard curve constructed from which
to extrapolate the concentration of albumin in the
serum samples.
3.2.4 Electrophoretic Mobility by the RBH Schedule
The system of the Royal Berkshire Hospital
(RBH) laboratory (TaTnoky, 1980) comparing the
mobility of albumin variants on five media was employed
(electrophoresis on filter paper was omitted). The
details of the electrophoretic conditions are given
in Table 3.1. The systems used for Albumin Carlisle
were cellulose acetate (two different media), agar,
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agarose and disc PAGE. Staining was with Ponceau S
(0.2% w/v) in TCA (3% w/v) and destaining in acetic
acid (7% v/v).
3.2.5 Ligand Binding by the RBH Schedule
Ligand binding was approximated for five
dyes, bromocresol green, Ponceau S, Congo Red, bromo-
phenol blue and bilirubin. Incubation of the ligand
(0.05% »r/v', 50 ).11) with serum (100 u l.) in a 2:1 molar
excess of dye:albumin for ten minutes at 37°C was
followed by analysis by the electrophoretic means
already used to quantify mobility. The only exception
was that for disc PAGE, serum-sucrose solution (0.3 ml)
was incubated with each of the dye solutions (50 ).11)
and the total volume loaded over the spacer gel.
At the end of each run qualitative estimation
of the amount of ligand bound was made by eye and the
positions of the albumin bands and any unbound ligand
noted, and compared to the results after staining
and destaining which were as described in Section 3.2.4.
3.2.6 Ratios of Normal and Variant Albumins
in Serum
The albumins were separated by cellulose
acetate electrophoresis in barbitone buffer (0.075 M,
pH a.6) at a v/cm until the marker dye had nearly
eluted. The strip was stained using Ponseau S
[(0.9 g) in TeA (13.4 g), sulphosalicyl1c acid (13.4 g)
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per litre of water] for 10-20 minutes and destained
in acetic acid (5% v/v), and rinsed with water to
remove the acid. The normal and variant bands were
individually excised and the dye eluted using NaOH
(0.4 M, 1 ml) with agitation for several hours. The
red colour was restored by addition of acetic acid
(40% v/v, 100 ~l) and the fragments of cellulose
acetate removed by centrifugation. The absorbance of the
supernatant was measured at 512 nrnagainst a reference
solution of 5% acetic acid and the ratio of normal to
variant albumin estimated from the relative absorbances.
3.2.7 Stability to Freeze-Thawing (Izquierdo,
et aL, 1971)
In order to determine the stability of the
variant albumin to freeze-thawing,aliquots (20 ~l)
were twice frozen to -20oC for several hours and thawed
to 370C for a similar period. Similar aliquots were
repeatedly frozen and thawed ten times during 6-8 hours
and further sampl~s were rapidly frozen and thawed 35
times over a period of several days.
Any effects upon the sera due to these
treatments were assessed by disc PAGE in 7.5% non-
denaturing gels with untreated normal and Carlisle
sera run for comparison (see Section 3.2.10).
3.2.8 Thermal Stability
Due to the thermal instability of some
variants (Arends, et aL., 1969) samples of Carlisle
sera were heated at 56°C for 30 minutes and 2 hours
and any effect on the albumins determined by cellulose
acetate electrophoresis.
3.2.9 Molecular Weight of the Variant Albumin
The molecular weight of the variant and
normal albumins were determined by SOS-PAGE using
purified, isolated double albumins from Carlisle sera
and also pooled normal and Carlisle sera. The
gel systems used were of two types;
(a) The discontinuous buffer system of Laemmli
(1970),employing a 12% separating gel (16 x 16 x 0.15 cm)
with tris-HCI (0.375 M), SOS (0.1% w/v), pH 8.85 (T =
12%, C = 2.6%) and a 3% stacking gel with tris-HCI
(0.125 M), SOS (0.1% w/v), pH 6.8. It was helpful to
include sucrose (40% w/v) in the stacking gel so as
to increase its mechanical strength. The electrophore-
sis buffer was tris (0.05 M), glycine (0.384 M), SOS
(0.1% w/v) with the pH corrected to 8.3 with HCl.
Samples for electrophoresis were boiled for 5 minutes
in loading buffer tris-HCl (0.0625 M), glycerol (10%
v/v), SOS (2% w/v), 2-mercaptoethanol (5% v/v),
bromophenol blue (0.01%) pH 6.8), and protein
equivalent to 10-20 ~g per sample well were loaded and
electrophoresis carried out at 50-60 V constant
voltage (C.V.) while the tracking dye focused in the
stacking gel followed by 100-120 V C.V. for the
remainder of the run or at 50 V C.V. overnight.
Electrophoresis was stopped when the tracking dye
had migrated to within 1 em of the bottom of the gel
and the gel was simultaneously fixed and stained in
PAGE Blue G-90 [(0.25% w/v) in methanol (45% v/v),
acetic acid (10% v/v)] overnight and destained in the
same concentrations of methanol/acetic acid at 400C
for one to two days with successive changes of the
destaining solution.
(b) A second gel system employed was that outlined
in the BDH booklet "Molecular weight markers for SDS-
PAGE (BDH Chemicals Ltd., Poole, U.K.) using a
similar buffer system but with a 5-20% gradient of
acrylamide.
Loading, running and staining conditions
were as for the 12% gels and in both systems
commercial HSA and molecular weight markers (12,300-
78,000) were used in order to estimate the molecular
weights of the samples under study.
3.2.10 Detection of Proalbumin by Limited ProteolYSiS
Albumin Carlisle serum was tested by the
procedure of Rousseaux, et aZ. (1982) in order to detect
any proalbumin. TPCK-treated trypsin was dissolved
in ammonium hydrogen carbonate (0.1 M) with calcium
chloride (0.1 mM) pH 8.0 at a concentration of 3 mg/ml.
Serum (60 ~l) was taken, trypsin (30 ~g, 10 ~l)
added to it and the digest incubated at 37oC,
'1 J
aliquots (20 ~l) being removed for analysis at
2 hours, 4 hours and finally 6 hours after addition
of the enzyme. Soyabean trypsin inhibitor (1.2 mg of
a 60 mg/ml solution in water) was'added to the
aliquots in order to stop further digestion and the
samples subsequently frozen at -20oC. Analysis of
the effects of proteolytic digestion was performed by
electrophoresis at two pH values. Electrophoresis
at pH 8.6 was performed in non-denaturing disc PAGE
(Davis, 1967) using a T = 7.5%, C = 2.6% separating
gel containing tris-HCl (0.375 M, pH 8.85) and a
3% stacking gel (0.125 M tris, pH 6.8) with a
reservoir buffer comprising tris-Hel (0.05 M) with
glycine (0.384 M), pH 8.3.
Aliquots of the digested serum samples (10 ~l)
were thawed and loading buffer (20 ~l, 40% w/v sucrose,
0.01% w/v bromophenol blue) added and the mixture briefly
vortexed before application to the gel. Electrophoresis
was performed at ~ 100 V C.V. until the bromophenol
blue had eluted. Staining and destaining were
essentially as described in Section 3.2.9.
Electrophoresis at pH 5.0 was performed on
cellulose acetate strips (150 x 78 mm, 'Sartorious)
pr~equi11brated in sodium acetate buffer (0.031 M) with
EDTA (4 mM (pH 5.0) by soaking and blotting off the
excess buffer. Serum samples (10 ~l aliquots) were
diluted with loading buffer {20 ~U as before and applied
using a rnicrosyringe around 2 cm from the cathode.
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Electrophoresis was carried out in the sodium acetate
buffer for 6.5 hours at 14 'Vcm and the strip
subsequently stained in Amido Black lOB/methanol/
acetic acid (1:90:10 v/v/v) overnight and destained in
methanol:acetic acid (9:1 v/v) for several hours with
repeated changes of destaining solution (Fine, et aZ.,
1983) .
In both systems undigested normal serum and
Carlisle serum,containing both albumins, were used as
controls, together with commercial HSA, purified double
Albumin Redhill, trypsin and trypsin inhibitor, also
run for comparison.
3.2.11 Determination of Isoelectric Point (pI)
of Variant Albumin
Purified albumin Carlisle and double
albumin were analysed together with commercial HSA
using both isoelectric focusing gel rods in the pH
interval 4-6.5 and pre-cast thin layer gel slabs in
the pH internal 3.5-9.5. In both systems the pH
gradient in the gel was determined by means of pI
standard markers.
3.2.11.1 .1 Isoelectric Focusing {lEF} in Thin
Layer Polyacrylamide Gel Slabs
(T = 5%, C = 3% )
Pre-cast slabs were a gift from LKB and
contained ampholyte in the range pH 3.5 to 9.5. The
experimental details were basically as outlined in the
LKB booklet number 1804 accompanying the gels and
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as described in the LKB application note 250 "Analytical
Electrofocusing in Thin Layers of Polyacrylamide Gels".
The pre-cast gel was unwrapped and placed upon the
water-cooled platten of an LKB 2117 Multiphor
apparatus, using a small amount of liquid paraffin to
ensure good contact and taking care to eliminate air
-bubbles. The appropriate electrolyte solutions were
made up (see Table 3.2. ) and absorbent wicks,
cut to size so as to be slightly shorter than the gel
widt~ were soaked in the electrolytes, with slight
swelling, and blotted on filter paper to remove
excess fluid. The strips were then applied on to the
gel in line with the Multiphor electrodes. An initial
experiment was performed across the width of half a
gel and a subsequent experiment was carried out across
the length of another gel.
pH Range Anolyte (+) Catholyte (-)
3.5-9.5 H3P04 (0.1 M) NaOH (l .OM)
4-6.5 COL) glutamic acid L-histidine
(0.01 M) (0.01 M)
Table 3.2 Electrolyte solutions for IEF experiments.
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3.2.11.1.2 Preparation of Samples
Samples of normal albumin, Albumin
Carlisle, and double Albumin Carlisle were dissolved
in distilled water, and were defatted by the method of
Chen (1967). Aliquots of each sample (~ 10 ~g) were
absorbed onto small pieces of Whatman 3 MM filter paper
(1 x 0.5 cm) and placed onto the gel surface positioned
about 3 cm from the cathode according to the grid guide-
line situated beneath the gel, so as to ensure no
overlapping of the tracks occurred on electrophoresis.
The exact position of the sample origin on the gel is
unimportant as the proteins will migrate in the
ampholyte gradient to their isoelectric point irrespectively
providing the gel is runfur sufficient time. A vial of pI
marker proteins (Pharmacia) were reconstituted according
to the manufacturer's instructions and loaded either
side of the albumin samples.
3.2.11.1.3 Electrophoresis, Staining and Destaining
The samples having been applied using the filter
paper strip, the lid of the apparatus was put in place
and the electrophoresis commenced using an LKB 2197
constant power unit set at the following conditions;
Across the width of the gel: 600 V
max. voltage, 20 rnA max. current, 10 W maximum power.
The electrofocusing was performed for 5~ hours, with
cooling by a continuous flow of water through the platten.
Across the length of the gel: electro-
phoresiswascarried out as above, but for a total of
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5250 volt hours (5 hours at 600 V and 3 hours at
750 V).
All sample applicator strips were removed
after ~-1 hour when the pH gradient was deemed to have
formed and the samples had migrated into the gel. Once
electrophoresis was completed, the gels were removed from
the apparatus and,still supported on their thin plastic
backsheet,were fixed in trichloro-acetic acid w/v (TCA)
U1.5% w/v),sulphosalicylic acid (3.45% w/v), in
distilled water for 0.5-1 hour, and then briefly soaked
in destaining solution (ethanol 25% v/v, acetic acid 8%
v/v in distilled water) in order to remove the unfixed
ampholyte molecules from the gel before staining. The
gels were stained in PAGE Blue G-90 (0.460 g in 400 ml
destaining solution) for ten minutes or so at 60oC,
and subsequently destained in the destaining solution
for several hours with changes of buffer until the
background was clear.
3.2.11.2 Isoelectric Focusing in polyacrylamide
Gel Rods (T = 5%, C = 3%)
Isoelectric focusing was performed on
double and normal albumins by electrophoresis in
polyacrylamide gel rods (9 x 0.8 cm i.d.) which
contained Pharmalyte in the pH range 4-6.5 according
to the details outlined in "Isoelectric Focusing,
Principles and Methods" from Pharmacia Fine Chemicals
(Milton Keynes, U.K.). The glass rods were cleaned
thoroughly and sealed at one end with Parafilm.
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Acrylamide gels (T = 5%, C = 3%) containing 13.3% v/v
glycerol and 6.3% v/v Pharmalyte were cast into the
glass rods and the rods placed into the gel rod
apparatus, the electrolyte buffers being as stated in
Table 3.2.
Samples of albumin were dissolved in a 1:15
solution of Pharmalyte (of the same interval as in the
gel) in water containing sucrose (15%. w/v) and a
trace amount of methyl red in order to follow the course
of the electrophoresis. Loads equivalent to 5-10 ~g
protein per band were added and electrophoresis carried
out at 500 V max. voltage, 6 rnA max. current for seven
hours, until the current was negligible.
The gels were carefully excised from the glass
tubes and fixed in trichloroacetic acid (11.5% w/v)
sulphosalicylic acid (3.45 w/v) in methanol:water
(3:7 v/v) for one hour and then stained overnight in
PAGE Blue G-90 (0.115 g in methanol (500 ml), acetic acid
(160 ml) diluted to 2 L in water). Destaining was in
repeated changes of the same solution, but without the
dye, until a clear background was obtained.
The migration of proteins of known pI contained
in the Pharmacia low pI calibration kit was used to
calibrate the pH gradient in the gel rods as before,
a vial was resuspended in the Pharmalyte/sllcrose
loading solution (100 ~l) and aliquots (50 ~l) loaded
onto the surface of the appropriate gels. The migration
distances were plotted against the tabulated pI values
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(see Table 3.3) and the pI of the albumin samples
extrapolated from the resultant graph.
Protein pP (240 C ± 1.50C)
pepsinogen 2.80
amyloglucosidase 3.50
methyl red (dyer" 3.75
glucose oxidase 4.15
soybean trypsin inhibitor 4.55
13-lactoglobulin A 5.20
bovine carbonic anhydrase B 5.85
human carbonic anhydrase B 6.55
". Methyl red is a dye and does not appear in final stained gel.
Table 3.3 List of pI marker standards used to
calibrate pH gradient in IEF.
3.2.12 Determination of Immunological Identity
Albumin Carlisle was compared to normal
albumin by two iMmunological ~ethods: by the double
"immunodiffusion procedure of Cuchterlony(1949) and
by immunoelectrophoresis: using goat anti-human
albumin A antibodies (3.5 mg/ml) in both processes.
"3.2.12.1 Ouchterlony Double Immunodiffusion
3.2.12.1.1 Preparation of Agar Gel (Clausen, 1981)
Agar Noble (electrophoretic grade)
was used as received and dissolved with heating at
a 1.5% concentration in aqueous NaCl (0.83% w/v),
'IU4-
sodium azide (0.1% w/v). The agar solution was boiled
at 1000C for 40 minutes with the flask loosely stoppered
by an inverted beaker to prevent excess evaporation.
Microscope slides were washed with alcohol
and then diethyl ether and then covered with the molten
agar solution (~ 3 ml) using a pipette, and the agar allowed
to set at room temperature. Wells (approximate volume
10 ~l) were punched into the agar with a truncated
Pasteur pipette using a template so that eight wells
were cut out at a (8.5 cm) radius around a central
well~ the agar being sucked out under vacuum by
attaching the pipette to a water pump. The plates were
kept at a constant humidity in petri dishes containing
a moist piece of filter paper and the plates stored at
40C until use.
3.2.12.1.2 Determination of a Balanced Immunological
System
Initial experiments were performed to
ascertain a balanced proportion of antigen and
antibody which gave a strong precipitin line without
artefactual spurs. Two trials were set up:
A fixed quantity of antigen diffusing
against a series of antibody dilutions
Pure albumin A (10 ~l, 1 mg/ml) or pure
albumin Carlisle (10 ~l, Img/ml) was applied to the
(1)
central well of an agar plate and antiserum, diluted
in the ratios, undiluted, 1:1, 1:2, 1:3, 1:4, 1:5,
1:10, and 1:15 with water, was applied in 10 ~l
aliquots to the surrounding wells using a microsyringe.
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The slides were replaced in a Petri dish humidity
chamber and diffusion allowed to occur for 16 hours
at 4oC.
(ii) A fixed quantity of antibody diffusing
against a series of antigen dilutions
Undiluted antiserum (10 ~l) was applied to the
central well of another agar plate and pure albumin A
or pure Albumin Carlisle (1 mg/ml), diluted with water
in the same ratios as above, was applied to the
surrounding wells, and diffusion performed as above.
3.2.12.1.3 Gel Staining
The gels were washed for 24 hours after
the diffusion was completed using phosphate buffered saline
(0.05 M disodium hydrogen phosphate pH 7.0 with NaCI
(0.8 w/v) to remove unreacted antigen and antibody.
The agar was washed free of the salts with distilled
water for several hours and then stained with Amido
Black lOB {0.1% w/v in acetic acid (S.4% v/v),
sodium acetate (6.72% w/v), glycerol (1% v/v» for
10 minutes and destained in acetic acid (5% v/v) for
several hours. Gels could be dried by careful
blotting with filter paper (Whatrnannumber 542) or
by leaving open to the air at room temperature for
two days.
3.2.12.1.4 Inttnunodiffusionof Albumin Carlisle
A balanced immunological system having
been determined for normal albumin and Albumin Carlisle,
this ratio was used to set up a further experiment
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where normal albumin, Albumin Carlisle, and albumin A
isolated from Carlisle serum were applied undiluted
as 1 mg/ml solutions to wells surrounding undiluted
anti-albumin A antiserum (10 ~l), and also in a
second experiment where the albumin A was diluted 1:1
with distilled water. Diffusion and subsequent
washing, staining and destaining were as described
previously (Section 3.2.12.2 and 3.2.12.3).
3.2.12.2 Immunoelectrophoresis (Scheidegger, 1955)
3.2.12.2.1 Preparation of the Agar Gel (Clausen, 1981)
Agar Noble (electrophoresis grade, 1% w/v) was
dissolved in sodium veronal-HCI buffer (0.05 M, pH 8.4)
containing sodium azide (O.1% w/v) by heating at 100oC,
again loosely covering the mouth of the conical flask
to prevent evaporation. Alcohol-washed microscope
slides were covered with the molten buffered agar
(2-3 ml) and the agar allowed to set. Two wells were
cut in parallel approximately 2 cm from the one end of
the slide and one filled with Carlisle serum (2 ~l)
and the other with normal pooled serum (2 ~l).
3.2.12.2.2 ImmUnoelectrophoresis in the Agar Gel
The agar plate was placed in a Shandon
cellulose acetate electrophoresis apparatus with
filter paper wicks (Whatman number 1) positioned on
either side and electrophoresis carried out longitudinally
in sodium veronal-HCl buffer (O.OS M pH 8.4) at 80 V
C.V. for 3~ hours. The slide was removed from the
apparatus, a narrow longitudinal channel cut equidistant
'j 0'/
between the two sample wells with a scalpel and the
agar strip removed. Antiserum (40 ~l) was spread
equally along the channel and immunodiffusion proceeded
for 16 hours at 40C in a Petri dish humidity chamber.
The gel was washed and the immunoprecipitation
lines stained using the method previously described
(Section 3.2.12.1.3). A second gel was run in parallel
up to the end of the electrophoresis step and then
stained to show the extent of the separation of the
normal and variant albumins before the immunodiffusion
was performed.
3.3 RESULTS AND DISCUSSION
The serum of the mother who carried the
Carlisle variant as well as normal albumin was used
in the tests described in Section 3.2. The total protein
concentration in her blood was estimated by the Biuret
method to be 59 giL by interpolation from the graph of
the standard curve (Fig. 3.1). Evaluation by the RBH
schedule gave a total protein concentration of 80 giL.
Serum protein levels may vary with disease and other
nutritional factors and this may explain the discrepancy
in these values which were taken over a six month
period. The nature of the bisalbuminemia remained
unaltered over this period. The normal range of total
serum protein is 60-80 giL and so Albumin Carlisle
serum does not significantly differ from normal serum
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in this respect.
The total albumin level for the serum of the
mother with Albumin Carlisle was estimated by the
bromocresol green method to be 47-50 giL (80% of
the total protein) derived from the values of the con-
structed standard curve (see Fig. 3.2). The level in
the initial sample of the maternal serum received six
months earlier had been higher <.53-59giL) possibly
due to the effects of the recent illness. By the
densiometric scanning of serum samples of the maternal
serum, the RBH test schedule estimated the total albumin
concentration to be 66-74% of total protein, dependent
on different electrophoretic conditions. It may be
that the bromocresol green method had over-estimated
the actual albumin concentration, which would explain
the discrepancy between these two methods, or than
the densiometric scanning had overlooked minor protein
constituents. The son and daughter of the patient had
serum albumin levels of 35-38 giL and 46-49 giL
respectively, the levels being lower as might be expected
in children. However, the level in the son is low
compared to the average value of 40 + 5 giL, and it may
be related to some medical condition or illness at the
time the sample was given.
The electrophoretic mobility of Albumin
Carlisle using the RBH schedule is given in Table 3.4.
The mObility of Albumin Carlisle is compared to that
of 12 other slow variants reported using the RBH test
TABLE 3.4 RELATIVE MOBILITIES OF ALBUMIN VARIANTS
'1"11
Albumin Variant C.A. Helena Disc New Agar Agarose
Carlisle 84 95-89'-10090:100
90:100
Redhill
(Brand 1983)
Incomplete
Separation
,
94 97
-96:-100
84 92
-91'-100
Incomplete
Separation
85 94
-91:-100Warwick-l(Au 1982)
90:100 93:100 82 93-92: 100
84 94
-90:100Warwick-2(Brand 1983)
88:100 91 :100 82 94
-91'-100
78 89
-87: 100
81- 90,S
89,5:-100Vancouver(Frohlich,
et al.;, 1978)
89,5:100 89,5:100 84,5 94
-93:-100
92:100
Jaffna (Bayliss
et al.. 1983)
94:100 88:100 88_91:100
85-93: 100
84 91
-89:-100Stirling(Curnow, et al. ,
1978)
89:100 89- 96-
94 :100
86 92
-90'-100
85 92
-89'-100
Yorkshire
(Curnow, et al-, ,
1978)
90:100 89 95-
-94:100
86 94
-92'-100
84 95
-93'-100
83 93
-89'-100
RIH (Chapman,
et al., 1978)
91:100 87.5,96
-92'-100
86 92
-92'-100
81 91
-90'-100
76 91
-85:-100Amsterdam(Sa .nders,
et al., 1979)
86:100 86 94
-92'-100
84 92-
-89: 100
71 88
-81'-100
Kashmir (from
H, Au, 1982)
90:100 93: 100 81 92 84 93,S-91 '-lOa -90.5:100
84 93
-90.5'-100Hussain (fromH. Au, 1982)
89: 100 92: 100
94:100Birmingham 92:100
Bradwell, et al. ,
1975)
92: 100
*All distances expressed on a 0-100 scale where 0 is the cathodic
trailing edge of the protein pattern and 100 is the leading edge
of albumin A.
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previously. It can be seen that Albumin Carlisle has
a unique electrophoretic profile, although it appears
most similar to Albumins Warwick-2 and Kashmir, both
of which are of Asian origin. The other European variants
compared, Albumins RIH, Yorkshire, Amsterdam, Stirling,
and Redhill, differed in their electrophoretic profile
in most of the systems used. No direct comparison
with albumin B was possible but Tarnoky made no indication
that Albumin Carlisle was identical to any variant
in his collection.
Albumin Carlisle is different to the three
albumin variants previously studied in this laboratory,
being slower than Albumin Redhill (see Fig. 3.3) and less
slow than Albumin Warwick-2. Albumin Warwick-l was of
similar mobility on cellulose acetate, agar and agarose
but comparison of sera of the two variants on disc PAGE
indicated that both albumin bands on Warwick-l migrated
further than the equivalent bands in Albumin Carlisle
sera and were broade~ suggesting that the similarities may
be due to the poorer resolving powers of the previous
media.
The qualitative ligand binding studies on
Albumin Carlisle from serum suggests (Table 3.5) that
Albumin Carlisle binds less bromophenol blue than normal
albumin in all the media tested and that its binding of
Ponceau S might be reduced also. The binding of
bromocresol green differed only in the disc PAGE system
and the binding of Congo Red may also be slightly less
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than that of albumin A from the same serum. The binding of
bilirubin is less for Albumin Carlisle in both agar and
agarose systems; ligand streaming ahead to the anode
was observed for both bilirubin and Congo Red on disc
PAGE. This has been interpreted by Tarnoky as being due to
reduced binding by the variant. However, Wieme, et al.
(1975)have criticised this method as previously recorded
in Section 1.4.7.2.3 and so whether this evidence
represents real differences at the molecular level is
open to question. However, the initial appearance of the
serum of Albumin Carlisle was intensely yellow, which
might indicate excessive levels of free bilirubin due
to reduced binding to albumin.
On comparison of the binding displayed by
Albumin Carlisle to that of other variants studied in
this laboratory and other variants for which data is
recorded, it was found (Table 3.6) that Albumin
Carlisle was most similar in its dye binding to
Albumin Amsterdam and Albumin Warwick-2. There are
differences even between these variants, however,
especially in the binding in different media.
Albumin Carlisle is quite dissimilar to Albumin Redhill,
or Albumins Stirling and Yorkshire, all British
variants.
It would seem that Albumin Carlisle is
different to those variants already classified by the
RBH schedule in electrophoretic mobility and dye
binding, and these differences may be due to changes
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at the amino acid level.
The ratio of variant to normal albumin in
the Carlisle serum was derived from the relative
ratios of eluted Ponceau S to be within experimental
error 1:1 (48:52) variant:normal and the data from
the RBH tests support this finding.
Albumin Carlisle was unaffected by repeated
freeze-thawing of serum over 30 times, no significant
difference being visible on electrophoresis. This was
confirmed by Tarnoky and Curnow (private communication
to Dr. D. W. Hutchinson), and they also reported
Albumin Carlisle to be stable to heating at 560C
for two hours. No change in the electrophoretic
properties of Albumin Carlisle was noted over eighteen
months of storage at -20oC. It therefore would seem
unlikely that Albumin Carlisle is a transient or
dimeric variant, as these have been found to be unstable
under these conditions (see Section 1.4.6.2).
The molecular weight of Albumin Carlisle
by SDS PAGE was indistinguishable from that of normal
albumin (~65,000) using double Albumin Carlisle in serum
and purified double Albumin Carlisle (10 ~g) in both
12% SDS PAGE and 5-20% gradient SDS PAGE. An extra
band was detected on some gels with increased loading
but was absent at lower concentrations on the same
gel. It can be inferred that Albumin Carlisle is
a monomeric variant essentially of the same molecular
weight as HSA.
I ';/
Limited proteolysis with trypsin gave no
apparent difference in the electrophoretic pattern of
Albumin Carlisle, at pH 5.0 or 8.6.Although anodic
bands were present ahead of the albumin, they were
identified as being due to the excess trypsin inhibitor.
The relative ratios of variant and normal albumins was
unaltered by tryptic digestion when compared to
untreated normal and Carlisle sera (see Fig. 3.3).
This suggests that Albumin Carlisle is not a proalbumin
variant as it has no trypsin cleavable propeptide.
ALBUMIN
-=a- CARLISLE
-ALBUMIN A
+
II In IV V VI VII VJIl'
Fig. 3.3 Limited tryptic digestion of double Albumin
Carlisle in serum. Analytical disc-PAGE of
two (v), four (iv) and six hour (iii) tryptic
digestions of Carlisle serum was carried out.
HSA (i), normal serum (vli),double Albumin
Redhill (ii), Carlisle serum (vi) and trypsin
inhibitor (viii) were run for comparison.
l18
The isoelectric point (pI) of Albumin
Carlisle was determined to be 5.74 for defatted albumin
compared to 5.63 for normal albumin on a long isoelectric
focusing gel slab, and 4.75 compared to 4.45 for HSA
when run widthways, both in the pH 3.5-9.5 range.
Isoelectric focusing in the narrow pH range 4-6.5
in gel rods gave the pI value of 5.8 for double
Carlisle, 5.4 for HSA but 5.26 for purified abnormal
albumin. The higher pI value is consistent with the
elution profile of Albumin Carlisle on chromatofocusing
and so it can only be assumed that the lower value is
due to the presence of bound ligand reducing the pI of
the albumin. It may be possible that some of the
Polybuffer used in chromatofocusing (see Section 4.4.2.2.1)
was still attached to the albumin, despite attempts to
remove it.
Normal albumin has been shown to be extensively
heterogeneous on isoelectric focusing (Gianazza,et al.,
1984 and Candiano, et al., 1984) and this is probably
due to endogenous ligands still being bound as defatted
HSA has a pI ~ 5.7 but native albumin one ~ 4.7 due to
the presence of fatty acids and bilirubin •. Brand (1983)
reported a low pI band (4.65) in all normal and variant
albumin samples electrofocused on the pH range 4-6.5.
In the present experiments, thin layer IEF
revealed 6-7 bands in the defatted commercial albumin
(some presumably being due to dimeric forms) and 3-4
bands in the defatted pure Carlisle although most
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of these were comparatively minor components. Less
heterogeneity was noticed in the rod gels due to their
lower sensitivity.
From the results obtained on Albumin Carlisle
it would appear that it has an isoelectric point 0.1 to
0.3 pH units higher than albumin A.
Albumin Carlisle and normal HSA were reacted with
anti-human antibodies raised in goat sera. From trial
studies to establish a balanced immunological system,
dilutions of antibody gave strong preciptin lines
at dilutions to 1:2 antibody:water for pure Carlisle
and to 1:3 for commercial HSA. Subsequently, a system
with undiluted antibody and Albumin Carlisle solution
(1 mg/ml) but with both undiluted and diluted (1:1)
commercial HSA solution was implemented for the
immunodiffusion experiment. Pure Albumin Carlisle,
commercial HSA and albumin A from Carlisle sera
(stock solutions of 1 mg/ml) were cross-reacted with
undiluted anti-albumin antiserum (Fig. 3.4). The
precipitin line obtained was continuous for HSA and
for Albumin Carlisle indicating overall antigenic
identity. The preparation of albumin A from Carlisle
serum gave slightly ambiguous results possibly due
to contaminants remaining from the purification
process. Slight differences in the distance between
the central well and the precipitin line are most
likely due to inaccuracies caused by using a manual
procedure to cut the wells and do not seem to indicate
a significant immunological trend.
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Fig. 3.4 Double immunodiffusion of Albumin Carlisle
and albumin A. Undiluted anti~alburnin A
antibody was added to the central wells,
HSA was added to the outside wells S~8 (1 mg/ml)
and B-E (0.5 mg/ml), Albumin Carlisle to wells
2-4 and F-H (1 mg/mll and Carlisle serum normal
albumin to wells 1 and A (1 mg/ml) .
Immunoelectrophoresis of Carlisle serum
containing variant and normal albumins supported the
conclusion that Albumin Carlisle is antigenically
indistinguishable from albumin A. Both proteins, after
separation by electrophoresis, reacted to the
anti-albumin antibody and gave an elongated precipitin
arc which encompassed both albumin bands, other
non-antigenically identical proteins having been
washed out of the gel during staining (Fig. 3.5).
No appreciable spur formation was seen in the arc
which could have indicated small degrees of antigenic
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difference, although this does not mean that all the
antigenic sites are necessarily identical in the
variant albumin. Doyen, et aL. (1985) have proposed
thirteen different epitopes on normal albumin using
monoclonal antibodies raised against albumin polypeptide
fragments. It has been noted in Section 1.4.4 that
it is possible to distinguish some albumin variants by
use of monoclonal antibodies and such studies if
applied to Albumin Carlisle might show small differences
in its antigenic determinants not detectable with the
polyclonal antibodies used in these experiments.
A
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Origin
Fig. 3.5
+
Immunoelectrophoresis of normal (i) and
Carlisle (ii) sera; (a) after electroohoresis
only (A) and after subsequent immunodiffusion
(:8 ) •
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3.4 SUMMARY
Albumin Carlisle appears to be a heat
stable monomeric slow (cathodic) variant with
unique electrophoretic properties as far as can be
ascertained. It is inherited in the two offspring of
the initial carrier and appears to be antigenically
indistinguishable from normal albumin. Albumin Carlisle
has an isoelectric point (pI) at approximately 5.74
compared to normal albumin (5.63) and this is consistent
with it being more cathodic on electrophoresis. Levels
of the albumin in serum indicate that it contributes just
under half of the total albumin and the total levels
are within the normal range. Albumin Carlisle may have
slightly decreased affinity for bilirubin and Congo
Red, possibly caused by some mutation in the polypeptide
chain. However, Albumin Carlisle does not appear to be
a proalbumin variant.
CHAPTER FOUR
PURIFICATION OF ALBUMIN VARIANTS
4.1.1 Introduction
The properties of normal albumin and variant
albumins are for the most part very similar; molecular
weight and antigenicity, for example, vary little if
at all. There are three possible properties where
the differences, caused mostly by a single amino acid
mutation, are sufficient to be utilised for
separating the albumin forms. These are:
(i) net charge (ion exchange chromatography and
preparative electrophoresis);
(ii) pI values (chromatofocusing and preparative
isoelectric focusing);
(iii) ligand binding (affinity chromatography).
This Chapter outlines the various
separative methods employed over a two year period
in order to obtain pure variant albumin from
Carlisle and Redhill sera.
4.1.2 Methods Used for Variant Purification
Methods which have previously been used
successfully to purify albumin variants are listed
in Table 4.1. The easiest approach is to screen
sufficient patients to locate an individual homozygous for
the variant albumin. Alloalbuminemia is generally
TAIlLS ·1. 1 METIIODS OF ALnU~Utl ISOLATION
Var ia ntMethod of Isolation
IL4
Author
Naskapi
Mi/Fg
Homozygote obtained
2 Ion Exchange Chromatograohy
(i) DEAE Se?hadex, sodium phosphate buffer
0.2 M pH 5.75
DEAE Se?hadex, ?hosphate buffer 0.1 M
pH 5.75
DEAE Sephadex, phosphate buffer 0.15 M
pH 5.75
DEAE Sephadex, phosphate buffer 0.15 M
pH 5.75'
DEAE Sephadex A50, sodium phosphate
buffer 0.4 M pH 5.75
(ii) DEAE Cellulose, phosphate buffer 0.02 M
pH 7.0 with 0-1 M NaCl gradient
3 Ion Exchange Chromatography with pH Gradient
(i) DEAE Sephadex ASO, sodium acetate buffer
25 mM pH 5.2 to 4.5
DEAE Sephadex A50, sodium acetate buffer
25 mM pH 5.2 to 4.5
(ii) DEAE Sepharose CL6B, sodium acetate
buffer 25 mM pH 5 to 4.65
(iii) QAE Sephadex A50, sodium acetate buffer
0.1 M pH 5.1 to 4.6
Preparative Electrophoresis
(1) Starch block electrophoresis, veronal
buffer 0.1 M pH 8.6
Agar electrophoresis, veronal buffer
0.1 M pH 8.8
Cellulose acetate electrophoresis,
tris veronal buffer 0.06 M pH 8.6
Agarose electrophoresis, barbital
buffer 0.02 M pH 8.6
PAGE
PAGE
PAGE
(H)
(iii)
(iv)
(v)
5 Chromatofocusing
(i) Start buffer; histidine HCI 25 mM pH 6.2
(ii) Eluting buffer; Polybuffer 74-HCl
(1:12 in water pH 4.0)
(some experiments with piperazine HCI
25 mM pH 5.5)
6 FPLC Chromatof0cusing
(i) Start buffer; piperazine-HCl (25 mM pH 6.3)
(ii) Eluting buffer; Polybuffer 74-HCl
(1:10 dilution in water pH 4.0)
Franklin e t: al. (1980b)
Vanzetti at al. (1979)
\Hnter c t: al. (1972) Oliphant/Ann Arbor
Ga Ll.La no ~L" al. (1984) Pollibauer
Lapresle (1977) Gainesville
Lapresle and \~al (1979) Penicillin transient
Rousseaux dt al. (976) Penicillin transient
Bradwell e t: al. (1975) Birmingham
Brennan and Carrell
(1978)
Brennan (1985)
Christchurch
Park lands
Walsh e t: al. (1983) IMVS
Bradley and Hornbeck
(1974)
Unnamed slow and
fast variant
Gitlin et al. (1961) B
Gentou and Plazzonet Unnamed variant
(1978)
Abdo et al. (1981) Lille
Bianchi dt al.(1974) Unnamed variant
Franklin et al. (1980a) Mexico-2
AU l?t: al. (1984) Warwick-1 and 2
Brand (1983) Redhill
Tiliyer et al. (1982)
TiUyer et al. (1984)
Brand et aL(l984)
Kashmir
Jaffna
Redhill
This work Redhill
Carlisle
U5
considered to be a co-dominant trait but its incidence
is still comparatively rare(l in 1,000 to 1 in 10,000
in Europeans) in most populations, so that this
solution to the problem of obtaining pure variant
albumin has been possible mainly for polymorphic
variants such as Albumins Naskapi (Franklin et al. ,
1980b) and Mexico-2 (Franklin et al., 1980a), although
the Italian variant Mi/Fg has also been found in a
homozygote condition (Vanzetti et al., 1979). In
the absence of homozygous individuals variants must
be purified from heterozygotes by either ion-exchange
chromatography, chromatofocusing or preparative
electrophoresis.
4.1. 3 Ion Exchange Chromatography
Ion exchange chromatography separates molecules
on the basis of differences in net charge and can
distinguish even small variations between proteins
such as albumin, which have a high negative charge at
near neutral pH and so bind tightly to anionic exchangers
such as DEAE (diethyl-amino-ethyl) and QAE (quaternary amino-
ethyl) Sephadex. Elution of bound protein can then be
achieved by raising the ionic strength of the eluant
until the proteins are desorbed. The degree of
separation possible with ion-exchange chromatography
is dependent primarily upon the differences in affinity
for the column matrix of the proteins to be separated.
Therefore albumins which differ substantially in their
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net charge from albumin A may well separate from it
on ion-exchange chromatography. An example of such
an albumin is the Ann Arbor/Oliphant variant (Winter,
et al., 1972) and also Albumins Gainesville (Lapresle,
1977) and Pollibauer (Galliano, et al., 1984). Two
penicilloylated transient variants are also
separable for normal albumin by this means (Table 4.1).
Albumin Birmingham was also separated on DEAE cellulose
by a fairly low salt concentration gradient (Bradwell,
et «i . 1975).
4.1. 4 Use of Ion Exchange Chromatography
with a pH Gradient
By using a pH gradient rather than a salt
gradient Brennanand Carrell (1978) separated
proalbumin Christchurch from albumin A in the sera of
a heterozygous patient. The gradient was formed from
two buffer reservoirs at the pH values of the two
extremes of pH and the underlying principle of the
technique is that at values above its pI a protein is
negatively charged and so is bound to the column but
that below its pI the protein is positively charged and
is desorbed from the column. The pH interval of the
gradient is chosen so as to encompass the pI values
of both albumins and elution should occur in the
order of decreasing pl. However, the pH gradient
formed in this manner is not entirely smooth.
This method has been successfully used to
isolate other variants including Albumins .Parklands
'I}_ 'J
(Brennan, 1985), IMVS (Walsh, et al. I 1983) and using
a QAE Sephadex exchanger for the separation of a fast
and slow variant by Bradley and Hornbeck (1974).
4.1. 5 Preparative Electrophoresis
Electrophoresis has been the main method used
for identifying albumin variants and as such it might
at first seem to be an ideal method for their isolation.
However, although some variants have been separated
in this way there are severe limitations. The maximum
loading of albumins is far lower than for chromatographic
methods (only 1-10 mg dependent on the type of
electrophoresis) and resolution is often lost when
scaling up to preparative systems, reducing the maximum
loading still further. Contaminants from the media may
also prove troublesome if the isolated protein is to be
used in other studies.
Some variants have been purified by this technique
including albumin B (Gitlin, et al., 1961) using starch
block electrophoresis, proalbumin Lille (Abdo, et al. ,
1981) using cellulose acetate electrophoresis and two
unnamed variants by agar and agarose electrophoresis
(Table 4.1) i all using veronal buffer. Preparative
polyacrylamide gel electrophoresis (prep-PAGE) has been
used by Franklin, et al. (1980a) to isolate the variant
fragment from Albumin Mexico-2 and in this laboratory
to isolate Albumins Warwick-1 and 2 and Albumin Redhill
(Au, 1982, Brand, 1983).
4.1. 6
4.1.6.1
Chromatofocusing
Introduction
Chromatofocusing is a relatively new technique
(Sluyterman, L. A. lE. and Elqersma, O. (1978».
Separation is achieved according to the isoelectric point
of the proteins to be separated and as such it has some
similarities to ion exchange chromatography with a
pH gradient (Section 4.1.4). However, the special
ion-exchange resins used in chromatofocusing (Polybuffer
Exchanger PBE94 and 118 (Pharmacia Ltd.,UK.) and the
elution media (Polybuffer 74 or 96) consist of a large
number of buffering species so as to give an even
buffering capacity over a wide pH range and so give a
smoother and more reliable pH gradient than is
possible using ion exchange chromatography.
The pH gradient is self-generating and so
the need for a gradient mixer with two solvent
reservoirs is eliminated. The exchangers have a
high capacity and the technique is simple to use:
theoretically bands of 0.05 pH units can be
generated and so the proteins are eluted in tightly
focused bands.
4.1.6.2 Principles of Operation
The pH interval of the experiment is chosen
so that the isoelectric pOints of the proteins to be
separated are mid-way between the two extremes of
pH, the actual range of the pH interval being as
narrow as possible so as to give maximal resolution.
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The PBE exchanger is equilibrated at a pH slightly
above the higher pH limit. A small volume (5-10 ml) of
Polybuffer, appropriately diluted and brought to the
~
value of the lower pH limit with HCI, is added so as
to commence gradient formation before the protein sample
is applied. After sample application, the column
is eluted with Polybuffer and the pH gradient formed
down the column until the bottom of the column is at the
same pH as that of the top. In order to prevent any
artefacts due to dissolved CO2 the buffers are all
thoroughly degassed before correcting pH and subsequent
use.
4.1.6.3 Protein Separation by Chromatofocusing
The protein is applied at a pH above its pI
and so is negatively charged and will be rapidly bound
to the exchanger. As the pH of their environment
decreases below the pI values of the protein components
they become positively charged and are desorbed and
migrate down the column until they are reabsorbed at
pH values above their pI values. In this manner
proteins are progressively eluted in the order of their
pI values and will leave the column in the same order.
Elution may not be at the pI value of some proteins
due to their insolubility and hence precipitation at
this value only to be resolubilised at slightly lower
pH. As separation is dependent on pI values, proteins
applied to the column later will overtake those initially
loaded if their pI values are higher.
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4.1.6.4 Application of Chromatofocusing
Tiliyer, et at. (1982) used chromatofocusing
for the isolation of Albumin Kashmir from double
albumins. However, in a later paper (Tiliyer, et al. ,
1984) the same authors reported that another electro-
phoretically more cathodic variant was not separable by
chromatofocusing from albumin A, although another
Indian variant, Albumin Jaffna was isolated successfully.
For both these isolated variants a repeated chromato-
focusing run was necessary on the partially purified
peak before completely pure variant was obtained. A
similar finding was reported by Brand (1983) for Albumin
Redhill, and the yields in these purifications were low
(typically 20-25%) with unexplained losses. There
is considerable time and expense involved in repeated
runs of conventional chromatofocusing and these
factors,combined with the unpredictable outcome
(Tiliyer, et al., 1984) detract from its usefulness
as a viable means of isolating variant albumins.
4.1. 7 FPLC Chromatofocusing
The development of high-performance liquid
chromatography (HPLC) has revolutionised separation
processes for proteins and peptides in the last
five years (Hearn, et al., 1983). The main advantages
are:
(i) greatly improved resolution, even of multi-
component mixtures;
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(ii) much reduced experimental run times from
many hours or days to minutes;
(iii) easy recovery of isolated polypeptides in
much smaller elution volumes.
Fast protein liquid chromatography (FPLC) is a
modification of E~LC; the latter was initially developed for
small organic molecules and later used for PTH-amino acids
and small peptides. Traditional HPLC column matrices
were made from derivatised silicas of uniform small
pore size and so required pressures of 500-1500 p.s.i.
in order to elute them at a reasonable flow rate.
This necessitated the use of stainless steel pump .
heads and tubing in order to withstand the high
pressures. The resolution of larger polypeptides and
proteins on such columns was often poor.
FPLC has advantages over HPLC in the following
respects:
(1) High speed separations equivalent or faster
than those obtainable on HPLC but with high recovery
of protein, unlike traditional HPLC where often
inexplicable losses occurred.
(2) High resolution of components using far
lower pressure than conventional HPLC, resulting in
cheaper glass columns, and the Drotection of sensitive
samples from high pressure conditions.
(3) High biocompatibility with separations being
achieved without contact with metal ions which may well
inactivate some sensitive enzymes.
Several FPLC matrices are constructed from
new synthetic polymers which have been developed from
the more traditional resins but with a small highly
uniform bead size so that surface area has been
greatly increased, dead space reduced and flow rate
improved. This provides better separation than was
possible with conventional soft gels.
The application of FPLC technology to
chromatofocusing gives improved resolution in far
shorter experimental run times (one hour compared
to 10-20 hours).
4.2 EXPERIMENTAL
Isolation of Double Albumin from Serum
Introduction
Several methods have been used to isolate
albumins from serum, the most successful being that of
Cohn, et al. (1946) who used ethanol (40% v/v, pH 4.8,-SoC) to
4.2.1
4.2.1.1
precipitate albumin fraction V from human serum.
Commercial fraction V albumin is prepared by an
essentially similar process, and is often contaminated
by a number of impurities which can be removed by
recrystallisation to give a product of 99% purity but
which still contains substantial levels of dimer. Foster
(1977) criticised the recrystallisation process for
introducing unusual contaminants into the preparation.
Dimers and any contaminant proteins can be
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removed by gel filtration. Foster recommended gel filtra-
tion, ion exchange chromatography, ammonium sulphate
precipitation and electrophoresis as being the only
four processes which in his opinion did not modify
albumin.
More recently, Travis, et aZ. (1976) have
used affinity chromatography with Cibacron Blue F3GA
immobilised on Sepharose 6LB to obtain high purity
albumin. The albumin binds tightly to the column,
the other protein contaminants of serum are eluted and
the albumin may be desorbed afterwards. Dimers are
still presumably present in such a preparation and
indeed form spontaneously especially in defatted
lyophilised albumin and this dimerisation is
catalysed by Cull ions (Foster, 1977). Spencer and
King (1971) have proposed a means of obtaining pure
monomeric albumin after blocking the free thiol
residues with cystine.
Ammonium sulphate precipitation at 45% and
75% saturation followed by gel filtration was chosen
as a suitable purification process to obtain double
albumins. It is simple to perform, requires only
1-2 days and is inexpensive. Aging of albumin
preparations due to amidation of carboxylate residues
and similar transformations can occur and it is wise
to avoid such artefacts by prompt use of samples after
purification.
]j4
4.2.1.2 Ammonium Sulphate Precipitation
(McMenamy, et aZ., 1971)
Blood was collected from patients without
addition of an anti-coagulant, serum was obtained
by centrifugation and stored frozen at -20oC until
required. An initial armnoniurnsulphate precipitation
was performed by dissolving ammonium sulphate (45%
saturation (277 giL» in serum by stirring at OOC
(and correct ina.the pH to 6.5). Stirring was continued
for 20 minutes and the soluble fraction including
albumin removed by centrifugation at 7,000 r.p.m.
(MSE 18/16 x 15 ml rotor) at 40C for 30 minutes and
the supernatant collected. Saturation of the
supernatant was increased to 75% by further addition
of ammonium sulphate (final concentration = 516 giL)
and the pH corrected to 4.5. The solution was stirred
on ice for 10-20 minutes then centrifuged for 0.5-1
hour at 12,000 r.p.m. (MSE 18,16 x 15 ml rotor) at
4°C. The supernatant was discarded and the albumin-
containing precipitate resuspended in a minimum of
tris-HCl (0.01 M,pH 7.0 with NaCl (0.05 M».
4.2.1.3 Gel Filtration of the Second Ammonium
Sulphate Precipitate
The pH of the solution was checked and
,corrected if necessary to pH 7.0 before it was loaded onto
a column of Sephadex GlOO (84 x 1.6 cm) equilibriated
in .tris·-HCl(0.01 M, pH 7 with O.05 M NaCl). The
column was eluted in the same solution at 14 ml/hour
and the eluate monitored at 280 nm. Approximately
4 ml fractions were collected and albumin-containing
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fractions pooled into two peaks and dialysed against
distilled water at 4oC. Analysis of the purity of the
albumin fractions was made by non-denaturing disc-PAGE
(Section 3.2.10).
Defatting of Double Albumins
Double albumins, obtained from serum as
described above, were defatted by the method of
4.2.1.4
Chen (1967). Albumins were dissolved in a minimal
volume of wate~ activated charcoal (~ the weight of
protein) was added and the pH brought to 3.0 with
HCl. The solution was stirred on ice for one hour then
centrifuged in a bench centrifuge to remove the charcoal.
The supernatant was restored to pH 7.0 with NaOH
and the purified albumins dialysed against distilled
water overnight at 40C and lyophilised.
4.3 PURIFICATION OF ALBUMIN REDHILL
4.3.1 Introduction
Purification was attempted by the procedures
recommended by Brand (1983) and also by several other
HPLC and affinity methods.
4.3.2
4.3.2.1
Chromatofocusing
Chromatofocusing on Soft Gels
Chromatofocusing was performed essentially
as described by Tiliyer,et al. (1982) with the modifica-
tions of Brand, et at. (1984). Double Albumin Redh1ll
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was applied in start buffer (histidine-HCl,25 mM, pH 6.2)
and elution with Polybuffer 74-HCl (diluted 1 'in 12 with
distilled water, pH 4.0) was performed,collecting 2 ml fractions
and analysing the eluate at 280 nm. Albumin-containing
peaks were redissolved in a minimal volume of trislNaClbuffer
and freed of Polybuffer by elution on Sephadex GIOO,
equilibriated and eluted in tris-HCl (0.01 M tris ~
0.05 M NaCI, pH 7.0).
4.3.2.2 FPLC Chromatofocusing of Double Albumin Redhill
FPLC chromatofocusing was performed on a
Pharmacia FPLC system with two PSOO pump units, a UV-2
absorbance monitor, an injection valve, chart recorder
and FRAC 100 fraction collector and the chromatography was
controlled by a GP2S0 gradient programmer. The
chromatofocusing column (HRS/20 mono 200 x 5 mm
Pharmacia U.K.) was used according to the manufacturer's
instructions, and all solvents were thoroughly degassed
and filtered through a 0.5 ~m filter before use.
The column was equilibriated in piperazine-
HCl (25 mM, pH 6.3) diluted to this concentration with
MilliQ water. Double Albumin Redhill was dissolved
in start buffer at a nominal concentration of 20 mg/ml
(w/v) and centrifuged briefly to remove solid
contaminants. The sample was filtered to remove large
particles and applied to the column in 500 ~l
injections. Elution with Polybuffer (diluted 1:10 in
MilliQ water, degassed, filtered and corrected to pH 4.0
with HCI) was commenced at 1 ml/min at room temperature.
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After 40 minutes the pH gradient was completed and the
column was purged with NaCI (2 M, 1.2 TIl) to remove any
bound material before re-equilibration in the start
buffer. A complete experimental run took ~ 1 hour.
Fractions (~ 1 ml) were collected and a new fraction
commenced automatically for every peak.
4.3.2.3 Purification of Isolated Albumins
The fractions from a single run were
passed through Sephadex G25~ (6 x 1 cm i.~) equilibrated
and eluted in distilled water,in order to desalt
the proteins and fractions (1 ml) were collected.
Aliquots (10 ~l) of each were spotted onto a silica t.l.c.
plate (Merck) and prot.eLn+cont.a.i.n.Lnqfractions
2+detected by spraying with ANS (0.03% w/v Mg salt in
sodium dihydrogen phosphate 0.1 M, pH 6.8) and observing
any fluorescence at 350 nm. Protein-containing peaks
were lyophilised, resuspended in distilled water (100 ~l)
and aliquots (20 pI) diluted in load buffer (30 pI)
and applied to a 7.5% non-denaturing PAGE for analysis.
From the results obtained, the fractions from
each run that contained only pure Albumin Redhill were
pooled and Polybuffer removed by gel filtration on
Sephadex G 75 (35 x 0.6 cm i.d.) equilibriated in NaCI
(0.9% w/v in distilled water). The eluate was measured
at both 280 and 254 nm. Fractions (1-2 ml) were
collected and the albumin peaks pooled and dialysed
against distilled water before lyophilisation.
4.3.3 other Separative Techniques
A number of other purification methods were
tried in order to isolate Albumin Redhill before the
successful use of FPLC chromatofocusing. These are
briefly described below.
4.3.3.1 Preparative PAGE
Preparative PAGE (T = 7.5%, C = 2.6%) was
performed in non-denaturing discontinuous gels
(18 x 16 x 1.5 cm) essentially as outlined in
Section 3.2.10. Samples of double Albumin Redhill
(5-10 mg) were dissolved in bromophenol blue/sucrose
0.01%/37%, w/w in water. Electrophoresis was carried
out at 150 V C.V. until the bromophenol blue tracking
dye had eluted. After electrophoresis, albumin bands
were visualised, without fixing and staining in PAGE
90, by one of the three methods listed below:
(i) The gel was viewed over a F2S4 fluorescent
silica t.l.c. plate (Merck) under UC254 nm illumination
(Brand, 1983). Proteins appeared as absorbent bands
and so quenched the fluorescence.
(ii) Gels were sprayed briefly with ANS (0.03%
w/v Mg2+ salt in NaH2P04, 0.1 M, pH 6.8) and viewed
under UV3S4 nm illumination. Protein bands fluoresced,
especially after exposure to HCl fumes.
(iii) The bromophenol blue concentration in the
loading solution was increased so that some was
retained, bound to the albumin bands, which were then
detectable under illumination.
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The excised albumin A and Albumin Redhill
bands were individually stained briefly in bromophenol
blue and placed over a second 7.5% gel. A 3% acrylamide
stacking gel was cast around the gel band as described
by Mendel-Hartvig (1982) and reverse electrophoresis
performed. Protein was collected at the top of the
gel in a layer of glycerol. overlayed with NaCl (2 M).
After electrophoresis was judged to be complete this
layer was removed, dialysed against distilled water
at 40c and lyophilised.
Analysis of the extracted albumin fractions
was performed on disc-PAGE as before, against normal
albumin and double Albumin Redhill.
4.3.3.2 Preparative Cellulose Acetate Electrophoresis
Cellulose acetate electrophoresis was performed
essentially as described by Abdo et al. (1981) but using
a veronal buffer composed of sodium barbitone (15.4 giL) and
5',5'-diethyl barbituric acid (2.76 giL) pH 8.6. Double
albumins (1-5 mg) were loaded in sucrose/bromophenol blue solutio}
as before and electrophoresis carried out at 10-20 V/cm
for 4-6 hours so as to obtain maximum separation of the
albumin bands. The individual bands were detected by
their binding of bromophenol blue and excised. The pooled
strips from several runs were eluted and purified as
described by Abdo, et aZ. (1981). Analysis of purified
albumin fractions was by disc-PAGE as previously
described.
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4.3.3.3 HPLC
The separation of double albumins was attempted
by HPLC without success. The following systems were used:
(i) Ion-exchange chromatography was performed
on a TSK 5PW DEAE anion exchange column (75 x 7.5 mm i.d.)
equilibrated in tris-HCl (50 mM, pH 7.4) with a 0-0.5 M
NaCI gradient over 30 minutes at 1 ml/min using an
LKB chromatographic system.
(ii) Ion-exchange chromatography was performed on a
MonoQ (HR 5/5, 50 x 5 mm i.d.) column (Pharmacia)
equilibrated in piperazine-HCI (20 mM/pH 5.5) using
a 0-0.35 M NaCl gradient over 10 minutes at 2 ml/min
on a Pharmacia FPLC system.
(iii) Reverse phase HPLC was performed on a pro-
RPC column (HR 5/10, 50 x 5 mm i.d.) (Pharmacia) equilibrated
in trifluoroacetic acid (TFA 0.1% v/v aqueous) and applying
0-70% gradient of TFA (0.1% v/v) in acetonitrile over
30 minutes at a flow rate of 0.7 ml/min on a Pharmacia FPLC
system.
All solvents were thoroughly degassed and filtered
before use and the double albumins (typical loading 200 ~l
of a 1 mg/ml solution) were filtered through a 0.45 ~m filter
before injection onto the column.
4.3.3.4 Affinity Chromatograohy
Albumin Redhill had been reported to have
ed d ff' lt; f 'II dell (r uce a ~n~ y or N~ an u ions Brand, et at.,
1984) and it was thought this could be utilised to
achieve separation of the variant and normal albumins
by Cull N,II ff" hor ~ a ~n~ty c romatography.
4.3.3.4.1 Preparation of Affinity Column
(i) Chelex-100 (Bio Rad, 5 g) was resuspended
in nickel(II) chloride solution (0.1 M) and a column
(5 x 1 cm i.d.) was filled with this resin and washed
with the nickel(!!) chloride solution (50 ml) and then
with water until no further Ni,IIwas removed. The column was
then equilibrated in buffer (N-ethylmorpholine 0.1 M, pH 7.8
or NaCl 0.15 M). A CuII-Chelex-100 column prepared in a similar
mrumer, was also used.
(ii) Chelating Sepharose 6B (Pharmacia) was
a gift from Mr. E. Groundwater of Pharmacia, and was
prepared as directed in the booklet "Affinity Chromatography
on Chelating Sepharose 6B" from Pharmacia using a solution
of nickel(II) chloride (5 mg/ml in water, 50 ml). Excess
Nil! was removed by repeated washing in water and then in
urrfer and the column (4 x 1 cm i.d.) equilibrated in either
disodium hydrogen phosphate (0.05 M, pH 7.5) or HEPES
(0.05 M, pH 7.5) both of which contained NaCI (0.5 M) to
overcome any ionic interactions.
4.3.3.4.2 Elution of Double Albumins on
Affinity Columns
Small amounts (1-5 mg) of double Albumin
Redhill were applied to the affinity columns in a minimal
volume of buffer. Samples for chelating Sepharose 6B
chromatography were deionised before use, on Chelex-100
as described in Section 7.
(i) Ni-Chelex-lOO. After application of double
albumins, the column was eluted at 10-20 rol/hour in the same
buffers used for equilibrating the column. The eluate was
monitored at 280 nm and fractions (~ 1 ml) were collected.
(ii) Cu-Chelex-100. Solutions of double
albumins were loaded and the column was initially eluted
at ~ 20 ml/hour in NaCl (0.01 M) and subsequently
purged with copper(II) chloride (0.05 M) to remove
any bound protein. The eluate was monitored at 280 nm
and fractions (~ 1 ml) were collected.
(iii) Ni-Chelating Sepharose 6B. Double albumins
were applied and the column was eluted at ~ 20 ml/hour in the
initUU equilibration buffers (phosphate or HEPES) and then
with one of the following solutions to d Lsp Lac.e the
bound proteins:
(a) Phosphate with a gradient of glycine
(0-20 mg/ml) .
(b) Phosphate with a gradient of EDTA
(0-10 mM) •
(c) HEPES with a gradient of nickel(II)
chloride (0-10 mg/ml) .
Eluate was monitored at 280 nm and fractions (1 ml) were
collected and analysed, after desalting, on disc-PAGE.
4.4 PURIFICATION OF ALBUMIN CARLISLE
4.4.1 Introduction
Albumin Carlisle was thought to be a new
variant and a wide range of previously successful
techniques (Table 4.1) were used in order to attempt
misolate it, some of which have already been
described.
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Experimental
Chromatofocusing
Soft gel chromatofocusing was carried out
on double Albumin Carlisle as outlined in Section
4.4.2
4.4.2.1
4.1.6.4. Double Albumin Carlisle (~ 10 mg) was loaded
and elution perfonned at ~ 12 ml/min until the pH of the
eluate was the same as that of the Polybuffer 74 eluant.
Fractions (2 ml) were collected and the pH and the absorbance
at 280 nm were measured. Peaks were analysed, after
purification, by disc-PAGE.
4.4.2. 2..1 FPLC Chromatofocusing
FPLC chromatofocusing was performed on double
Albumin Carlisle at Guy's Hospital Medical School
essentially as previously described in Section 4.3.2.2.
Solutions of double albumins in start buffer (nominally
20 mg/ml w/v) were loaded in aliquots (0.5 or 1.0 ml)
and a flow rate of 1.0 or 0.5 ml/min was used. Fractions
were collected as before and aliquots (10 ~l) used
without purification and loaded onto disc-PAGE in
bromophenol blue/sucrose loading solution (40 ~l) for
analysis against normal albumin and double Albumin
Carlisle.
4.4.2.2.2 Purification of Albumin Fractions
Purification of Albumin Carlisle, isolated by
FPLC from Polybuffer contaninantswas attemptedby chranatography
on hydroxyapatite (Bio.Gel IiTP', alioRad.) after the
method of Satyanarayana and Klein (1984). A column
(15 x 0.4 cm i.d.) of hydroxy-apatite was equilibrated
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in potassium dihydrOCJ=llphospha te (0.01 M, pH 7.45) and
the sample of albumin and Polybuffer applied. Elution
was at ~ 15 ml/hour and the eluate was monitored at
280 and 254 nm, by collecting 2 ml fractions and
reading manually in a spectrophotometer. After
30-50 ml of buffer had eluted, a stepwise gradient
wasfurmed by eluting with potassium dihydrogen phosphate
(0.1 M, pH 7.45) and elution continued using 50-100 mlof
this buffer.Purified protein was dialysed against
distilled water and lyophilised.
Ion Exchange ChromatographY
Separation of double Albumin Carlisle was
attempted unsuccessfully by ion exchange chromatography
4.4.2.3
using the following systems.
(i) DEAE cellulose (DE52,Whatman) equilibrated in
sodium phosphate buffer (0.2 M, pH 5.75) and eluted
according to the method of Winter, eta L (1972).
(Lf, ) DEAE cellulose equilibrated in tris-HCl
(0.01 M, pH 8.6) and eluted with a gradient of 0-0.5 M NaCl
after the method of Bradwell, et a l , (1975).
(iii) Ion exchange HPLC using a Partisil SAX anion
exchange column (25 x 0.46 cm i.d. Whatman) with a
I
0.01-0.5 M gradient of potassium dihydrogen phosphate
(pH 7.0) eluting at 1 ml/min over 30 minutes followed
by a gradient up to 1.5 M KH2P04, using a Waters HPLC
system (one 6000A pump, one M45 pump, and a 600 series
gradient programmer with U6K injector and 441 absorbance
detector, monitoring at 280 nrn). Fractions were collected
manually.
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4.4.2.4 Ion Exchange Chromatography with pH Gradient
Double Albumin Carlisle (10 mg) was applied to
a DE52 column and a gradient of pH from 5.5 to 4.5
applied using solutions of sodium acetate (25 mM) as
eluant (essentially after Brennan and Carrell, 1978) at
a flow rate of 27 ml/hour. Eluate was monitored at
280 nm and fractions (5 ml) were collected.
A similar gradient was used on QAE Sephadex
A25 essentially after the method of Bradley and
Hornbeck (1974) and an analogous HPLC experinent performed
on a Partisil SAX anion exchanger using a pH gradient
from pH 5.1 to 4.5 in potassium dihydrogen phosphate
(0.1 M). Any separation was estimated by disc-PAGE.
4.4.2.5 Preparative Electrophoresis
Preparative electrophoresis on cellulose acetate
and polyacrylamide was performed as described in
Sections 4.3.3.1 and 4.3.3.2 using the reverse elution
electrophoresis method of Mendel-Hartvig (1982) and
the cellulose acetate method of Abdo, et a l , (1981).
Fractions from each method were analysed on
dis~PAGE against double Albumin Carlisle and normal
albumin.
4.5 POLYACRYLAMIDE GEL TITRATION CURVE FOR
ALBUMIN CARLISLE
4.5.1 Principle
Double Albumin Carlisle was analysed using a
PH t'1tration curve method in polyacrylamide gel
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containing carrier ampholyte (pH 3-10,Pharmacia). A
pH gradient was formed in a square polyacrylamide
thin layer slab gel by electrophoresis of the
ampholytes until they reached their isoelectric
pOints and were stationary. A sample of double
albumin could then be applied to a central well cut longi-
tudinally across the pH gradient and electrophoresis
carried out at 900 to the initial focusing. The protein
mixture was thus electrophoresed at different pH
values along the gradient and the degree of separation
possible at each pH value was seen by staining the
gel with Coomassie Blue. A titration curve for
the normal and variant albumin was obtained, their
subsequent mobilities reflecting the charge make-up
of the proteins at each pH, along a continuous curve.
4.5.2 Bxperimental
The method used was as described in the
booklet "Isoelectric Focusing, Principles and Practice"
by Pharmacia and was performed for us by Dr. R. W. Evans
of Guy's Hospital Medical School, London. A polyacrylamide
gel (10 x 10 cm x 1 mm thick) was cast containing ampholyte
in the pH range 3-10 (T = 5%, C = 3%~ as for isoelectric
focusing in thin layer slabs,only with a sample notch
former already in place. Isoelectric focusing and
electrophoresis were performed at 40C on a cooling
plate. The anode electrolyte was H2S04 (0.05 M) and
the cathode electrolyte NaOH (1 M). Isoelectric
'14 'j
focusing was performed in the first dimension at 15 W
with a limiting voltage of 2000 V (unlimited current)
and the gel focused for 800 volthours.
After focusing the gel was rotated through
o90 , fresh electrode strips positioned and double albumin
(~1-2mg)in water (50 ul) applied to the sample trough.
Electrophoresis was carried out at 15 W (limiting
voltage 1000 V) in the same buffers for 250 volthours
(using a Pharmacia power supply and flat-bed apparatus
such as the FB~3000).
Fixing, staining and destaining were as
described previously for isoelectric focusing
(Section 3.2.11.1).
4.6 RESULTS
4.6.1 Albumin Redhill Purification
Albumin Redhill and normal albumin co-
precipitated in the second ammonium sulphate precipitation
step. The double albumins chromatographed together
on G-IOO (Fig. 4.1) giving two major peaks, one at
60' ml and the other at 175 rnl of buffer .eluted. Non-denaturing
disc-PAG~ showed these to contain primarily the monomeric
albumins with small amounts of dimer and polymeric albumin.
The dimeric content of the first peak may have been higher
than the second, also it possibly contained more lipid.
A small amount of a protein running behind the double
albumins was seen in the same preparations and may
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have been transferrin, or possibly an albumin degradation
product due to storage. Double albumins were defatted
by the method of Chen as described and after dialysis
and lyophilisation gave a white fluffy powder, which
was used without further purification in the experiments
to isolate pure Albumin Redhill.
Previously successful methods such as
preparative PAGE and chromatofocusing in soft gels gave
disappointing results. On preparative PAGE, although
albumins A and Redhill separated, therewas considerable
difficulty in being able to visualise the distinct
bands and only the method of pre-staining with bromophenol
blue gave discernably separate bands. Albumin Redhill
obtainedfram reverse elution did not give a recognisable
280 rumabsorbance even after dialysis and non-dialysable
contaminants with a high UV absorption were present,
possibly due to acrylamide monomer, or other gel
contaminants. Despite attempted purification on
DE52 mini-columns elutingwith a NaCl gradient,the contaminants
were still present and electrophoretic analysis of the
isolated albumin. gave a diffuse band from which it
was impossible to tell the degree of purification from
Albumin A. The actual recovery of total protein also
seemed to be very low compared to the amount
initially loaded. Although Brand (1983) gave photographic
evidence of pure Albumin Redhill by this method, it is
possible that UV contaminants may have resulted in
over-estimation of the albumin concentration and hence
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explain why sequence analysis of such material failed to
reveal any albumin.
Preparative cellulose acetate was similarly
unsuccessful in yielding pure variant. The separation of
Albumin Redhill from albumin A is poor on this medium
and despite long run times the isolated Albumin Redhill
bands still contained some albumin A on analysis by
disc-PAGE. The electrophoretic pattern of this isolated
variant was also diffuse and this may have been due
to the presence of excessive salts or to molecular
aging of the albumin during extraction.
Ion-exchange HPLC failed to resolve the
double albumins, yielding only double albumimon analysis
of the peaks obtained. The several peaks obtained may have
been attributable to dimeric albumins or albumins with
endogenous ligands still tightly bound and so possessing
different net ionic charges.
Reverse phase HPLC also failed to resolve
the variant and normal albumins vmich co-eluted in a
single peak. It would appear that the net differences
in charge or hydrophobicity between Albumin Redhill and
normal albumin are insufficient for these techniques
to be able to resolve them.
Nickel and copper affinity chromatography also
failed to resolve the two albumins. On Cu-Chelex-lOO
two peaks were obtained, the latter containing just
albumin A and the former althou~h slo~!1 ., migrating on PAG~
was shown to consist of both albumins by cellulose
acetate electrophoresis. The experiments using
Ni-Chelex-IOO gave no significant separation as both
albumins were eluted without binding. A reason for this
may have been that the metal was bound too closely to the
matrix and was thus inaccessible to the albumin. Chelating
Sepharose was therefore used where the metal ion is bound
to a side chain at a greater distance from the matrix.
Two peaks were obtained on chromatography of the double
a~s with either a glycine gradient in a phosphate
buffer or with a Nill gradient in a HEPES buffer. The first
peak contained pure albumin A, the second a mixture of
the two albumins. With a Ni!l gradient in a HEPES buffer
albumin A was the major component even in the second peak.
This result seemed contrary to expectations as one would
expect albumin A to be bound to the column and Albumin
Redhill to be eluted. However, instead the albumins
were eluted together or albumin A on its own, no band
axraining just Albumin Redhill could be found during several
runs.
Chromatofocus1ng on a soft gel gave a poor
result - 10 hours or more were needed to develop the
full gradient, and although a main peak with two
shoulders was eluted early in the experiment, the pH
at this point was between 6.5 and 7.0. Two peaks were
eluted much later but they contained little or no
albumin by PAGE. Due to the excessive time taken and
poor pH gradient formation a second round of chromatofocusing
was not attempted.
FPLC chromatofocusing yielded two sets of
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peaks at the start and end of the gradient, and three
peaks in the middle of the gradient which
contained the albumins that had separated (Fig. 4.2).
The first peak contained protein not bound to the column
at pH 6.3 and the last peak contained proteins eluted from
the column with the salt wash, and otherwise still bound
at pH 4.0. The total OD280 nm of these regions was far
higher than that of the three middle peaks. The three
peaks consisted of pure normal albumin, double albumins,
and pure Albumin Redhill. The total yield of pure
Albumin Redhill was quite low (~ 5% by relative 2~O nm
peak heights). The reason for there being three peaks
may be due to aggregation of the normal and variant forms
to give a mixed dimer resulting in the middle peak, or
alternatively/incomplete resolution at the pI value
due to precipitation and mixing on resoluilisation may
have occurred.
Although the yield of variant was very low
the run time was short and so the pooled peaks from
~ral runs could be taken. The analytical PAGE
of fractions from a run (Fig. 4.3) revealed that
the third peak contained pure Albumin Redhill.
Application of the pooled pure Albumin Redhill
to gel filtration resulted in the albumin being eluted
quickly but the contaminant Polybuffer far more slowly.
The UV of the albumin was at 280 nrnand that of the Poly-max
buffer at 254 nm (Fig. 4.4). However, despite dialysis and
gel filtration of the 'pure' albumin on Sephadex G-25
r:;:'
F
I
10
''''
(WI) 4"M IJ'N c:
@
...-i
0
0
p..
s·~ Hd .... 0
c:
0
S
rcl
C
0
...-i
I ...-i
t;:; ·rlul .cI 'd
! Q)
I ~f~ C.;-1
<cl
..... _ @
=-=== '" -" .QE ...-i.:x:
Cl>
Q)E
:::l ...-i
(5 .Q::l> 0
i~ -o4-1
0
ty\
c~
til
::l
0
0
4-1
0
+l
rcle:
0
~
..c:o
o
H
p..
~
P»U'WWO) >OJ Jnq~lod N
-:r
ty\
J>JJnq ),1'1' 5·9 Hd uOll)alU
•.-1
~
'" .... r:<
0
6 6 6 0 6
(WU OS?;) aoUeqJOsq'v'
153
154
II III .IV
Fig. 4.3
PAGEof albumin fractions:
(iv)P~akC from chromatofocusing
Redhill.
0.2
-.-.- 'OD
254nm
-0-0- 00280nm
CDo
cca
.0~
g 0.1
.0«
10J
VOlume (mI.)
+
v
(f., ii & iii) HSA,
(v) double Albumin
Fig. 4.4 Gel filtration of fractiohs from c'hromatofocusing (fig.4.2)
in order to remove Polybuffer, on.Sephadex G75.
1 5S
in wate4 UV contaminants were still present. These
may be due to some component of Polybuffe4 which
is thought to have a large molecular weight of several
thousand. The isolated Albumin p.edhillwas pooled and
lyophilised.
Purification of Albumin Carlisle
Albumin Carlisle was isolated from serum
together with albumin A with an elution profile on G-lOO
4.6.2
essentially the same as that of Albumin Redhill (Fig. 4.5,
Section 4.6.1). The albumin containing fractions were
pooled,dialysed and lyophilised. Small traces of EDTA
were included in the dialysis to chelate any metal
ions and retard aggregation. Double Albumin Carlisle was.
defatted as previously describedand the resultantpowderShCMn to
be 70-80% pure albumin by Coomassie Blue protein assay
(Bradford, 1976) and free of any major contaminant
on gel electrophoresis, though a small amount of
transferrin may have been present in some runs.
A simple elution on DES2 (Winter, et aL.,
1972) did not resolve the variant from the normal
albumin. Gradient elution on DES2 used to successfully
purify Albumin Birmingham (Bradwell, et at., 1975)
was also unsuccessful. IWIC ion exchanqechrrmato-rraohv
did not give improved resolution of the albumins and it
appeared that albumin bound on the column and was only
later de.sorbed at hi~her salt concenr ratiQn.
None of the examined
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peaks contained pure albumin variant. The use of a
pH gradient on an ion-exchanger was also completely
unable to separate variant from normal albumin, both
on soft gel or HPLC. In a similar experiment with
QAE Sephadex no separation was achieved either.
Attempts to purify Albumin Carlisle by
preparative electrophoresis were also frustrated due
to inconclusive analysis of the extracted bands. The
qlycerol containing layers and those from cellulose
acetate showed high absorbances which blotted out
any protein assignments at 280 nm. Analysis on
disc-PAG~ was ambiguous,sometimes yielding two bands
and at other times a single band which
migrated over the same distance as both albumins.
These efforts were abandoned in favour of chroma to-
focusing. Conventional soft gel chromatofocusing required
long run times and the resultant peaks were very broad and
were in large volunes thus giving ambiguous results.
However, FPLC chromatofocllsing of double Albumin Carlisle
yielded two major peaks of roughly equal ~80 nm absorbance as
well as peaks for unbounn protein and that eluted in the
salt wash (Fig. 4.6). Aliquots from these peaks
analysed on disc-PAGE showed that the first major peak contained
Albumin Carlisle (Fig. 4.7) and the other albumin A.
Variations in loading and flow rate affected
resolution, better separation being achieved at
0.5 ml/min. although baseline separation of the peaks
did not occur in any run. The yield of pure Albumin
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Fig. 4.7 PAGE of FPLC fractions from the chromatofocusing
of double Albumin Carlisle (numbered as in
Fig. 4.6): (L & ii) nori+aLbumi,nproteins,
(iii) Albumin Carlisle, (iv) mainly Albumin
Carlisle, (v) double albumins, (vi) mainly
albumin A, (vii) albumin A.
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Carlisle was sliqhtl'l larger than for albumin A and
eluted before albumin A in the pH gradient, consistent
with its pI being higher than that of normal albumin. The
minor peaks contained dimers (first two peaks) and
normal albumin in the small fifth peak (see Fig. 4.7).
Although only ~ 16% pure Albumin Carlisle was
obtained (as a % of total 280 nm absorbance) on a
single run,because the experimental run time was short
~
and the technique far less expensive in solvents than
traditional chromatofocusing, FPLC chromatofocusing
was the technique of first choice in purifying Albumin
Carlisle.
From analysis of the pH titration curve
(Fig. 4.8) it is clearly seen that Albumin Carlisle
and albumin A are most distinctly separated at pH
values in the region pH 6.0-7.5 and that the
resolution between them is very poor at pH values of
pH 4.0 or below. Thus, the pH range for the ion
exchange separations was correct for separating the
variants in most cases and a separation in the pH
range 6-7.5 should theoretically be possible. Any
further intensive ion-exchange studie& if carried ou~
I
should be in this pH range. From the reduced mobility of
Albumin Carlisle at neutral and slightly alkaline pH values it
would seem that Albumin Carlisle is caused by an acid to
neutral mutation) from the flredicrions of Righetti et at. (197S)
The isoelectric pOint of
Albumin Carlisle (calculated from the potnt of no net
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migration of the protein) was shown to be higher than
for albumin A (pI = 5.22 for Albumin Carlisle compared
to 5.09 for albumin A), although accurate values would
have to be calculated using a pH electrode to define
the gradient in the gel, which would also be true
for obtaining accurate values of the optL~al pH for ion
exchange separation.
4.7 CONCLUSIONS
A variety of well established separative techniques
were unsuccessfully attempted in order to isolate Albumins
Carlisle and Redhill from sera also containing albumin A.
Bowever, FPLC chromatofocusing was successful for both
variants although with differing elution profiles and
recoveries. The technique is rapid, simple to perform
and inexpensive. The relative effectiveness of the
technique was shown to be variable and so complete trials
would need to be performed on each variant to be purified
by this method. Both albumin variants were obtained in
~ 90% purity from traces of 'albumin A and with further
modifications to run conditions higher yields and
greater purity may be possible.
Albumin Carlisle was shown to have a higher
pI value than albumin A by chromatofocusing and a pH
titration curv~ but Albumin Redhill appears to have
a lower pI value than normal albumin from its elution
profile. The pH titration profile is consistent with
an . acid to neutral amtno ac.id
transformation in the Albumin Carlisle molecule.
+
+
("
pH3+-----------!i*-10
Fig. 4.8' pI titration curve of double Al.bum i.n
Carlisle.
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CHAPTER FIVE
PEPTIDE MAPPING OF ALBUMIN VARIANTS
5.1. 1 Peptide Mapping
The chemical or enzymatic digestion of a
protein and the subsequent separation of the fragments
has been a popular method of structural analysis for
nearly 30 years and has been termed "finger-printing"
or peptide mapping. Several excellent reviews of the
techniques used in these processes have been compiled
by James (1980) and Hermodson (1983).
The earliest two-dimensional peptide maps
were reported in the late 1940's. In 1959 Ingram
pinpointed, by use of a combination of chromatographic
and electrophoretic separations of a tryptic digest,
a mutant peptide in the haemoglobin variant responsible
for causing sickle cell anaemia, having a glu + val
mutation. Subsequently, peptide mapping has been
used to identify mutations in protein variants, to
carry out comparative biochemistry and to classify
the subunit structures of viral proteins. Proteins
to be studied are often either S-carboxymethylated
after reduction with thiol reagents, or are reduced
and oxidised with performic acid.
Enzymes used to digest proteins include
trypsin, with specificity for lysine and arginine
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residues; chymotrypsin, which cleaves after
hydrophobic residues such as phenylalanine, and
several less widely used enzymes such as thermolysin
(which cleaves at the amino- terminal side of hydrophobic
residues), clostripain (specific for arginine residues),
and mouse submaxillary proteases (also specific
for arginine residues). Less specific enzymes, which
are occasionally used include papain, su~tilisin,
pepsin, pronase and Staphylococcal protease.
Chemical cleavages can be classified into
three main groups:
(i) Cleavage at methionine - using cyanogen
bromide (CNBr) (Gross and Witkop, 1961). This is
the most specific chemical cleavage method, and due
to the relative scarcity of methionine residues, it
usually gives rise to a small number of relatively
large peptides.
(ii) Cleavage at tryptophan - using a variety
of reagents including N-bromo-succinimide, N-chloro-
succinimide, o-iodosobenzoic acid, BNPS-skatole
and CNBr after the modification of all methionine
residues.
(iii) Cleavage at other residues - including
cysteine using 2-nitro-S-thiocyanobenzoic acid (Stark,
1977). These cleavages are less specific and so suffer
from cross-reaction contaminants due to undesired
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cleavages at other residues. The asp-pro bond is
particularly sensitive to acid hydrolysis and this
has also been used to analyse protein structure
(Marc.us,1985).
5.1. 2 Peptide Resolution
The peptides produced by proteolytic or chemical
means may be separated by several different procedures.
The first system used for the analysis of tryptic
peptides was chromatography followed by high-voltage
electrophoresis on Whatman filter paper (Bennett,1967).
This was replaced in the late-1960's by thin-layer
methods, mainly on silica or cellulose, which required
less sample for detection of the peptides and gave
improved resolution and reduced run times. A typical
solvent used for chromatography was a combination of
acetic acid, pyridine, butan-1-ol and water, followed
by electrophoresis in pyridine-acetate buffers, although
more non-polar solvent systems are now often used for
silica thin-layer experiments (James, 1980). Two-
dimensional chromatographic separations have also
been used successfully with the dansylated peptides
of proteolytic digests (Gerday, et aZ., 1968; Tichy,
1975) •
More modern methods for peptide separation
have included isoelectric focusing in polyacrylamide
gels, SOS-PAGE and a variety of chromatographic
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systems. 50S-PAGE has been used by Cleveland,
et aZ. (1977) to analyse the peptides produced by
enzymatic digests in the presence of SOS, and it
has been applied to proteins still contained within
excised polyacrylamide gel bands. This work has
since been extended to include chemical cleavages of
proteins still contained within gel slices with
subsequent analysis by 50S-PAGE (Lam and Kasper, 1980).
Possibly one of the most popular new methods of peptide
separation has been the use of reverse phase and ion
exchange HPLC (see Section 5.3).
5.1. 3 Peptide' L'ocalisation and Elution
Early peptide maps were developed using
ninhydrin sprays or dips, often containing cadmium
acetate to increase sensitivity or 2,4,6-collidine
to give different coloured spots for various amino
acids. The use of dansyl chloride (Gray and Hartley,
1963) to derivatise the amino-terminal residues of peptides
to give fluorescent amino acid derivatives on hydrolysis
has been widely used and is extremely sensitive.
Other detection methods have included the
use of o-phthaldehyde (Benson and Hare, 1975) and
more recently fluorescamine (Stephens, 1978) which
can be used to detect picomoles of peptide as
fluorescent moieties (Fig. 5.1). A highly sensitive
method of ~eptidemappin9 is to label the peptides
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·th 125I t· t 14C 32p h· hWl or 0 lncorpora e or w lC can
then be easily detected by autoradiography. Although
the radioactive hazard is a disadvantage this method
is often used when only small amounts of protein are
to be digested (Jay, 1984).
5.2 METHODS OF PROTEIN CLEAVAGE
5.2.1 Aims
Human albumin has six methionine residues,
one tryptophan and a single asp-pro sequence at
residues 365-6. The methods for structural analysis
of the protein chosen were dictated by cleavages at
these residues and so CNBr, NCS and similar agents
were used to generate large fragments of normal and
variant albumins. The Nand C -termini of the variant
albumin were determined and tryptic and other
enzymatic digestions performed, which generated a
large number of much smaller fragments.
5.2.2.1 Reduction of Disulphide Bridges
The sites of cleavage of many chemical and
enzymatic agents are often buried in the tertiary
structure of the protein. It is therefore necessary
to disrupt the disulphide bonds and unfold the
protein before fragmentation can take place. Once
reduced, refolding of the protein can be prevented
by performic acid oxidation or S-carboxymethylation.
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5.2.2.2 Performic Acid Oxidation
Performic acid oxidation is used to
denature albumin before determination of the N-terminus
by dansylation and prior to tryptic digestion. As
well as converting cystine residues to cysteic acid,
performic acid oxidation also causes oxidation of
methionine residues to the sulphone and so prohibits
subsequent CNBr degradation without prior reduction of the
methionine sulphone to its original form. Tryptophan
residues are also modified by performic acid to
N-formylkynurenine, with cleavage of the indole ring.
This prevents further cleavage at this residue with .
tryptophan-specific reagents (Fig. 5.2).
5.2.2.3Reduction and S-Carboxymethylation
A more useful technique for denaturing
proteins if they are to be subsequently cleaved by
other agents is to reduce the disulphide bonds and
S-carboxymethylate the resultant thiol residues.
Reduction of the disulphide bridges can be achieved
using 2-mercaptoethanol (Hirs, 1967) or dithiothreitol/
dithioerythreitol (Cleland, 1964) usually anaerobically
with excess reagent present at alkaline pH. Reduction
is usually carried out in the presence of denaturants
such as guanidinium hydrochloride or urea. Once
denatured and reduced the thiol resudues are blocked
wi.th either iodoacetamide or iodoacetic acid, the
latter causing an increase in the net negative
charge of the protein (Fig. 5.3).
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Fig. 5.1 Some N-terminal labelling reagents.
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5.2.3.1. Determination of N-terminal Amino Acid
N-terminal residues were first detected
by Sanger (1945) using fluorodinitribenzene (FDNB),
to generate a yellow amino acid derivative which
could be identified by chromatography. A far
better method is that of Gray and Hartley using dansyl
chloride, described in Gray, 1972, although other
procedures have been devised including:
(i) Phenylisothiocyanate - Edman's reagent (1950)
used infue stepwise sequencing of proteins.
(ii) Dimethylaminoazobenzene-4-isothiocyanate
(DABITC) introduced by Chang, et al. (1976) and
producing strongly coloured derivatives.
(iii) Cyanate (Stark, 1972a).
(iv) Aminopeptidases for the enzymatic cleavage
of N-terminal residues (Light, 1972).
Dansyl chloride is probably the most
popular of these methods and it has been used here
because of its high sensitivity, requiring only
1-5 nmol of protein, and its comparatively simple
protocol for use (Fig. 5.4).
5.2.3.2Mechanism of Reaction
Dansyl chloride reacts with primary amino
groups such as those of N-terminal residues and
E-lysine residues and also with secondary amines.
Other side chains are modified in the order cys >
tyr> lys > his (Gray, 1972): however, the cysteinyl
1 / I
(S-Dimelhylamlnonaphlhalene-l-
sulfonyl Chloride)
Fig. 5.4 structure of dansyl chloride.
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Fig. 5.5 Coupling of dansyl chloride to the
N-terrninal residue of a ~rotein.
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and histidinyl side-chain derivatives are unstable
under the acidic conditions of peptide hydrolysis.
The coupling reaction (Fig. 5.5) must
occur at alkaline pH, as only the NH2 group is
attacked and not the protonated NH3 form, and the
buffer is usually chosen between pH 8-10. A ratio of
dansyl chloride: protein of 5:1 is usually adequate and
SDS and urea may be added to improve peptide solubility
without interfering with the dansylation process.
Once dansylation has occurred (about one hour) I
acid hydrolysis at lOSoC is used to cleave all the
peptide bonds. Hydrolysis is normally continued for
16 hours: however, some residues are more susceptible
than others; DNS-proline being a secondary
sulphonamide is rapidly broken down, DNS-threonine,
DNS-cysteine and DNS-serine all decompose to
l,dimethyl naphthalene-I-sulphonamide (DNS-NH2),
and DNS-tryptophan is also destroyed. Other dans"l
derivatives such as DNS-valine, DNS-Ieucine and DNS-alanine
are stable to such hydrolysis. The dansylated N-terminal
amino acid can be determined after hydrolysis
by two-dimensional chromatography against known
standards.
5.2.4 Determination of C-Terminal Residue
Methods of determination used for C-terminal
analYSis are less satisfactory than those for the
N-terminus. Hydrazinolysis has been used by
1/3
Schroeder (1972) and C-terminal tritium labelling by
Hatsuo, et a l , (1966); other methods include
hydantoin formation (Stark, 1972b) and digestion with
carboxypeptidases (Ambler, 1972). The latter has been
the method chosen here as it is a far simpler procedure
than the others. However, one problem encountered with
carboxypeptidases is their differing specificities.
Carboxypeptidase A releases non-polar residues rapidly
from the C-terminus, but acidic or glycyl residues are
released very slowly and prolineor argininenot at all. The
nature of the penultimate residue also affects the
rate of release of the C-terminal residue, and
difficulties arise if the C-terminal residue is
released slowly but the penultimate residue quickly.
Endopeptidase contamination is a common problem and
must be inhibited with pepstatin A. Carboxypeptidase B
removes arrriruneand lysineresiduesfrxmthe C-terminalof
peptides and proteins without difficulty but is not
very stable. Carboxypeptidase Y (Hayashi, 1977)
from baker's yeast has a broad specificity but with
a preference for hydrophobic residues. Glycine at the
penultimate residue reduces the rate of C-terminal
hydrolysis. oThe enzyme is stable at -20 C and at
o20 C for 8 hours, but is inhibited by heavy metal
ions; Lee and Riordan (1978) have given details
of its practical use. Once released the C-terminal
amino acid can be detected by chromatographic means
against standards, or by amino acid analysis.
5.2.5 Cleavage at Methionine with CNBr
Cyanogen bromide (CNBr) was introduced by
Gross and Witkop (1961) and is the most specific of
the chemical cleavages available. It causes cleavage
at the carboxyl side of methionine under strong acid at
room temperature, giving rise to a homoserine residue which
is interconvertible with homoserine lactone (Ambler,
1965) (Fig. 5.6).
Cleavage occurs to a lesser extent at met-ser and
met-thr bonds. Met-cys bonds may fail to be cleaved
due to formation of a homoserine residue without peptide
bond lysis. Doyen and Lapresle (1979) have shown that met 123
in HS} is only partially susceptible to CNBr cleavage
due to its neighbouring cystine residue,as conversion
to a homoserine residue can take place without bond
breakage, so giving rise to a possible eight CNBr fragments.
The oxidation of methionine to methionine
sulphone or sulphoxide prevents cleavage and any such
auto-oxidation must be reversed using thiols before
treatment with CNBr (Neumann, 1972). Oxidative
destruction of the tryptophan residue is possible if
methionine residues are already modified and CNBr
has been used to cleave tryptoohan in proteins with
previously modified methionines (Huang, et al., 1983).
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Fig. 5.6 Cleavage at methionine with CNBr.
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Fig. 5.7 Cleavage at tryptophan with NCS.
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Cleavage at Tryptophan
N-Bromo- and N-Chloro-Succinimides (NBS, NCS)
HSA has a single tryptophan at residue 214
and this can be cleaved to give two peptides, an N-
terminal fragment of ~ 24,000 MW and a 42,000 MW
5.2.6
5.2.6.1
C-terminal fragment. Oxidative cleavage at tryptophan
using bromine or N-bromo-succinimide are not of
great value in sequence determination as they give
low yield cleavages with many side reactions, also
attacking tyrosine and histidine residues. N-Chloro-
succinimide is milder and more specific and has been
used in several cases «(Shec~er, et aZ., 1976),
(Lischwe and Sung, 1977) and has been used to cleave
proteins in polyacrylamide gel slices (Lischwe and
Ochs, 1982).
NCS appears to be more specific than NBS
and cleavage of the tryptophan is the only major
reaction; however, the yield of tryptophanyl bond
cleavage is slightly less than for NBS (20-60%
Shechter, et aZ., 1976). It is sometimes necessary
to reduce secondary structure before the nrotein
tryptophan residues are exposed and the inclusion
of 4-5 M urea, although not altering the cleavage reaction,
does cause substantial unfolding of the protein.
Optimal conditions appear to be a 10 M excess of
reagent over substrat~ with cleavage allowed to proceed
for 30 minutes at room temperature in acidic solution.
A mechanism (Fig. 5.7) has been proposed for the
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cleavage and the apparent specificity is thought to
be due to the absence of molecular chlorine (Lischwe
and Sung, 1977). The tryptophanyl residue is oxidised
to the oxindole residue and this promotes peptide bond
cleavage. Two molar equivalents of chlorine are
required per mole of tryptophanyl residue cleaved.
5.2.6.2 O-Todosobenzoic Acid
O-Iodosobenzoic acid was introduced by
Mahoney and Hermodson (1979) as a tryptophan-cleaving
reagent which cleaved in moderate to high yields (Fig. 5.8).
However, iodoxybenzoic acid (I02C6H4COOH) may be a
contaminant in the commercially prepared reagent, causing
some additional cleavage at tyrosine residues. In
order to protect these tyrosine residues p-cresol
was introduced (Mahoney, et al., 1981) as a scavenger
of any iodoxybenzoic acid. Fontana, et al. (1983)
have shown from amino acid analysis that some
methionine residues are also oxidised and cystine
residues converted to cysteic acid in the presence
of halides, the order of reactivity being met> trp >
cys > tyr > his.
The usual reagent conditions include 4 M
guanidinium hydrochloride with 80% v/v acetic acid
in order to denature the protein. The reagent may be
purified from iodoxybenzoic acid by either gel
filtration in 10% v/v acetic acid or ion-exchange
chromatography with a salt gradient.
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5.2.6.3 BNPS-Skatole
The reagent 2-(2-nitrophenylsulphenyl)-
3-methyl-3-bromo-indolenine (BNPS-Skatole) was
introduced by Omenn, et al. (1970) and has been used
extensively for tryptophanyl bond cleavage in
proteins. BNPS-Skatole is used in aqueous acetic acid
at several-fold molar excess over the total tryptophan
concentration of the protein. Solutions must be made
up freshly as the reagent rapidly decomposes, releasing
bromine, and should be kept refrigerated when not in
use. If used correctly the only side reactions which
occur are the oxidation of methionine to the sulphone
and cysteine to cystine. Tyrosine residues can be
protected by the addition of phenolic scavengers and
the tryptophanyl bond cleavage yield is then in the
range 50-70% (Fig. 5.9).
5.2.6.4 Other Methods of Tryptophanyl Bond Cleavage
Mild oxidation of polypeptides in acetic
acid/12 N HCl/DMSO followed by more vigorous oxidation
with 4B% v/v HBr will cleave the tryptophanyl bonds
in 60% yield, the only other residues to be modified
being methionine and cysteine (Savige and Fontana,
1977). However, yields are lower than for BNPS-skatole and
the harsh acidic conditions may promote non-specific
acid hydrolysis of peptide bonds.
Another similar method of tryptophan bond
cleavage is that of Huang, et aZ. (19B3) who treated
reduced and alkylated protein with DMSO/HCl to oxidise
the tryptophan residues to oxindolylalanine and methionine
residues to methionine sUlphone. The solution was
then partially neutralised with ammonia and CNBr in
formic acid added to cleave on the carboxyl side of the
oxindolylalanine. This method gave near quantitative
cleavage with no significant modification of other
residues (Fig. 5.10).
5.2.7 Peptide Mapping in SDS Gels
Enzymatic digestion of proteins in SDS-
containing buffers followed by direct analysis on SDS-
PAGE was introduced by Cleveland, et at. (1977).
Albumin is digested using a-chymotrypsin and papain
among other enzymes and the results analysed by
electrophoresis. Papain is a thiol protease, requiring
reducing conditions for full activity and of a general
specificity although dipeptide sequences after
phenylalanine residues are cleaved with some preference.
a-Chymotrypsin cleaves at the carboxyl side of tryptophan,
tyrosine, phenylalanine and other hydrophobic residues,
but is inhibited by a proline residue after the cleavage
site, and its activity is reduced for acidic residues
and increased for basic ones.
The enzymes are used in molar excess to
degrade the albumin dissolved in SDS buffer and the
resultant fragments separated by their molecular weight
on SDS-PAGE.
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Fig. 5.10 Cleavage at tryptophan with HC1/DMSO/
CNBr.
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Fig. 5.11 Schematic representation of an HPLC
system, suitable for gradient elution.
5.2.8 Digestion with Pepsin
Bradshaw and Peters (1969) cleaved albumin
with pepsin and studied the isolated fragments.
Geisow and Beaven (1977a) have further studied the
action of pepsin on albumin and analysed the results
by SOS-PAGE and so more recently have Ledden, et aZ.
(1982).
The specificity of pepsin is wide, though
cleavage of the protein chain adjacent to hydrophobic
residues is especially favoured, and at the site of
two adjacent hydrophobic residues cleavage occurs in
between them (Fruton, 1974). The prediction of
cleavage sites is difficult but by controlled digestions
44,000 and 29,000 MW fragments have been isolated
(Geisow and Beaven, 1977b).
Fragments are often held together by
disulphide bonds and the inclusion of 2-mercaptoethanol
will alter the pattern of peptides obtained on electro~horesis.
5.2.9 Digestion with Trypsin
Trypsin has been one of the most widely used
enzymes in protein sequencing and is the most specific
of the commonly used proteases cleaving after arginine
or lysine residues, depending upon reaction conditions.
The initial protein sequencing of human albumin was
achieved by the combination of tryptic and chymotryptic
digestion, and an albumin variant (albumin B) was
analysed by this method (Winter, et al., 1972).
Lysine or arginine followed by proline
are poorly cleaved and the rate of cleavage is
variable, being reduced by acidic residues. Trypsin
is usually pre-treated with N-tosyl-L-phenylalanyl-
chloromethyl ketone (TPCK) to inhibit any contaminant
chymotryptic activity.
5.3 THE USE OF HPLC IN PEPTIDE MAPPING
5.3.1 Introduction
The traditional methods of peptide separation
(ion exchange and gel filtration chromatography and
two-dimensional finger-printing) have in the last
decade largely been replaced by HPLC either in ion
exchange or reverse phase (RP) modes. Several
excellent reviews of the techniques and their
applications have been written (Hughes and Wilson,
1983), (Regnier, 1983) and at least one symposium
compiled (Hearn, et aZ., 1983).
The main advantageof HPLC are that it gives
vastly improved resolution of peptides due to the
improved matrices, which have a smaller, more uniform
particle size giving rise to greater surface area.
The experimental time required per run is greatly
decreased and the method allows simple collection
of isolated peptides and can be used semi-preparatively,
allowing greater loadings and easier recoveries than
would be possible by two-dimensional chromatography.
Ion exchange HPLC (IEX-f{!"'lLC)is in theorvcm improvEment
of existing ion-exchange chromatography. However,
reverse phase (RP) has been used mainly as an HPLC
technique although it is analogous in some respects
to hydrophobic interaction chromatography.
Typically, both IEX-HPLC and RP-HPLC require
gradient elution techniques with one or two pumps,
a sample injector, the column and an absorbance
detector or other means of peptide identification
positioned after it (see Fig. 5.11).
Reverse phase HPLC (RP-HPLC)
Reverse phase HPLC is usually performed on
silica-based columns with alkyl chain substituents
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of varying sizes. The common chain lengths are
octyl (Ca) or octadecyl (C1S) and excess Si-OH groups
are normally blocked (referred to as "capping"). The
principle of the separation depends primarily upon
hydrophobic interactions between the alkyl side chain
and the proteins or peptides to be separated. The
mobile phase is provided by a solution of gradually
increasing non-polarity and usually a gradient of
either methanol, acetonitrile or propan-2-ol is used.
The peptides or proteins elute in the order of
their increasing hydrophobicity, as they remain bound
to the column until their interactions with it become
less than those wi.th the mobile phase, where upon they
I (j 5
are eluted. The polar aqueous buffer used initially
is usually acidified (pH 2-6.5) and acid at the
same concentration is included in the organic buffer,
resulting in a consistent pH from one experiment to
the next. Trifluoroacetic acid (TFA) is the most
commonly used acid as it is an excellent solvent
for polypeptides and alters the mobilities of peptides
on the column by an ion-pairing effect (Acharya,
etal.,1983).
The. separation achieved is little affected
by column length but the solvent system, pore size
of the column, and the degree of "capping" are ~ll
important. Due to the harsh solvent conditions of
RP-HPLC some enzymes are permanently inactivated by
it although others seem to be unaffected. For peptide
mapping, where no residual activity is required,
RP-HPLC is a popular choice and the digested fragments
of an ever increasing number of proteins are being
separated in this manner.
Application of RP-HPLC to Albumin Variants
RP-HPLC has already been widely used for the
isolation of mutant peptides of variant haemoglobins
(Wilson, et al., 1979) but has not been applied to
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the problem of albumin variants until recently.
Iadarola, et al. (1984) separated the CNBr fragments
of an Italian albumin variant by RP-HPLC and more
recently Brennan (1985) used RP-HPLC to separate
the tryptic fragments of Albumin Parklands.
The use of HPLC in the separation of such mutant
fragments may well become more widespread in the
future.
5.4 EXPERIMENTAL
5.4.1 Determination of the N-Terminal Residue
5.4.1.1 Perforrnic Acid Oxidation
Performic acid was prepared by the addition
of formic acid (8 volumes, 99%, v/v, AR grade,
distilled) to hydrogen peroxide (2 volumes, 30%, v/v),
allowing the mixture to stand at room temperature
for 2 hours in a sealed vessel, at which time the
concentration of perforrnic acid was at a maximum.
The perforrnic acid solution was cooled on ice for
15 minutes, and HSA and double Albumin Carlisle
(1-2 mg dissolved in formic acid (99%, v/v, 0.5 ml)
were chilled on ice for a similar length of time.
Performic acid (0.5 ml) was then added to each
protein solution and oxidation allowed to proceed
for 2.5 hours at OOC.
The oxidised proteins were precipitated
using TeA (80%, w/v, 0.5 ml) and centrifuged for
5 minutes in a bench centrifuge. The precipitate was
washed three times with ethanol, and once with diethyl
ether before being dried in Vacuo over NaOH.
5.4.1.2 Labelling with Dansyl Chloride (Gray 1972)
The precipitate was redissolved in ammonium
hydrogen carbonate (0.2 M, with 0.1%, w/v, SOS,
500 ~l) to neutralise any residual acid andfuen
lyophilised. The lyophilised material was
resuspended in SOS (1%, w/v, 150 u L) and heated at
1000e for 5 minutes, before allowing to cool at
room temperature. N-ethyl morpholine (50 ~l) was
added and the solution vortexed; the ~H was then estimated
with indicator puper, and further corrected if
necessary until the pH was ~ 9.0.
Dansyl chloride (25 mg/ml, 75 ~l) in
anhydrous dimethylformamide was added and any
precipitate re-dissolved with sos (1%, w/v). Dansyl-
ation was allowed to proceed for 4 hours in the
dark at room temperature. Acetone (0.5 ml) was
added and the protein precipitated using a bench
centrifuge. The precipitate was washed with acetone
(80% v/v aqueous, 0.5 ml) and centrifuged again
before drying in vacuo over NaOH pellets.
5.4.1.3 Analysis of Dansylated Amino Acids
The dried sample was resuspended in HCI
(6.1 M, 1-200 ~l) and transferred to a constricted
glass vial which had been pre-cleaned by heating
to soooe overnight. The sample was frozen in
i 8d
liquid nitrogen and the vial flame-sealed.
Hydrolysis was performed at 1050 + 100e for
16 hours and the vials were then opened and dried
~n vacuo over NaOH pellets.
The dansyl derivative was redissolved in
aqueous pyridine (50% v/v, 10 wI) and spotted onto
a 15 x 15 cm double-sided polyamide t.l.c. plate
(Chen0 Chin Trading Co.) and resolved in two
dimensions using four buffer systems.
First Dimension:
(i) ~-;rater:formicacid (90% v/v), (200:3, v/v)
Second Dimension:
(ii) Toluene:acetic acid (9:1,v/v)
(iii) Ethvl acetate:methanol:acetic acid (20:1:1,
v/v/v)
(iv) Ammonia:ethanol (1:1 v/v).
The dansyl amino acids were identified by their
fluorescence under UV light at 365 nm and their
mobilities compared to those of dansyl amino acid
standards run on the reverse sice of the plates.
DNS-arginine, DNS-aspartate, DNS-E-lysine and di-DNS-
lysine were run as standards together with DNS-
glycine and N-O-di-DNS-tyrosine.
5.4.2 Determination of C-Terminal Residue
5.4.2.1 Reaction with Carboxypeptidase Y
(Lee and Riordan, 1978)
Double Albumin Carlisle (1-2 mg) and an
equal amount of albumin A were resuspended in
MES buffer (2-(N-morpholino)-ethane sulphonic acid)
(10 mM, pH 6.8, 200 ~l). Carboxypeptidase Y (5 ~g
aliquots of 12.5 ~mol/mg protein, pH 6.75, 250C)
'.<.1e1::-eresuspended in water (20 u Ll overnight at OoC
before use. Endopeptidase activity was inhibited
by incubation with pepstatin A (7 ~g) in MES buffer
(20 ~l) for 20 minutes.
Enzyme was then added to each of the albumin
solutions and digestion carried out at 370C for 7
and 100 minutes. The reaction was stopped by lyophilisation.
Analysis was by the method detailed in Section 5.4.2.3.
Digestion with Carboxypeptidase 'P.
The method of Geisow and Beaven (1977a) was
used. Carboxypeptidase A(2.2 mg/mU was incubated at
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OoC overnight in water. Albumins (0.5 mg) were
dissolved in N-ethylmorpholine buffer (0.2 ~1,pH 8.5,
50 ~l) and enzyme added (1 ~l, 20 ~g) and the
digestion allowed to proceed for 3 hours, after which
time the solutions were lyophilised to stop the
reaction. Digests were analysed as described in
Section 5.3.2.3.
5.4.2.3 Analysis of Carboxypeptidase Digests
The samples were resuspended in MES buffer
(10 mM, 40 ~l) and applied to a 20 x 20 cm silica gel
t.l.c. plate (Merck BDH). Ascending chromatography
was performed in chloroform:methanol:ammonia
(2:2:1 v/v/v), until the solvent front had migrated
to within 2 em of the top ofllie plate. The plate was
then air-dried and sprayed with ninhydrin (0.2% w/v
in 95% ethanol:acetic acid 20:1, v/v) and heated
at 600C for 15-30 minutes in order to visualise the
amino acid spots. Standard solutions of L-leucine,
L-alanine, and glycine were chromatographed
simultaneously.
Cleavage at Methionine
Digestion at Methionine with CNBr
The method used was essentially that of
Franklin, et a Z. (1980a,b). Normal and double
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albumins were dissolved in N2-saturated formic acid
(70% v/v, 2 ml) and CNBr (a weight equal to that
of the protein) was added, dissolved in formic
acid (70% v/v). The reaction was allowed to proceed
for 24 hours in the dark at room temperature. The
mixture was then diluted with 15 volumes of distilled
water and lyophilised. Lyophilisation was repeated
to ensure complete removal of excess reagents.
Alternatively, normal and heterozygous
sera (25-100 ~l) were taken and diluted with formic
acid (70% v/v, 200 ~l). An equivalent weight of
CNBr dissolved in formic acid (70% v/v, 10 mg/ml)
was added and digestion allowed to proceed as
described above.
5.4.3.2 Reduction and S-Carboxymethylation
of CNBr Fragments
Reduction and S-carboxymethylation was
performed in triethanolamine acetate buffer (0.2 M,
pH 8.6, with urea,O M, methylamine, 25 mM, dithiothreitol,
60 mM and EDTA, 10 mM). The albumins were resuspended
in this buffer (300 ~l) and heated at 370C for 4 hours
in order to fully reduce the disulphide bridges.
Iodoacetamide was then added to a concentration of
130 mM and alkylation allowed to proceed at room
temperature in the dark for 30 minutes. The reaction
was stopped by the addition of excess dithiothreitol
and the fragments diluted with distilled water (5
volumes) and precipitated by addition of TCA to a
concentration of 20% w/v. The peptides were centrifuged
and the supernatan~discarded. The precipitates were
washed with acetone:HCl (100:0.2 v/v) and acetone and
then dried in vacuo over NaOH. In all the stages of
precipitation each solution contained 1% thiodiglycol
(v Iv) .
5.4.3.3 Analysis of CN13r Fragments by Triton-Urea
PAGE
Analysis of the CNBr peptides was on Triton X-lOa
urea gels (T = 12%, C = 0.66%) with Triton X-lOa (5 mM),
acetic acid (6% v/v ) and urea (6 M) as described b~/
Zweidler (1978). The fragments were dissolved in
loading buffer (urea (8 M), thiodiglycol (1% v/v) and
dithiothreitol (20 mM» at 370C for 90 minutes
before electrophoresis.
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The Triton-urea gels were subjected to
pre-electrophoresis for 3.5 hours, overlaying the
gel surface with acetic acid (5% v/v) with the same
urea and detergent content as the gel, using a
solution of acetic acid (5% v/v) as the electrode
buffer. A further half-an-hour of pre-electrophoresis
was carried out with the same overlaying solution but
with the addition of 2-mercaptoethanol (0.5 M). The
electrode buffer was replaced with a fresh solution of
acetic acid and the CNBr fragments (~ 100 ~g) were
loaded and electrophoresis performed at 50-100 V C.V.
overnight. Electrophoresis was stopped when the
tracking dye (basic fuschin (0.01~ w/v) dissolved in
the load buffe~ had almost eluted from the gel.
Peptides were fixed and stained in PAGE Blue G90
(0.25% w/v in methanol,45% v/v, acetic acid, 10% v/v)
and destained in the same solution without the dye.
5.4.4 Cleavage at Tryptophan
Cleavage with N-Chloro-Succinimide (NCS)
=-rShechter, eta L ,1976)
Albumin A and double Albumin Carlisle (~1 mg
5.4.4.1
each) vlere dissolved in acetic acid (80% v/v, SO ~l)
and NCS (2 mg/ml in dimethylformamide) was added in
la-fold molar excess over the total tryptophan content
of the protein. The reaction was allowed to proceed
for 40 minutes at room temperature and then residual
reagent was destroyed by the addition of excess L-meth-
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ionine. The samples were diluted 1:5 with water and
the protein fragments precipitated by the addition
of TeA to 20% (w/v) and collected by centrifugation.
The precipitate was washed with acetone containing
Hel (0.2% v/v) and then with acetone alone and dried
in vacuo over NaOH. A control was performed without
the addition of Nes and analysis of the digestion
was on 10% SOS-PAGE, performed as previously described
(Section 3. 2.9) •
Cleavage with BNPS-SkJ1tole (Fontana, 1972)
No:r:rna.land doublealbuinins(= 1 rrg) were takenand dissolved
in acetic acid (66% v/v, 100 ~l). Freshly prepared
5.4.4.2
BNPS-Skatole in acetic acid (80% v/v) was added so as
to give a lOO-fold molar excess of reaqent over total
tryptophan content and cleavage was allowed to proceed at
room temperature in the dark for 28 hours, with
continual stirring. The solutions were then lyophilised
and stored frozen until analysed on SOS-PAGE (either
T = 7.5% or T = 10-20% gradient PAGE).
5.4.5 Proteolysis in SOS (Cleveland, et al., 1977)
Normal and double albumins ('"1 mg) were
dissolved in sample buffer (-tris-HCI (125 mM, pH 6.8)
with SOS (0.5% w/v), glycerol (lO~ v/v), and bromo-
phenol blue (0.001% w/v), 400 ~l) and boiled for
five minutes to fully denature the proteins. After
cooling, papain (36 ~g, Sigma) or chymotrypsin (133
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~g, Sigma) was added to denatured solutions of
albumin A, double Albumins Redhill and Carlisle and
heterozygous Albumin Warwick-l sera (50 ~l).
Digestion was allowed to proceed for 30 minutes
and then 2-mercaptoethanol and SOS were added to
final concentrations of 10% v/v and 2% w/v
respectively and the samples boiled for five minutes
to stop the digestion.
Aliquots (~ 100 ~g) of the digests were
analysed directly on 50S-PAGE (T = 20%, C = 2.5%)
and electrophoresis performed at 100 V C.V.until the
bromophenol blue tracking dye had almost eluted
from the gel. Electrophoresis buffer was as
described in Section 3.2.9.
Digestion with Pepsin
Digestion was performed as outlined in
Ledden, et aZ. (1982). Monomeric albumins were formed
from double Albumin Carlisle and albumin A (I mg
5.4.6
of each) by the haLf=-cyst.LnyLi.sattonprocess of King
and Spencer (1971). The albumins were dissolved in
tris-HCI (0.1 M, pH 7.96, 100 ~l) and 6.24 x molar
excess of cystine, dissolved in the same buffer,
was added. Disulphide exchange was carried out
for 17 hours at room temperature by which stage
all albumin present should essentially be monomeric
(King and Spencer, 1971) and the samples were
desalted using a Centricon ultrafiltration apparatus,
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and lyophilised. Digestion with pepsin was performed
by resuspending the albumins in ammonium formate
buffer (0.1 M, pH 3.7, 200 ~l) with 4.2 mM octanoic
acid and digestion with pepsin WAS allowed to nroceed for 12
minutesat a ratio of enzyme:substrate 1:1000.
Resultant digestion was analysed by 50S-PAGE
(T = 7.5%, C = 2.6%) using a constant voltage of
50 V C.V. overnight essentially as described for
50S-PAGE in Section 3.2.9. flepticdigestions
of HSA, double Albumins Carlisle and Redhill and also
Albumin Warwick-1 serum were performed.
Digestion with Trypsin
Albumin A and double Albumin Carlisle were
digested with trypsin by the method of Behrens (1975).
5.4.7.1 Performic Acid Oxidation
5.4.7
Normal and double albumins (5 mg of each) were
oxidised using a modified performic acid reagent
(Behrens, 1975). Formic acid (88% v/v), hydrogen
peroxide (30% v/v) and phenol (90% v/v in water)
were mixed in the ratios 100:10:6 and stirred at
rOOM temperature for one hour before chilling on ice.
Albumins were dissolverlat 50 mg/ml concentration in
fOrMic acid (88% v/v) and an equal volume of the
performic acid reagent was added and allowed to
react for 1.5 hours at OoC. The oxidised proteins
were precipitated with diethyl ether (8 volumes)
and the precipitates washed with diethyl ether
twice and finally once with cold acetone and dried
in vacuo.
5.4.7.2 Tryptic Digestion
The precipitates were C}roundup and
dissolved in ammonium bicarbonate (0.5% w/v, pH 8.2, 1-2 ml).
Try~sin (T~CK-treated, Sigma) was added at a ratio
of 1:50 and digestion allowed to proceed for 4~ hours
at room temperature, with periodic stirring. The
digestion was stopped by bringing the pH to 2.0 with
88% formic acid, and after allowing any carbon dioxide
to be released, the ~sts were frozen until further use.
5.4.7.3 Peptide Mapping -
Tryptic digestions were resuspended and
chromatographed in butan-1-ol:pyridine:acetic acid:
H20, 90:60:18:72 v/v/v/v (Bennet, 1967), loading
1-2 mg of albumin for each map. Chromatography
was performed on 20 x 20 cm t.l.c. cellulose plates
(made from Avicell microcrystalline-cellulose (Merck)}
with repeated application of the sampleabout 4 an in fzrm
the left hand side, approximately 1 cm up the plate.
Chromatography was stopped when the solvent front
had migrated to within 2 cm of the top of the plate,
and the plate was then thorouqhlvair-dried.
Thin layer electrophoresis was performed
at 900 to the chromatographic separation in a Shandon
cellulose acetate apparatus at 300 V C.V.for 4-5 hours,
the greater distance being that to the cathode. The
plate was thoroughly air-dried and sprayed with
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ninhydrin, as made up in Section 5.4.2.3, or with
the ninhydrin-cadmium acetate reagent (Heilmann,
et al., 1957). Identical runs were performed for
albumin A and double Albumin Carlisle.
5.4.8 Peptide Mapping by HPLC
Organic solvents used were of HPLC grade
(BDH Ltd., U.K.) and were of the lowest uv absorbance
obtainable. All solvents were thoroughly degassed and
filtered through a 0.5 ~m filter before use.
5.4.8.1 CNBrFragments
Albumin A and double Albumin Carlisle'
were digested with CNBr and reduced and S-carboxy-
methylated essentially as described by Iadarola,
et al. (1984) or Franklin, et al., (1980a).
Initial experiments were performed on
CNBr-treated S-carboxymethylated albumin A in order
to devise a suitable separative system for the CNBr
fragments on a Waters HPLC system (as described
in Section 4.4.2.3) with a ~C18 Bondapak (30 x 0.8 cm
i.d.) column (Waters Associates Inc.). A variety of
RP-HPLC solvent systems were tried ana samples
('"500 1l!J) applied with peptides being detected by
ultraviolet absorbance at 280 or 214 nm.
The cleavage method of Iadarola, et al. (1984)
was followed and senaration of the CNBr fragments
thus generated was attempted on the llC18Bondapak
column at 1 ml/min,using a 20-60% gradient of
propan-2-ol:acetonitrile 1:2 v/v with 0.05% v/v TFA
over aqueous TFA (0.05% v/v) in 30 minutes. Fractions
from repeated runs were collected, pooled and analysed
after lyophilisation. Fractions were resuspended
in loading buffer and applied to 10% Triton X-IOO/
urea gels as detailed in Section 5.4.3.2.
5.4.8.2 Tryptic Fragments
Tryptic digestions were performed essentially
after the method of Behrens (1975). Aliquots of the
digested albumin solutions (50-100 ~l of a nominal
concentration of 3-5 mg/ml) were taken, after centri-
fugation to remove undigested material, and applied
to RP-HPLC using a range of gradients of acetonitrile:
propan-2-ol (2:1, v/v) containing 0.05%, v/v TFA over
aqueous TFA (0.05%, v/v) to elute the peptides from
the column. A flow rate of 1 ml/min was used and
the absorbance followed at 214 nm.
5.4.8.3Peptic Fragments
Albumin A, pure abnormal Albumin Carlisle
and double Albumin Carlisle (= 1 mg of each) were
digested with pepsin (0.2 mg/ml in 1 mM, HCl,
Worthington Enzymes) in the·ratio of 1000:1,
substrate:enzyme in a total volume of ammonium
formate buffer (0.1 M, pH 2.5, 500 ul). Digestions
were allowed to proceed at room temperature for
0, 35, 80, 105, 135, 225, 285, and 470 minutes and
for an overnight period. Aliquots (50 ul) were taken
after each time interval and the reaction
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stopped by addition of 2 M tris until the pH was> 8.0.
Fractions were frozen at -200C until loaded and analysis
performed on 10% non-SDS-PAGE and by RP-HPLC on a
'Waters HPLC system as before on a PC18 Bondapak
column. A 0-100% gradient of acetonitrile:propan-2-
01 ~:l, v/v) with 0.05% (v/v TF~) over aaueous TFA
(0.05%, v/v) was used at 1 ml/min. ~low rate,rront.torfnq absorbanceat
214 nm, 1.0 AUFS.
Samples of HSA and double ~lbumin,Carlisle were also
digested for 35 minutes and then analysed by the
HPLC as above.
5.5 RESULTS
The N-terminii of Albumin Carlisle and
albumin A weredetermined by dansylation of the
N-terminal residues. After acid hydrolysis, the
dansyl amino acids obtained were compared to known
standards on two-dimensional polyamide plates. The
dansyl amino acids derived from the hydrolysis of
double Albumin Carlisle when chromatographed in
the first three solvents gave a single dansyl
amino acid-DNS aspartate (Fig.5.12). No DNS-arqininecould
be detected in the hydrolysate indicating that the
N-terminal residue of Albumin Carlisle is aspartate,the sane
as that of albumin A and 'thftt"itis not
a proalbumin variant (which have ar9inine at the N-terminus). It
was possible to use a fourth solvent system, in
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the second dimension, in order to clarify poorly
separated dansyl amino acids. This was unnecessary in this
instance and did not alter the conclusion obtained from
the three solvent system results.
The C-terminus of Albumin Carlisle was
determined using both carboxypeptidase A and Y. Both
albumin A and Albumin Carlisle gave leucine and
glycine ninhydrin-positive spots on t.l.c. when run
against amino acid standards. The C-terminus of
albumin A was already known to be gly-leu-COOH and
the pattern of released amino acids was identical
using carboxypeptidase A for both double Albumin
Carlisle and albumin A. This would indicate that the
C-terminal leucine and penultimate glycine residue
were excised from the albumins by carboxypeptidase A
after a 5-10 minutes digestion (Fig. 5.13).
In some experiments with carboxypeptidase
Y only glycine was released from both albumin A and
double Albumin Carlisle, orobably because of the
slow release of the leucine residue bv this enzyme.
However, digestions for longer periods (100 minutes)
showed that both leucine and glycine were released
from both samples.
The incubation of double Albumin Carlisle
and normal albumin with CNBr and subsequent
electrophoretic analysis revealed that double
Albumin Carlisle showed an extra band on gel
electrophoresis, althoucmseveralotherbandspresent ID normalalbtmUn
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were absent. The pattern of bands was consistent on
two independently run gels (see Fig. 5.14).
Franklin, et aL. (1980a,b) have characterised the
fragments generated under these conditions and from
correlations to their results it would appear that
the extra peptide band corresponds to CNBr fragment
V or VI (residues 329-446 or 446-548). Double
Albumin Carlisle appeared to lack any modified fragment
III (residues 123-298) or fragment I
(residues 1-87). These latter differences may be
due to variations in the degree of amino acid
modification (cysteine oxidation and lysine alkylation)
in the different preparations of CNBr digests.
Cleavage at tryptophan using both N-chloro-
succinimide and BNPS-Skatole (Fig. 5.15) yielded two
anodic fragments on SOS-PAGE. From their migration
compared to known molecular weight markers, these
bands are consistent wlth the la..~rC-terrninalfragment(residues
215-585) and the smaller N-terminal
fragment (residues 1-214). In neither gel could any
discernable extra band be noticed with the C-terminal
fraqments, suggesting that the point mutation in
Albumin Carlisle does not alter the properties of
these large peptides sufficiently to separate them
from the normal fragments on 50S-PAGE.
The percentage cleavage with BNPS Skatole
was far higher than for the Nes digestion although
the fragments from the latter were clearly visible.
Fig.
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Cleavage with o-iodosobenzoic acid gave poor results
and one reason for this may be due to loss of
peptides in the supernatant on TCA precipitation.
Cleavage with pepsin in the presence of
octanoic acid, as detected by 7.5% SDS-PAGE gave
essentially the same number of fragments for double
Albumin Carlisle and albumin Ai with two bands, one at
~ 42,000 MW and the other at ~ 36,000 MW. Double
Albumin Redhill, however, contained two components
instead of one for the first band, at 44,000 and 40,000
~V. This may be due to the increased MW of Albumin
Redhill variant, giving rise to fragments of higher
molecular weight. Peptic digestion and analysis
were performed after the method of Ledden, et al.
(1982) who also reported two fragments under reducing
conditions, of 50,000 and 30,000 MW. Electrophoresis
in 10% non-SDS gels revealed four anodic bands ahead
of the albumin and these were again similar for double
Albumin Carlisle and normal HSA.
Pepsin appears to digest albumin fairly
non-specifically from the C-terminal end and to
leave a number of fragments consisting of the first three
hundred residues of the protein (Geisow and Beaven,
1977a). If the mutation in Albumin Carlisle was
in the last 100-200 amino acid residues then no
differences would be expected in the fragments
from peptic digestion, as the mutation would most
likely have already been excised.
Digestion with papain, which is a fairly
non-specific proteas~ revealed gross homology between
the generated peptides of double Albumin Carlisle
and those of HSA (Fig. 5.16). Several differences
do occur in the electrophoretic pattermon 20% SDS-~AGE
but it was not possible at present to pinpoint
these to a mutation at the molecular level.
Digestion with a-chymotrypsin also
revealed gross homologies between the double albumins
and albumin A. However, double Albumin Carlisle showed
two extra bands and other bands of different mobility
to the other albumins. The bands in the double
Albumin Redhill were all also present in albumin A
but some had differing mobilities, possibly indicating
a mutation in these oeotides. Double Albumin
Warwick-l showed a similar pattern of bands to
albumin A but again with some differences in
mobility. Differences at the cathodic end of the
tracks may reflect varying degrees of completion of
the proteolytic process.
In the hope of obtaining better resolution
RP-HPLC was used to separate fragments derived
from CNBr cleavage and also peptic and tryptic diges-
tions. The separation of all the CNBr-derived fragments
would have been a major advantage in locating the
point of mutation. Therefore much time was spent on
assessing different solvent systems for such a
ii. iii iv! V
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Solvent System Conditions Resolution Achieved
1 Trifluoroacetic acid (TFA)/ Isocratic Elution Single peak only ~n
methanol + 0.1% vlv T FA methanol wash
2 10% v/v acetic acid/
methanol + 10% v/v
acetic acid
3 0.009 M HZS04/aqueousacetonitr~le + 0.009 M
H2S04
4 0.05% v/v TFA/60% v/v
acetonitrole + 0.05%
v/v TFA
5 0.05% v/v TFA/aceto-
nitrile: propan-2-ol
2:1 (v/v) + 0.05% v/v
TFA
0-60%methanol in ,Single peak at 80%
20 minutes 60-80% methanol
in 20 minutes
0-60% ace toni trile Several peaks
in 40 minutes resolved
40-48% aceto-
nitrile in
60 minutes
Several peaks
resolved but separa-
tion of fragments
incomplete
20-60% aceto-
nitrile:propan-2-
01 in 50 minutes
Several peaks
resolved but separa-
tion of CNBr frag-
ments not subs tan-
ti.a 11y improved.
TABLE 5.1 Solvent systems used for separation of CNBr fragments of
albumin by RP-HPLC.
l.0'/
separation (see Table 5.1). However, reduced and
alkylated CNBr fragments were poorly soluble in
aqueous TFA buffers and therefore separation of non-alkylated
fragments was also attempted.
The best separation was obtained with
a gradient of 30-48% v/v acetonitrile with 0.1% v/v TFA over
0.1% v/v aqueous TFA i hovJever,even then resolution was
poor and the individual fragments were not isolated,
although the three more cathodic fragments (on gels)
were separable from the other fragments in some
runs.
During late 1984, Iadarola, et a le (1984)
published a method of separating the CNBr fragments
of albumin using HPLC on two different columns. One,
a Vydac C19,was a large pore size column (= 300 R)
and 50 allowed better interaction with the column
matrix for the peptides chromatographedi the other
was the smaller pore size (= 100 R) ~C18 Bondapak
colurm..The acetonitrile :propan-2-ol gradients used
were as described previously (Section 5.4.3.1).
Attempts to repeat the results of Iadarola
et al. using similar conditions on a ~C18 Bondapak
alone met with no success. The elution profile
obtained was very different and the separation of the
peptides was not significantly improved, and their
identification on gels was hindered by their low
concentration. The probable reason for this poor
result was the small pore size of the Bondapak
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column. Small pore sizes have been correlated to
non-specific retention of peptides and poor elution
profiles with variable peptide recovery. In their
paper Iadarola, et al. (1984) reported that they were unable
to separate all the albumin CNBr fragments in a single
run and that the ~C18 Bondapak column gave poorer
resolution than the 300 R pore size Vydac column. They
used the ~C18 Bondapak column to separate fragments
I and V and to analyse the tryptic digest of the isolated CNBr
fragment (Iadarola, et al., 1985). This evidence
would suggest that a separation under the conditions
used above was unlikely to give good resolution.
The HPLC of 35 minutes peptic digests of
RSA revealed two peaks after 10 minutes (17% solvent
Bh a large ~eak after 35 minutes at = 58% B, and
several peaks which\A.IE!reeluted afterwards. The first two
peaks also appeared in double Albumin Carlisle
and the only discernable differences were in the
fine structure of the peaks eluted after 35 minutes
of the gradient.
Controlled-time digests of RSA with pepsin
revealed a gradual progression; the main peak at
35 minutes was absent in subsequent experiments,
a major peak was noticed at 45 minutes (= 90% B)
and the peak gradually decayed with time. Fine
structure both before and after this increased with
time and was presumably due to the peptic fragments
generated; these peaks were maximal at 30 hours
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after digestion.
Peptic digestion of purified abnormal
Albumin Carlisle was also studied over a similar
time course. Although some extra peaks were present
by about 6 hours, they were different and less
distinct than those for albumin A. Aliquots were
simultaneously collected and run on non-50S gels and the
digested albumin bands were most distinct after '"4
hours.
Tryptic Digests
The tryptic digests analysed by two-
dimensional peptide mapping gave inconclusive results
on thin layer cellulose and so RP-HPLC was atternnted in order to
analyse the fragments.
Initially a 0-100% gradient of acetonitrile:
propan-2-ol,2:1 was used over 45 minutes with gradient
3 on the l"1aters660 gradient programmer. The pattern
of peaks obtained was too constricted for good
resolution and other systems were tried until a
20-80% gradient of solvent B over 50 minutes using
gradient 3 was found to be optimal; with a low concentra-
tion of organic solvent maintained initially to elute
the polar fragments and a gradient to higher concentrations
being formedlater to elute the other fragments.
Comparative runs of double Albumin Carlisle
and albumin A (Fig. 5.17) were repeated several times
and a consistent difference in the relative heights
of a quartet of peaks was noticed for the Albumin
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Carlisle samples after '" 43 m], of elution ('"80% B).
The new pattern was seen only in chromatograms of double
Albumin Carlisle, not in those of albumin A, and was
similar to the type of difference found by Brennan (1985)
for the tryptic digest of Albumin Parklands, and for
similar variant proteins analysed by HPLC. As double
albumin was used a total absence of the normal peaks
would not be possible and so the difference generated by
the albumin mutation would most likely be detected as
a change in relative peak intensities.
The hydrophilic fragments eluted early on
in the gradient were poorly resolved and there may
be other differences in the albumins masked in this area,
which further study might elucidate.
Due to lack of time the repeated pooling of
these peaks was not possible, but this would seem the
most logical progression in order to obtain sufficient
material to attempt peptide sequencing.
It may be relevant at this stage to point
out that Iadarola, et al. (1985), working with albumin
from a homozygous patient, noted no differences in the
HPLC profile of the tryptic fragments of the variant CNBr
peptide and only pinpointed the mutation in Albumin
Mi/Fg by subsequent collection and sequence analysis
of the separated fragments.
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5.6 CONCLUSION
Albumin Carlisle has been studied by
peptide mapping on polyacrylamide and cellulose and by
HPLC. The Nand C-terminii are identical to those
described for albumin A and digestion with CNBr
revealed a possible mutation in the region residues
329-548 . This is consistent with the evidence of
peptic digestions which could reveal no difference in
the albumin fragments generated, most of which have
been digested from the C-terminus. Hence, it seems
likely that the mutation has been excised by the
peptic digestion, and as such is localised in the
C-terminal region.
Digestion with papain and chymotrypsin
and subsequent peptide mapping revealed differences between
Albumin Carlisle and albumin A,which possibly
implies differences in the susceptibility to proteolytic
attack at certain residues within Albumin Carlisle,
caused by an amino acid mutation.
Although RP-HPLC of CNBr fragments did
not give satisfactory separation on the columns
available enzymatic digestions using pepsin and
trypsin were subsequently resolved. RP-HPLC
does appear to be a powerful technique for the
analysis of peptides generated by these means, provided
that a ran~e of columns of differing properties
are available for use.
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RP-HPLC of the tryptic digestion of double
Albumin Carlisle revealed a consistent difference
in the elution profile of a quartet of peaks and,
had time allowed, further analysis of the amino
acid composition of these peaks may have elucidated
important details about the amino acid mutation in
Albumin Carlisle.
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CHAPTER SIX
AMINO ACID SEQUENCING OF ALBUMIN REDHILL
6.1 INTRODUCTION
6.1.1 Sequencing Methodology
The amino acid sequence of a protein is the
most important data for comparing normal and variant
forms. It is the most basic information about protein
structure from which secondary and tertiary structure
can be predicted and ligand binding, or enzymatic
fUnctions understood at a molecular level. As such it
is not surprising that much effort has been put into
developing modern and efficient protein sequencing methods.
Over thirty years ago Sanger and Tuppy (1951) deduced the
amino acid structure of insulin B chain using fluoro-
dinitrobenzene (FDNB) to label the N-terminus and
identifying the dinitrophenyl amino acids by paper-
chromatography. Since then a number of methods for
protein sequencing have been devised and improved so
that by 1979 160,000 residues and 1,100 complete protein
sequences were known, and the number has grown
considerably since then. There are several methods
that can be used to obtain amino acid sequences:
(1) The Edman Degradation;
(2) Mass Spectrometry;
(3) Interpretation from the cDNA sequence;
216
(4) Other degradative methods, including amino-
peptidases and otherrumno-terminal cleaving
reagents.
Of these the Edman method is probably the most
well know~ although in the past decade vast numbers of
DNA sequences have been derived.
6.1.1.1 Edman Degradation
This technique is the most important for the
determination of amino acid seque~ of peptides. It was
developed by Edman (1950) as a manual procedure and later
by Edman and Begg (1967) in an automated form, and it has
been constantly improved upon since then. The basic
process is in three stages; firstly, the amino-terminal
residue of the protein is coupled to the Edman reagent
(phenylisothiocyanate, PITC) Secondly,this residueis then
cleaved of.f. the chain using strong acid to give, via
cyclisation, an anilinothiazolinone residue. The third
step is to convert the unstable anilinothiazolinone to
a phenylthiohydantoin amino acid (PTH-amino acid) which
can be compared to PTH-amino acid standards by
chromatography.
The technique is probably the widest used of
all protein sequencing methods and can by repeated cycles
identify 20-70 residues from the N-terminus of a peptide
or protein.
6.1.1.2 Mass Spectrometry
In principle mass spectrometry, by deriving
precise molecular weights for small peptides cleaved
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from the total chain, can be used to give amino acid
sequences. However, the equipment is expensive and the
data complicated so that it has been utilised by few
laboratories. One main disadvantage is that for electron
impact (EI) mass spectrometry the peptides must be
volatilised by derivatisation before a sequence can be
obtained. This problem has been overcome by use of
Fast Atom Bombardment Mass Spectrometry (FAB-MS) where the
sample, applied to the probe in a glycerol matrix, does not
need to be volatile. In this technique the sample is
bombarded with accelerated Xenon atoms and ionisation
occurs to give quasi-molecular ions which can then fraqment
The mass spectrafran such bombardments can be used to
determine the peptide sequence, as amino acids are
sequentially lost by fragmentation, or FAB-MS can be performed
on dipeptides released sequentially from the peptide by
dipeptidyl aminopeptidases.
Although still less common than the Edman method,
mass spectrometry is able to detect glycosylations and
other post-translational modifications of amino acids which
often prevent Edman sequencing methods from successfully
obtaining a sequence. The large number of proteins showing
post-translational modifications may well result in mass
spectrometric sequencing becoming more widely used. A
more complete review of the uses of mass spectrometry
in peptide sequencing can be found in Elzinga (1983).
6.1.1.3 DNA Sequencing
Although DNA sequencing does not directly give
the amino acid sequence, this can be derived using the
genetic code if the appropriate regions of DNA can be
identified. The cloning of complementary DNA (cDNA)
encoding the mRNA seauence has become an established
technique and it can be both nuicker and sin~ler to determine
the sequence of the orot.eLn bv these indirect methods (Sangeret al .
1977), Maxam and Gilbert, 1980). Often, if sufficient
residues of a protein are known:then a synthetic
oligonucleotide can be synthesised and can then be used
as a probe for the DNA sequence encoding the protein.
In this way many proteins which occur in such minute
amounts that obtaining sufficient protein for sequencing
is an almost insurmountable task may be sequenced from
their DNA. However, there are disadvantages in sequences
obtained in this way as no information about any post
translational modifications is given and a loss of a
base pair in the DNA sequencing may result in the
wrong assignment of amino acids for a long section of
the chain. DNA sequencing can reveal little about the
disulphide bond assignments and positions, bein0 un-
able to distinguish between cystine andcysteine residues.
It does not detect the presence of glycosylations,
acylations or other modifications to the amino acids
which can be detected by combined protein sequencing
methods. Any post-translation chain cleavage, such as
Occurs in the insulin molecule, could not be deduced
from the DNA sequence alone. DNA sequencing in areas
of repetitive sequence is also prone to difficulties
as is the protein sequencing. Therefore DNA se~uencing is
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best performed in conjunction with modern highly
sensitive protein sequencing methods so as to avoid
such difficulties and present a complete picture of the
rost-translational gene product.
6.1.1.4 Other Methods
Other reagents for cleaving amino acids from the
N-terrninus have been developed since the widespread
introduction of the Edman reagent; however, they have
not attained routine use. Thioacetylthioglycolic acid
(TATG) may be used, and this generates the free amino
acid in mild conditions after cleavage (Doolittle, 1983).
Enzymic analysis of the N-terminus may be achieved with
amino dipeptidases (Light, 1972) such as leucine
aminopeptidase, which preferentially releases hydrophobic
amino acids, or aminopeptidase M, which has a broader
specificity. Such enzymes are common in mammalian
cells and their use,combined with mass spectrometry, may
be a powerful means of sequencing blocked N-terminal
and other modified proteins. (D. W. Hutchinson,
private communication).
Another possibility is the determination of
C-terminal residues usin~ the carboxyoeptidases (see
Section 5.2.4). Althou0h prin~rily used for the identification of
the C-terminal amino acid it may also be possible to utilise such
enzymes to determine short regions of sequence from the
C-termini of peptides and proteins.
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6.1.2 The Edman Degradation
There are presently three main formats for
using the Edman degradation, they are:
(i) manual liquid phase;
(ii) automated (spinning cup) liquid phase;
(iii) automated solid phase.
Each of the three use the same basic reaction and so
the chemistry of the degradation will be considered first.
A more complete analysis has been reported by Tarr (1977).
6.1.2.1 The Degrada'tive Process
6.1.2.1.1 Coupling
As previously stated, the Edman degradation
has three major steps, the first of which is coupling of
the PITC to the amino-terminal residue. The coupling
reaction (Fig. 6.1) takes place in alkaline solution
between pH 8-1~ so as to allow the amino group to be in the
unprotonated form,but not too alkaline so as to result
in the hydrolysis of the PITC to aniline,so competing
with the Edman process. The attachment to ~amino
residues is far slower at pH 8 and although different
N-termini react at different rates all should have been
coupled after 30 minutes at SOoC using a solution of PITC
in aqueous pyridine or similar solvent system.
Aldehydes in the buffer solution can
result in partial blocking of the free amino group:
reagents used should therefore be pure and molecular oxygen
and other oxidants should be excluded as they may cause
desulphurisation and stop further degradation (Isle and
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Edman, 1963). Other reasons for low percentage
coupling may include insufficient mixing or acidic
contaminants of the peptide reducing the pH. Prolonged
reaction times and higher temperatures may also produce
undesirable side reactions.
Coupling gives rise to a phenyl thiocarbamyl (PTC)
peptide, and solvents and by-products are removed by
solvent extraction using either an organic solvent for
solid phase or a two-phase aqueous/organic solvent for
the liquid phase. The aqueous layer is retained and
dried over p20S and NaOH in vacuo before the cleavage
step can occur.
6.1.2.1.2 Cleavage (Cyclisation)
Most procedures for the cleavage reaction
(Fig. 6.2) employ anhydrous perfluorinated carboxylic acids
usually trifluoroacetic acid or heptafluorobutyric acid.
Edman initially used HCI/nitromethane (Edman, 1950) and
HCI/acetic acid has also been used. Water is generally
avoided due to the danger of acid-catalysed peptide bond
hydrolysis, although heptafluorobutyric acid with 4% water
gave better results than the anhydrous acid. Other
possible problems include esterification of hydroxyl
groups on serine or threonine,as these are rapidly transferred to
the a-NH2 group in the alkaline media used for coupling
when theseresidues become N-terminal and so block further
degradation. Also, the acetylated PTH derivatives are
more susceptible to a-elimination which complicates
their detection.
1.1.2
Ph-N=C=S+ H,N-CH-CO-NH-CH-CO-NH-CH--CO--
- I I
RI R: Rl
S
"Ph-N-C-N-CH-CO-NH-CH-CO-NH-CH-CO- ...I I I I I
H H RI R~ R3
phenylthiocarbarnyl- (Ptc-jpeptide
Fig. 6.1 Edman Degradation: coupling reaction.
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N-CH-C-NH-CH-C- ...
/ II II
Ph-N-C C~ 0 0
-, / 0
N-C-H
H/ ""RI
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R2 R)
I I
+ H;N-CH-C-NH-CH-C- ...
II II
o 0
(an ilinothiazolinone)
(salt of released peptide, with new
N-terminal residue)
Fig. 6.2 Edman Degradation: cleavage reaction.
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phenylthiohydantoin
+
Fig. 6.3 Edman Degradation: conversion reaction.
223
After cleavage,volatile acid is removed in vacuo
and the anilinothiazolinone derivative formed is
extracted from the salt of the residual peptide by
two-phase extraction, although any remaining acid will
enhance the solubility of peptides in the butyl acetate
and so increase losses for the next cycle. The organic
phase containing the anilinothiazolinone derivative is
dried over nitrogen and conversion to the PTH-amino
acid carried out.
6.1.2.1.3 Conversion
The anilinothiazolinone derivatives of amino
acids are not sufficiently stable to be reliably chromato-
graphed and so conversion to the PTH derivatives is
carried out before chromatogra~hic identification (Fig. 6.3).
A commonly used method is heating at BOoC for 10 minutes
in 1.0 M HCl under N2• The thiazolinone ring opens to
give the intermediate phenylthiocarbamyl (PTC) amino
acid which then cyclises in a second step to the phenylthio-
hydantoin (PTH) amino acid. All derivatives but glycine
readily cyclise in thistime (Isle and Edman, 1963).
partial hydrolysis of asparginyland .,9'lutaminylde:o:-ivativesoccurs.
as does conversion of glutamateand aspartateto theirmethylesters.
To avoid such problems the aminothiazolinones can be
reacted with methylamine and the phenylthiocarbamyl
amino acid methylamides formed can be chromatographed
against standards.
6.1.2.1. 4 Identif·icationof PTH-Arnino Acids
(i) Edman (1950) identified his PTH-arnino
acids by back hydrolysis with barium hydroxide to
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give the free amino acids, and then performed paper
chromatography against amino acid standards. However,
the method is inefficient and several amino acids are
difficult to identify. Hydrolysis with HCI/SnCI2 has replaced
this method (Mendez and Lai, 1975), but the procedure
is time-consuming and the technique is usually used only
when other means of identification have failed.
(ii) The chromatogra~hy of PTH-amino acids on
paper was proposed in 1953 by Sioquist and was capable
of detecting 50 nmol,of PTH-amino acid. Since then
thin layer chromatography has been used successfully.
Silica gel fluorescent plates (Merck) have been used in a
two-solvent system to detect 5-10 nmol of PTH-amino
acid run against PTH-amino acid standards (Allen, 1981).
The discrimination of the hydrophobic amino acids
requires careful comparison as they resolve poorly from
each other, and spraying with reagents, producing different
colours for the various amino acids, has been used to aid
identification. Two-dimensional t.l.c. of PTH-amino acids
can detect up to 0.5-1.0 nmol of PTH-amino acid as
absorbant areas on fluorescent silica (Kulbe, 1974).
(iii) Gas-liquid chromatography was popular for
a long time in the 1960's and 1970's as being the most
important method of quantitatively identifying PTH-amino
acids. However, the more polar PTH-amino acids cannot be
identified directly, requiring conversion to more volatile
derivatives, and the PTH derivatives of arrrinineand cysteicacid
are not identifiable at all. Pisano (1972) gives
experimental details of the procedure but it has been
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superceded by HPLC.
(iv) In the 1970's reverse phase HPLC was
used to separate PTH-amino acids and this technique
has largely been adopted for most automated sequencing.
Reverse phase chromatography is performed on octyl or
octadecyl silica with either isocratic or gradient elution
of acetonitrile or methanol over an acidic aqueous phase
usually at elevated temperature (30-50oc). All of the
PTH-amino acids are separable using gradient elution
although good resolution is also achieved with the
simple isocratic elutions. Detection is usually by
absorbance at 254 nm though other wavelengths have been
used. Although the equipment is initially expensive it
provides separations in 20 minutes using 1-10 nmol of PTH-
amino acid and sequences in the pmol.range have
been reported.
6.1.2.1.5 Difficulties with the Edman Degradation
There are a number of competing side
reactions and other difficulties which limit the theoretically
infinitenumberof.cyclesof the Edman procedurewhich can be performed.
In practice only 20-50 steps can usually be performed
before the identification of the PTH-amino acid becomes
impossible.
There are a number of problems which cause this
loss of efficiency:
(i) The increase in proportion of preceding
residue due to a gradual decrease in the cleavage efficiency.
Although yields are optimally 98%,as the degradation
proceeds through many cycles an 'overlap' arises due to
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incomplete coupling and cleavage reactions. The newly
produced PTH-amino acid eventually becomes undetectable
against the increasing background.
(ii) Acid sensitive non-specific peptide bond
cleavage also results in an increase in the background
PTH-amino acids produced.
(iii) Small amounts of peptides may be lost at the
two-phase extraction steps. This reduces the amount of
material available for the next cleavage and serves to
aggravate the problem of background noise.
(iv) The presence of blocked N-terminal residues
due to the migration of acyl groups on serine and
threonine, or of acyl groups naturally occurring in the
peptide chain, prevents further degradation or reduces the
yield of PTH-amino acid.
(v) Difficulties are sometimes encountered with sequences
bearing O-glycosyl groups on serine and threonine. The
residue produced is often difficult to characterise and may
not extract into the organic phase after cleavage. Special
methods are needed for such glycosylated residues.
(vi) Asparaginyl-glycine bonds. Under acidic
conditions asn-gly sequences are converted to an imide
structur~ which forms a a-aspartyl peptide bond under
alkaline conditions and so blocks further degradation,
or allows it to proceed with very low yield.
(vii) N-terrninal glutamine residues may cyclise
under acidic conditions, although this can be avoided
by strict timing at each stage. Similarly,PTC-histidine
peptides are very rapidly cleaved and thus partial
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coupling may occur of the next residue and so two residues
are detected on analysis. This preview of the following
residue can also be controlled as it does not occur
in non-volatile buffers. Tryptophan oxidation can also
lead to blockages in manual processes if the exclusion
of molecular oxygen is not complete.
6.1.2.2 Modes of Operation for the Edman Degradation:
6.1.2.2.1 Manual LiqUid Phase Sequencing
Modern manual methods typically require
50-250 nmol of peptide and several procedures have been
described (Tarr, 1983; Zalut, 1983). The initial procedure
of Edman (1950) has been modified subsequently so as to
increase the sensitivit~ also several peptides can be
manually sequenced at the same time and the resultant PTH-
amino acids dereacted by HPLC or t.l.c. Although the
·technique has difficulties (the need for oxygen-free
environments and high vacuum together with small sample
volume requires some dexterity on the part of the
operator) several modifications have made it an invaluable
and less expensive alternative to automated sequencing.
6.1.2.2.1.1 Dansyl Edman Method
This is an indirect method whereby a
small aliquot of the peptide is removed after each cycle and
reacted with dansyl chloride. As only 0.2 nmol. are
required the repetitive yield is only slightly reduced
and 10-30 residues may be identified with2-50 nmo L of
peptide. Allen (1981) describes a methodology for a
dansyl Edman manual procedure. The major problem with
the dansyl Edman procedure is the poor differentiation of
the amide and acid groups, and the loss of tryptophan
228
residues which are not identified.
6 • 1 • 2 • 2 .1. 2 Microsequencing with DABITC
Chang, et at. (1978) used an alternative
isothiocyanate which gave intensely coloured PTH-
residues. The reagent,4-N,N-dimethylamino-azobenzene-4'-
isothiocyanate (DABITC),yields thiohydantoic amino
acid derivatives (DABTH-amino acids) whose properties
have been characterised by Chang, et at. and the technique
can be used for a solid phase sequencing orocedure (Chang,
1979). The DA.BTH·-aminoacids are separable by 2-dimensional
t.l.c. on polyamide plates against DABTH-amino acid
standards. Although the derivatives appear as a faint yellow
colour on chromatography a strong red is produced on
exposure to concentrated HCI. Separation of DABTH-leu
and DABTH-ile is poor. By coupling first with a small
amount of DABITC and then "lithexcess PITC, chang, et Qt.
(1978) succeeded in driving the otherwise slow coloured
reaction to completion. The use of DABITC is now
widespread and can be used for automated as well as manual
procedures. By use of pre-column derivatisation and HPLC
detection of the DABTH-amino acid at 436 nm, it is possible
to sequence peptides with as little as 5 pmol,of material
(Chang, et a l : , 1983).
6.1.2.2.2 Automated Liquid Phase Sequencing
The first automated system for liquid phase
Edman degradation was designed by Edman and Begg (1967). The
spinning-cuD device became the model for all liquid
phase sequencsrs thereafter" although many mechanical
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modifications have subsequently been made resulting in
greater sensitivity with 20-50 residues being located
at 24 cycles per day. The protein is dissolved in
heptafluorobutyric acid and introduced into the
spinning cup~ the solvent is then evaporated under
vacuum to leave the protein as a film around the sides
of the cup. PITC is then introduced in a coupling buffer,
usually Quadrol (N,N,N',N'-tetrakis (2-hydroxypropyl)-
ethylenediamine) in aqueous propan-I-ol. Coupling
occurs for ~ 30 minutes at SOoC and then excess reagents
are removed in vacuo and the Quadrol and by-products
extracted with benzene and ethyl acetate. The film of
PTC-protein is dried thoroughly and heptafluorobutyric
acid added. Cleavage is allowed to proceed for three
minutes and then most of the acid is removed in vacuo. The
cleaved anilinothiazolinone derivative is extracted in
l-chlorobutane and collected. The dried protein film is
then ready for another cycle. Due to the improvements
in sequenator technology over recent years it is possible
to sequence quite long peptides at the subnanomolar level
(Hunkapiller and Hood, 1980). The sequenator must be
cleaned regularly and correctly serviced for the
sensitivity to be maintained.
To be effectively removed Quadrol has to be
dissolved in a polar solvent, normally ethyl acetate;
however, some loss of coupled peptides into this
solvent is possible, thereby reducing the number of
cycles that can be performed. Two possible ways of
overcoming this problem have been proposed; dimethyl-
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allylamine (Niall, et al., 1969) which is volatile, and
dimethyl benzylamine (Herrnodson,et aZ., 1972) which
is soluble in benzene have been used in place of Quadrol
so as to reduce peptide losses. A second approach has
been to render the pe~tides more hydrophilic. Several
chemical means have been proposed, including sulphonated
isothiocyanates which react with the lysyl s-NH2 groups
(Braunitzer, et al., 1971)fand carbodiimide coupling of
carboxyl groups with hydrophilic amines (Foster, et al. ,
1973). However, the most effective method has been found to
be the addition of film-stabilising substances such as
the polycationic Polybrene (1,5-dimethyl-1,5-diazundeca-
methylene polymethobromide) which anchors peptides in
the aqueous phase and so reduces protein and peptide
losses in two-phase partitions.
6.1.2.2.3 Gas Phase Sequencinq
In 1981 Hewick, et al. reported a gas-liquid
phase protein sequencer which was capable of picomole
level sequencing. The polypeptide is embedded in a
matrix of Polybrene dried onto porous glass fibre in a
small cartridge-style reaction cell. Although not covalently
attached, the sample is effectively anchored throughout
the degradative cycle and is only exposed to relatively
non-polar extraction solvents. Only a very minimal
amount of trifluoroacetic acid is used and the
coupling is performed in trimethylamine/water vapour
and the cleavage in trifluoroacetic acid vapour. The
reaction chamber is much reduced in size compared to
the spinning cup (Hunkapiller, et at., 1983) and
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picomole sequences are reported.
6.1.2.2.4 Solid Phase Sequencin~
As an alternative method of dealing with the
problems encountered with peptide loss during two-phase
extractions, covalent attachment of the peptide to an
insoluble support was devised (Laursen, 1966). Efficient
extractions are now possible without loss of peptide, and
the process may be readily automated. The insoluble
support is placed in a column, fitted with lines for the
sequential delivery of reagents and collection of derivatised amine
acids. The automated system has been commercially produced
and several good reviews of the operation and characteristics of
solid phase sequencing have been written (Previero and Coletti,
Previero, 1977, Laursen and Machleidt, 1980).
The solid phase sequencing procedure was a
logical extension of the solid phase peptide synthesis
of Herrifield(1963) and the earliest support was made of
modified polystynmeresin. These resins are often used but
have distinct disadvantages, with differential swelling and
small pore size giving very low attachment efficiency for
larger polypeptides. These problems have been in part
overcome by the use of a large excess of glass beads to
pack the column.
6.1.2.2.4.1 Supoortin1Media
Supports should be chemically stable to the
Edman reagents, be accessible to the peptides and able
to be coupled to ~hem, and they should resist fracturing
or gross deformation. Two types of resin have been
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produced with this in mind; synthetic resin supports
and glass bead supports.
6.1.2.2.4.2 Synthetic ~esin Supports
Polystyrene resins give poor results with large
peptides or proteins since they swell considerably. Two
other types of polymeric support which have found wide
application for protein immobilisation are cross-linked
agaroses (Porath, 1974) and polyacrylamide (Inman, 1974)."
Polyacrylamide has been utilised in the E'.dr-1.:-m de-rradat.ionbut
agarose is labile to trifluoroacetic acid. Some modified
polyacrylamides have been used,but have not been fullystudied,
although proteins can be attached in reasonable yield.
6.1.2.2.4.3 Glass Supports
The most useful glass supports are prepared
from treatment with arninoalkyl silanes. Control pore
glass is usually chosen because of its high internal
surface area.
Two types of control pore glass (CPG) have been
used; 3-aminopropyl glass (APG) and N(2-aminoethyl)-3-
aminopropyl glass (AEAPG}.
APG is formed from the reaction of controlled
pore glass with 3-aminoFropyl triethoxysilane (Wachter,
et al-., 1973) (Fig. 6.4).
AEAPG is obtained by derivatising CPG with
N(2-aminoethyl)-3-arninopropyl trimethoxysilane (Bridgen,
1975). The CPG used has a nominal pore diameter of
75 R, although larger pore diameters may be better for
larger proteins.
Arninoalkyl glasses can also be prepared. CPG
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is accessible to solvents of all kinds. The beads
are filtered and washed with a non-nola'I:' organicsolventand then
methanol and dried in vacuo. Iodoacetyl glass can be
prepared by treating APG with iodoacetic acid and
dicyclohexylcarhodiimide, and then washed with aqueous
solvents and drying in vacuo.
6.1.2.2.4.4 Attac~~ent of Peptides to Solid Support
The ideal pOint of attachment to CPG would be
via the C-terrninal residue. It is sometimes necessary to
block the a-amino group to pre~Gnt side reactions, using
BOC (t-Butyloxycarbonyl) or BOC-ON(2-t-Butoxycarbonyl
oxyimino-2-phenyl-acetonitrile). Isothiocyanates have
also been used (reviewedin Laursen and Machleidt, 1980).
When trying to activate the peptide C-terminus the
COOH groups of glutamyl and aspartyl residues are also
often activated, possibly resulting in reduced sequencing effic-
iency. There may be a difference between the various
carboxyls which can be exploited.
Carbonyldiimidazole gives high attachment yields
but must be used in a solvent such as dimethylformamide
which is a poor peptide solvent. It is also essential
that the anhydrous conditions are maintained. When
sequencing a modified glutanvl residue it does not
appear as a PTH-amino acid, as the thiazolinone remains
bound to the resin. The same problem at aspartyl residues
prevents further sequencing.
Carbodiimides are the most widely used reagents
for the formation of amide bonds. They react only slowly
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with water in neutral and alkaline pH and so attachment
can be made in aqueous solutions so that no peptide
solubility problems occur. Aspartate and glutamate
residues can be sequenced normally when short coupling
times are used.
Homoserine residues created at the C-terminus of
CNBr fragments can be coupled to amino resins after treatment
with trifluoroacetic acid to give the homoserine lactone.
This yields > 70% coupling of the C-terminus to the 'resin.
p-Phenylene diisothiocyanate can be used to
activate peptide amino groups aLl.ox...in<Jat tachmerit;throu<Jhthe amino
residue, so circumventing the problem of coupling through
the carboxyl group (Laursen, et al., 1972). This causes
modifications of the terminal a-amino as well as the lysine
e-amino groups but treatment with acid under conditions
of the Edman reaction cleaves the first peptide bond to
liberate a new amino group. The first PTH-amino acid
remains bound to the resin and must be detected by dansylation,
or by differenc$in the composition of the pentide.
C-Terminal lysine residues as in tryptic peptides
may be attached through the £-NH2 groups of these residues to
isothiocyanato glass or resins. Cysteine residues may be
bound to iodoacetyl glass (Chang, et at., 1977 in
reducing conditions in the dar~under N2,for 30 minutes.
Choice of the coupling reagent is very
important and a wide range of methods have been developed
(Laursen and Machleidt, 1980).
6.1.2.2.4.5 Uses and Limitations of foolidPhase Seguencin~
Essentially, solid phase sequencing is similar
L3S
to the liquid phase but a greater choice of solvents is
possible as the peptide is covalently fixed to the support
so that a relatively polar solvent such as methanol may
be used to completely remove excess reagents and by-products.
The main problems with solid phase sequencing arise from
three areas:
(i) detection;
(ii) background;
(iii) repetitive yield.
(i) Detection Most analysis of automated sequencing
monito~PTH-amino acids by HPLC at 254 nm. However, the
maximum absorbance is nearer 269 nm and analysis at this
wavelength can improve detection by 8-50% (Horn and Bonner,
1983). Another improvement in the detection limit can be
brought about by using 35s radio-labelled PITC, although the
purity of commercially available reagents is generally
a limiting factor. The use of DABITC in solid phase
sequencing has further increased levels of detection;
monitoring absorbance in the visible rather than uv
spectrum reduces background and allows for picomole levels
of DABTH-amino acid to be detected. Chang, et a l , (1983)
have discussed the use of pr~column derivatisation with
DABITC or dimethylaminoazobenzene sulphonyl chloride
(DABS-Cl) to improve sequencing to picomole levels by
manual or automated means.
(ii) Background The background in solid phase
sequencing is mainly due to break up of the support
generating UV-absorbing fragments. However, these problems
can be alleviated by thorough pre-treatment of the
support before use. Isothiocyanates are often used to
block excess reactive groups on supports and can become
a problem if further isothiocyanate-blocking rea0ents are
not added. This problem can also be minimised by judicial
choice of conditions. As reagents and solvents are not
coated around the supporting medium they do not
contribute significantly to problems with background
absorbance. pyridinium salts can arise due to interaction
of the support with acidic pyridine buffers but this
also can be corrected for by choice of a different buffer
system.
(iii) Repetitive Yield The repetitive yield (RY),
that is the yield from one cycle to the next, can be a
problem. Theoretically 98% RY is possible,but in
reality values are nearer 90-94%. The noted decrease in
RY is not due to solvent or reagent impurities but to
the interaction between the support and the polypeptide.
The higher the polypeptide loading on the support the
higher is the repetitive yield. However, overloading the
support generates overlap in the sequence analysis.
Despite these limitations, Salnikow, et a l , (1983)
reported sequences of up to 34 residues using only
1-10 nmol. of peptide routinely with some peptides
being sequenced at lower levels. L'Italien and Laursen (1983)
reported 22 cycles per day of solid phase sequencing on as
little as 0.5 nmol of proteolytically~ derived peptides.
Solid phase automated Edman sequencing has
become an effective method of analysing very s~all
amounts of peptide~ and sequencing limits are continually
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being pushed further back as new innovations are applied
to fue basic regimen.
6.2 EXPERIMENTAL
6.2. 1 Albumin pur!f icat!on
Albumin Redhill was isolated as outlined in
Section ~.3.2. The albumin was desalted on
Sephadex G-25 and exhaustively dialysed overnight against
double distilled water before lyophilisation.
Protein concentration was estimated by the
method of Bradford (1976) using Coomassie Brilliant Blue
G-250, against a standard curve of 0-100 ~g HSA Fraction
V (Sigma).
6.2.2 Protein Sequencing
Albumin Redhill (300 ~g, 4.6 nmol) was
submitted to the S.E.R.C. Protein Sequencing Facility
at the University of Leeds, Department of Biochemistry.
Dr. J. B. C. Findlay sequenced the protein by a solid
phase Edman procedure usLnrr em unxeoor ted non-
commercial method. Full sequence data was obtained
including amino acids identified, peak areas, and
amounts of each residue in picomoles.
3-alllinopropyl glass /0"Glass-O-Si--CH -CH --CH -NB
"/ 2 2 2 2
°
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"/ 2 2 2 2 2 2
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Fig. 6.4 Some common glass supports for solid phase
sequencing.
-6 -5 -4 -3 -2 -1 1 2 3 4
(a) Asp-Ala-His-Lys
(b) Arg-Asp-Ala-His-Lys
(c) Arg-Gly-Val-Phe-Arg-Arg-Asp-Ala-His-Lys
(d) Arg-Gly-Val-Phe-His-Arg-Asp-Ala-His-Lys
(e) Arg-Gly-Val-Phe-Arq-Gln-Asp-Ala-His-Lys
\
(a)
(b)
albumin A Albumin Lille
Albumin Redhill,
(d)
(e) Albumin Ch~istchu~ch
( c) human p~oalbumin
Fig. 6.5 Comparison of the sequences of Albumin
Redhill and known proalbumin variants.
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6.3 RESULTS
The sequence data revealed a major component
(Albumin Redhill) and a minor component (identical to
albumin A) (seeTable 6.1). This minor albumin component
was not detectable on PAGE of the initially analysed
Albumin Redhill, but may have occu~rec due to the
accumulation of normal albumin over the pooling of fractions
from several runs ~ this albumin was not visualised bv the
PAGE Blue-90 staining method.
The minor component (the first 30 amino acids) was of
identical sequence to that found for albumin A by
Dugaiczyk, eta l., (1982). The detector was set to 0.02 AUFS
(absorbance units full scale) and the levels of PTH-amino acid
were from 600-45 picomoles. The peak areas were approximately
58% of those for Albumin Redhill. The residues 16 and
17 of HSA were not detected although by analogy with
the other known sequences they were probably glutamate
residues. Residues 23 onwards were marked by a number
of very low yields and residue 28 was also not determined.
However, the sequence of the first thirty residues from
5 nmol, of protein is a fairly good sequence result
even by solid phase methods. The repetitive yield for
.residues 8 to 21 of 90.7%, although good for such a
distance in to the nrotein chain.was already too low for
sequencing to ,proceed nany more cycles into the ~rotein.
Albumin Redhill (sequenced on two occasions) gave a
reliable sequence over 30 residues with only residue 16
being undetermined. The yield of PTH-amino acids
[,[ie PTH
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Table 6.1(i) Amino acid sequence of Albumin Redhill.
(Residues 1-30).
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Table 6.1(ii) Amino acid se~uence of albumin A
impurity. (Residues 1-30).
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was still good (> 100 pmol) even at residues 27-28,
and as might be expected the repetitive yield was 96.5%
for residues 8-24 and 89.6% over residues 9 to 27. The
later cycles therefore s~ to be proceeding at reduced
yields, and sequencing further than 30 residues
would probably haver>roduced projress.ive ly more ambi<]Uousresults.
The residue 1~ equivalent to residue 15 in
albumin A,was a glycine residue in the minor component.
It is possible that the solid phase coupling mechanism used
may have been responsible for the inability to identify
these three residues (one in Albumin Redhill and two
in albumin A) .
The yield of serine was comparatively poor
compared to the other residues. Sequencing of
serine and threonine residues often give poor results on
Edman degradation.
The sequence of Albumin Redhill appears to be
exactly the same as that of albumin A but with an extra
arginine residue at the N-terminus. As the sequence
was obtained twice and the assignments are unambiguous
it appears that Albumin Redhill, residues 1-30, consists
of an extra N-terminal arginine residue onto the normal
albumin sequence. Albumin Redhill does not seem to have the
modified hexa~eptide proalbumin sequence found previously
in Albumins Christchurch (Brennan and Carrell, 1978) and
Lille (Abdo, et aL, 1981).
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6.4 DISCUSSION
In the previously recorded N-ter:minal mutations
of HSA mentioned above the hexapeptide proalbumin is left
intact when mutations occur at residues -1 or -2. This
has led to the suggestion that an arg-arg specific
protease exists in the endoplasmic reticulum or Golgi
apparatus which fails to cleave the mutant proalbumins
in Albumins Christchurch and Lille (see Fig. 6.6).
However, in Albumin Redhill only an N-terminal extra
arginine is present. (Residue -1 of the proalbumin
sequence is arg.) Thus, it would appear that Albumin
Redhill is a new tyne of proalbumin variant in which five
residues of the prooectide but not the final arg are
cleaved from albumin.
It is interesting to note that an extra N-terminal
residue, especially a positively charged residue, would
disrupt the square Flan~r arrangement of the divalent
metal binding site, which would explain the defective
CU/Ni binding. Also, this would possibly explain why,
although the N-terminal residue is arginine,no propeptide
was removed on tryptic digestion; it may be that the
extra arginine is poorly cleaved by trypsin to give
a single amino acid and the "normal" Redhill albumin.
The sequence of normal human and bovine albumins
is known to be asp-ala and that of rat serum albumin glu-ala.
However, Leibowitz and Soffer (1971) have shown the
existence of an arginylated albumin in commercial bovine
serum albumin rBSA). The extra N-terminalarginine is
,1, f
L't+
analogous to the 9resent result but occurs in only
~ 10% of the total albumin. The authors proposed that
the extra amino acid is due to an acylation reaction
catalysed by t-RNA protein transferase.
This may possibly be the case in BSA, as
only ~ 10% of the pooled BSA was affected, but this
seems unlikely to be a valid explanation of Albumin
Redhill as the variant form is ~ 50% of the total serum
albumin and occurs in two related individuals. Rather,
it would seem to be that Albumin Redhill is caused by an
inherited difference in N-terminal sequence. This may
be due to:
(i) Lack of arg-arg specificity for the proalbumin
cleavages. The sequence of the two previous proalburnins
have resulted in the conclusion that the propeptide is
cleaved by either an arg-arg specific protease, membrane
bound in the Golgi apparatus, or endoplasmic reticulum.
The sole arginine at residue -1 in Albumin Redhill may
be due to a new earlier cleavage site being formed by
residues -3 and -2. If one assumes that residue -2
is arginine, then on examination of the codon for the
-3 residue it is not possible for mutation to an
arginine residue to result from a single base alteration.
However, leucine, valine, isoleucine, serine, tyrosine
or cysteine can be produced by a single point mutation.
Whether any of these residues together with arginine
can give a suitable dipeptide cleavage site is unknown.
There is no alternative cleavage site known for human
albumin but in chicken serum albumin the propeptide
245
is quite different and has 7 residues ending in ala-arg
(Hache, et aZ., 1983). If this is also a recognised
mutation site in humans then it may be that a
combination of one of the above residues with arginine
may also result in premature peptide cleavage and so give rise
to proalbumin Redhill. This is, however, pure speculation
at present.
(ii) It may be that due to a molecular defect in the
cleavage enzyme the dipeptide arg-arg in Albumin Redhill
is detected, but only the first arginyl residue is
cleaved off with the rest of the propeptide. This
would result in the extra N-terminal arginine seen in
Albumin Redhill and the genetic fault may then lie not
with the Albumin Redhill but with the cleavage enzyme
of the patients.
(iii) It may be that acylation of 50% of the
albumin has occurred, and that this is the cause of
the extra residue in Albumin Redhill. However, it does
seem rather unlikely that this hypothesis could explain
such a high percentage of modification.
Whatever the reason, the sequence of Albumin
Redhill describes a unique variant previously unreported,
and as such is important for the understanding of albumin
variants and their ligand binding properties. Albumin
Redhill may be a unique type of variant and mayor may not
be due to an N-terrninal mutation in the protein. The
C-terminal mutation reported by Brand (1983) for Albumin
Redhill has not been studied here and may also occur at the
same time as the proalbumin mutation.
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CHAPTER SEVEN
LIGAND BINDING PROPERTIES OF ALBUMIN VARIANTS
7.1.1 Introduction
The i~portant role of albumin in the
transport of ligands in the body has been outlined
in Chapter 1 and qualitative differences in the
binding of some ligands to alhumin variants have
been found (Section 1.4.7) . Brand, et a Z. (1984)
reported that Albumin Redhill displayed defective
binding of nickel and copper ions and the ligand-binding
properties of a ran~e of dyes and other ligands have
also been contrasted to normal albumin for those
albumin variants available in this laboratory
(Chapters 2 and 3).
7.1.2 Techniques Used fur Measuring Ligand Binding
A wide range of techniques have been used
to quantify the ligand binding properties of
albumins. These techniques are similar to those
in general use and whLl.ea brief outline of some
of the methods will be given, this review is far
from being exhaustive.
7.1.2.1 Equilibrium Dialysis
This is probably the most widely used
technique for the measurefflentof ligand binding.
It requires the ligand to be hound to be
1.4'/
dialysable but the protein to not be so. A solution
of albumin is placed in a dialysis bag and
suspended in a solution containing the ligand.
The solution is allowed to attain equilibrium and
the concentration of ligands inside and outside the dialysis
bag is measured. If no ligand is bound the
concentrations should be identical; however, if
ligands are bound by the albumin then the concentra-
tion inside will be higher. By repeated experiments
at varying concentrations a Scatchard analysis
(1949) of the binding constant can be performed.
Though in widespread use in pharmacological
studies, the process of equilibrium dialysis takes
a long time to perform; however, by use of radio-labelled
ligands analyses of the binding of a wide range of
drugs and other molecules have been performed using
this method.
7.1.2.2 Gel Filtration
This method for the analysis of ligand
binding to proteins was devised by Hummel and
Dreyer (1962) and is further outlined by Yoza (1977).
A column of Sephadex,of sufficiently small pore
size for the protein to be totally eXCluded, is
equilibrated in buffer containing a known concentra-
tion of ligand. The proteinjP:ceviously eqUilibrated
in the ligand-containing buffe~,is then applied
and chromatography carried out. The amount of
ligand in the eluate is monitored and is correlated
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to the elution of the protein.
Although the protein is at equilibrium and
so the interactions between protein and ligand are
analogous to those in equilibrium dialysis, it has
been shown that a Donnan effect occurs, due to the
confinement of the macro-ion in the mobile phase
resulting in a redistribution of small ions.
However, Jordan, et al. (1974) devised a modification
that corrects for the Donnan effect by increasing the
amouocof protein applied and obtaining a ~lateau rather than
a peak for the concentration of bound ligand.
This technique is rapid and com~aratively
simple, however, possible errors due to the Donnan
effect should be taken into account.
7.1.2.3 Electrophoresis of Bound Ligands
Tarnoky and colleagues (Curnow, et al.,
1978) introduced a series of simple dye binding
tests with which to characterise variant albumins. These
tests could be applied to other ligands that are bound
to albUmin and qualitative trends in ligand binding
determined after electrophoretic separation of the
variant and normal albumins. The method is
qualitative and open to criticism (as the ligand is
reversibly bound to the albumin and may dissociate
on electrophoresis giving artefactual trends). However,
it is quickly performed and is readilyapplicable to variant
proteins, as it separates variants as well as measuring
the amount of bound ligand to each. Cavalli-Sforza
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et al. (1977) screened serum proteins for their
affinities to a wide range of radioactive ligands
by a similar procedure.
7.1.2.4 Fluorescence Quenching
The quenching of intrinsic Drotein
fluorescence by. the bindinq of a ligand to an ad4acent site
has been utilised vzi.th albumin to study the binding
of thyroxine (Steiner, et aL., 1966) and bilirubin
(Levine, 1977). The intrinsic fluorescence of
aJburnins is due mainly to tryptophanyl residues.
Conformational changes resulting from the binding of
a ligand to an adjacent binding site causes a fractional
reduction in the fluorescence, which can be related
to the concentration of ligand bound and allowing a
Scatchard analysis to be nerformed.
7.1.2.5 Spectroscopic ChanCJes
The spectroscopic properties of labelled
probes can be utilised in order to quantify their
binding constants. Hsia, et a l, (1982) used
enantiorneric spin labels to quantify binding
to the bilirubin binding site by electron spin
resonance. Circular dichroism can also be used
to measure binding by following the changes in the
spectra of protein or ligand with sequential
addition of ligand. Pfaff, et aL. (1975) used a
range of spectroscopic techniques to study the
binding of bromosulphophthalein to albumin. The
binding of bromocresol green to albumin has been
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~onitored by UV absorbance, and that of ANS by
fluorescence (Reed, et at., 1975).
7.2 EXPERIMENTAL
The binding of the divalent metal ions
cuII and Nill, the drug warfarin, and the
physiological ligands thyroxine and bilirubinito
variant albumins was studied by either gel filtration,
electrophoresis or fluorescence quenching.
7.2.1 Metal Ion Binding
7.2.1.1 Removal of Trace Metal Ions from Serum
Sera or isolated double albumins, were
purified from any contaminant heavy metal ions
by chromatography on Chelex 100 (Bio Rad). A
column (6 x 1 c~ i.d.) of Chelex 100 equilibrated
in sodium acetate (0.5 M, pH 6.5) was washed with
4-5 bed volumes of sodium acetate solution as
above and then with 5 bed volumes of distilled water.
The Chelex resin was thereby converted to the Na+
form and serum (100 ~l) or double albumins (1-10 mg)
was applied in distilled water and eluted,collecting 1 rnl
fractions. The proteins were detected by snraying aliquots
with ANS(as described in Section 4.3.2.3); the fractions were
then pooled and lyophilised.
7.2.1.2 Electrophoresis on Cellulose Acetate
(Brennan and Carrell, 1980)
Purified sera or double albumins (?II1mg) w,re
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1}JCi,300mCi/mrncl,
incubated with (63Ni/nickel chloride'AP~ersharnlnternational
for 30 minutes at 370C with a trace amount of
bromophenol blue, and then applied to a cellulose
acetate strip ([150 x 78 ron], Sartorius) and
electrophoresis performed in veronal buffer as
described in Section 3.2.4 at 8-10 V/cm C.V.
After electrophoresis the strip was
thoroughly dried and incubated at room temperature
with a sheet of LKB Ultrofilm in the dark for· several days.
The autoradiogram was developed using commercial
developer and fixer solutions (Eastman-Kodak)
and the cellulose acetate strip stained briefly in
Ponceau S (as in Section3.2.4) and destained in
acetic acid (5% v/v in water). Electrophoresis
of double albumins and normal albumins was performed
in parallel for comparison .
Semi-quantitative Analysis
Electrophoresis on double Albumin Redhill
and double Albumin Carlisle was performed as
7.2.1.3
described in Section 7.2.1.2. However, only one
albumin sample was run per strip and after
electrophoresis two guide strips were cut, one at
each side, and stained in Ponceau S as previously.
Using the guide-strip the albumin peak was identified
without staining and a series of fifteen 0.5 em
strips cut across the protein track encompassing the
albumin band, and reference strips were also cut from
the cathodic and anodic regions of the track. Each
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strip was placed into a glass screw-cap scintillation
vial which was subsequently filled with scintillation
fluid (Optiphase (Fisons),4 ml per vial) and
counted on a Packard 2425 scintillation counter set
to read in the 3H window.
7.2.1.4 Gel Filtration on Senhadex (Yoza, 1977)
A more quantitative estimate of the nickel
or copper binding to albumin A and double Albumins
Redhill and Carlisle was made by the gel filtration
nethod of Hummel and Dreyer (1962), as described
byYoza (1977).
A column of Sephadex GSO (46 x 1.6 cm i.d.)
was equilibrated in 3 mg/L copper (II)nitrate (Spectrosol
atomic absorbance grade, BDH Chemicals) in tris-HCI
(0.01 M, pH B.O). A sample of albumin (of known
protein concentration by the method of Bradford,1976)
was stripped of any contaminant cull by passage through
Chelex 100 (Section 7.2.1.1) and redissolved in the
tris-cuII buffer (1-2 ml, for"" 3 mg albumin) .. The
sample was applied to the column and eluted at a flow
rate 0:: 40 ml/hr.
Fractions were collected (""1-1.5 rnl) and
the absorbance at 2BO nm monitored, and the concentra-
tion of cull estimated by atomic absorbance on a
Varian Tedhtron Atomic Absorbance Spectrophotometer
using an oxidising flame (air:acetylene 7.S:3) at
325.1 nm,calibrating the copper concentration using
a 0-10 ug/ml series of cull solutions.
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Similar experiments \..ere performed using
a nickel(!I) chloride atomic absorbance grade
solution (Spectrosol, BDH Chemicals) in tris-HCl
buffer (0.01 M, pH 8.0) on a column of Sephadex
G 50. Samples of albumin solutions, accurately
measured by the method of Bradford (1976), were
chromatographed and the absorbance at 280 nm
monitored as before. Atomic absorbance was used
to measure the concentration of Ni!I in the
fractions collected using an oxidising flame
(air:acetylene 8:3.5) and monitoring absorbance
at 232.2 nrn. A standard curve for solutions of 0-10
~g/ml NiII was constructed as before.
Thyroxine Binding
The binding of thyroxine to albumin was
performed essentially as described in Section 7.2.1.2.
125I-labelled thyroxine (0.1 ~Ci,40m[i/rnmol.Am,ersham
7.2.2
International) was incubated with each albumin (1 rng in ·30IIIwater)
for 12 hours at room temperature before loading
onto a cellulose acetate strip; electrophoresis Mas th~n
carried out at 10V/cm for 2.5 hours in 0.075 H
sodium veronal buffer pH 8.6. The strips were dried,
stained in Ponceau S as described previously, and the
albumin bands excised together with anodic and
cathodic strips to act as controls. The strip,
cathodic to albumin A, equivalent to the slow
alloalbumin,was excised from the normal albumin
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runs. A similar pattern of strips was excised
for doubl-eAlbumirs Warwick-I, Warwick-2, and
double Albumin Redhill, excising the normal and
variant albumins and anodic and cathodic strips as
controls. A strip was excised cathodic to each
albumin at the approximate migration distance of
the e-globins in order to ascertain the binding
to any specific thyroid binding protein still
present. Excised bands were placed in plastic
scintillation vials and counted on an LKB 1280 Ultrogarnrna
counter.
7.2.3 l·1arfarinB·inding
The binding of warfarin to albumin A and
Albumins Carlisle and Redhill was measured by gel filtration
essentially as described by Sun, et aL. (1984) except
by conventional chromatography rather than by HPLC.
A column of Sephadex G25 (40 x 1 cm i.d.)
was equilibrated in sodium phosphate buffer (0.2 M)
containing warfarin (27 mg/L). Albumin samples (of
known concentration = 3 mg) were dissolved in the
warfarin buffer and loaded onto the column. Elution
was at =, 0.5 mllmin and the fractions collected (= 1 mIl
test tube) were monitored at 280 nrnand 313 nm and
the resultant profil~plotted. Calculations of ligand
bound were made using th~ method outlined by
Yoza (1978)•.
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7.2.4 Bilirubin Binding
The binding of bilirubin to albumin A and
to double Albumin Carlisle was compared by the method
of Levine (1977). Bilirubin was used as received
from Sigma or purified by the method of Fog (1964)
by chromatography on anhydrous sodium sulphate. It
was dissolved at a concentration of 20 ~M in
sodium phos?hate buffer (125 ~1, pH 7.4) just before
use and vias kept wrapped in foi1.
Aliqucts (2-10 vI) of the bilirubin solution
were added to the albumin (2 ml of a known concentration
~ 1 ~M in sodi~ phosphate buffer 125 mM, pH 7.4) and
the cell inverted several times before reading
the fluorescence. Readings were taken on a Perkin
Elmer fluorescence spectrophotometer, exciting at
294 nm and monitoring emission at 343 nm. Readings
were performed in a darkened room to reduce photo-
isomerisation of the bilirubin.
The degree of fluorescence quenching increased
to a limiting value after which no further drop in
fluorescence was observed. Similar experiments
were performed for albumin A and double Albumin
Carlisle, and the percentage fluorescence plotted against the
molar ratio of bilirubin:albumin. Absorbance at
294 and 343 nm was noted at the end of each experiment
in order to assess the inner filter effect.
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7.2.5 B' di f 14 Lrniln lng 0 C-pa mltate
The binding of fatty acids to HSA and
variant albumins was assessed for Albumin Carlisle and
Warwick-I, by electrophoresis using 14c-palmitate (Amersham
International). Serum (30 ~l) was incubated with 14c-pelmi~te
50mCi!mrnol. ~1 ~l, 0.1 ~Ci) or double albumin (4 mg/with
25 ~l) 2.5 ~Ci) for 30 minutes at 37oC. The samples were
then loaded onto a cellulose acetate strip together with
a trace of bromophenol blue to act as a marker.
Electrophoresis was carried out for 3-4
at 8-10 V/cm and after removing the strip it was air-dried
and incubated with a strip of LKB Ultrofilm 1Cr..autoradio-
graphy photographic film, and developed for several
days in the dark. To prevent adhesion of any moist
parts of the strip to the photographic film a thin
layer of cling-film was inserted between them. After
7-14 days incubation, the film was developed and
the strip stained in Ponceau S as described in
Section 7.2.1.2. The two were re-aligned (most
easily performed by marking a notch in the two
while still clamped together) and the areas of
exposed film compared to the bands stained by the
Ponce au S dye on the cellulose acetate strip.
7.3 RESULTS
7.3.1 Metal Ion Binding
Serum samples were freed of contaminant
metal ions after passage throgh a Chelex-IOO column
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and fractions (~ 1 ml) collected and checked for protein
content using the ANS method previously described
(Section 4.3.2.3. The protein containing fractions
were lyophilised and resuspended and used for the
63Ni binding experiment.
After development of the autoradiograms
both Albumin Warwick-l and Albumin Carlisle bound the
same amount of isotope as albumin A from the optical
density of the exposed film. Both variant albumins
showed strong exposed bands as well as the albumin A
in each run, and HSA from normal serum also bound
tJi63 in each experiment (Fig. 7.1).
h 't' f N,63 b' d'T e est1ma 10n 0 1 1n 1ng by this
method is only qualitative but supports the evidence
already accumulated (in this work and in Au, 1982),
that Albumins Carlisle and Warwick-l are not pro-
albumins and have no N-terminal mutations that would
prevent Ni!! binding to them.
Cellulose acetate electro~horesis in the
presence of Ni63 was also used to quantify Ni63
bound to Albumin Redhill and Albumin Carlisle.
After identical incubations Ni63-labelled double Albumins
Carlisle and Redhill and normal HSA were subjected
to electrophoresis so as to obtain maximal separation
of the albumins. Each cellulose acetate strip was
cut into strips widthways and each strip counted
using a sCintillation counter. The profiles of the
albumins are given in Fig. 7.2. The areas correspond-
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Fig. 7.2 Profiles of the binding of 63Ni to normal
and variant albumins, separated by cellulose
acetate electrophoresis.
LbU
ing to each albumin band were approximated and
the binc.ing was found to be essentially 1:1. However,
duplicate experiments on double Albumin Redhill showed
that Albumin Redhill bound only 40-50% of the 63Nill
bound by albumin A. These vnlues differ from the
results of Brand (1983) which by autoradiography
showed no binding of 63Nill to Albumin Redhill on
cellulose acetate electrophoresis.
Gel filtration studies on albumins were
carried out in order to characterise further the binding
of Nill and cull to variant and normal albumins.
Absorbance at 280 nm was used to monitor protein
concentration, and atomic absorbance used to monitor the
ell Noll t tou or 1 concen ra lons. Fig. 7.3 shows a typical
elution profile, the metal ion concentration rising
with the elution of the albumin and dropping to form a
trough afterwards. The peak area is correlated to the
metal ion concentration bound to albumin and the trough
area to the amount of metal ion removed from solution
by bindin0 to albumin.
The ratios of Nill and cull bound to normal
albumin and albumin variants assessed by these experiments
is summarised in Table 7.1.
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COE:eer Bindin9:
Albumin A: 1.0
Double Albumin Warwick-I: 1.32
Double Albumin Carlisle: 0.77
Double Albumin Redhill: 0.39
Nickel Bindinsr
Albumin A: 1.0
Double Albumin Carlisle: 1.52
Double Albumin Redhill: 0.60
TABLE 7.1 Ratios of metal ion binding to
albumin variants by gel filtration.
IIThe binding of eu to double Albumin Redhill
appears to be reduced to 30-50% of that for albumin A,
suggesting that the binding to Albumin Redhill is
negligible if one takes into account the 50% normal
albumin present. However, results for the binding
of NiII were more variable indicating that the binding
to Albumin Redhill was ~40% of that to albumin A.
The wide variation in the results was perhaps due to
the presence of varying amounts of dimeric albumin
in different Redhill preparations. Another factor may
be the rather unstable baseline in some experiments,
as the measurement of NiII was near to the lower
practical limit of detection.
The binding of cull to double Albumin Carlisle
was approximately the same as that for albumin A
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(80-96%) and the binding of NiII was in fact greater than
that for albumin A (1.52:1) though this may well be due to the
factors already cited as possible sources of error in the
Albumin Redhill determination. The binding of cull
to double Al.bumLn ~'larwick-l wa s aopr ox tmat.eIv equal or slightly
higher than that for albumin A (~'71:A 1.32: 1. 0) •
From the comparison of these results to those
already obtained by the electrophoretic methods it
would seem that the binding of cuII and NiII is normal
for Albumin Carlisle and Albumin Warwick-l but that
they are reduced considerably for the binding to
Albumin Redhill. Brand (1983) found a reduced cull
binding (z 28% of that for albumin A) and severely reduced NiII
binding. These t~ends are consistent ,vith the findings
presented here with cull binding considerably reduced
for Albumin Redhill and also the NiII binding being
substantially lower.
The effect of reduced binding on the cuII
d N' II, t b 1', ,an 1 lon me a 0 lsm ln patients vlith Albumin Pedhill has not
been studied: however, such studies may well be of
physiological interest.
The reduction in the NiII and Cull binding
by Albumin Redhill is most likely the result of the
extra N-terrninal arginine residue which may cause
distortion of the square-planar binding configuration
of the heavy metal ion binding site. The presence
of a positively charged arginine residue may well
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also cause charge repulsion of the cation and
so result in the reduced binding.
7.3.2 Thyroxine Bindinq
The binding of thyroxine to ~.lbumins
Redhill, 1'7arwick-land v.7arwick-2was assessed by
cellulose acetate electrophoresis, followed by ga~a
radiation counting.
The distribution of radioactivity over the
electrophoretic tracks was determined. The double
albumins were visualised by Ponceau S staining and
the normal and abnornal albumins excised as strips
together with four more cathodic strips in ordG- to
assess binding of thyroxine to the S-globulin thyroxine
carrier, or albumin dimers.
Strips were counted and the background
subtracted from the corrected c.p.m. The resultant
ratios of normal:variant binding obtained in a
series of exneriments on each double albumin were
calculated and are tabulated below (Table 7.2).
Corrections for the ratio of normal:abnormal
albumins in sera were made. The experiments were
performed prior to receipt of Albumin Carlisle
and so thyroxine binding studies have
not been performed on it.
The binding of thyroxine to the albumin
variants studied here indicatesa generally increased
binding by the variants u~ to twice that of albumin
A. Whether this is a real increase or an artefact
co
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of the electrophoresis can not be stated with
complete confidence. However, in an artefact one
would expect thyroxine to stream to the anode if
at all and so give reduced binding by the variants, and
not the increased binding seen. Others have
reported increased thyroxine binding to albumin
variants including Lalloz, et al. (1983) who reported
a variant with thirty times increased thyroxine binding.
The variants are all of the slow typ~ and it may
be that the net decrease in negative charge
encourages binding of the negatively charged
thyroxine to the albumin.
Lalloz, eta L (1985) have reported
a silent albumin variant solely on the basis of its
different thyroxine binding. This would suggest that
an electrophoretically discernable change in net charge
is not necessary for thyroxine binding to be affected. The
one patient described by Lalloz, et ale (1985) may
have suffered from hyperthyroxemia and in each of the three
cases known to them the affinity for thyroxine and
tri-iodothyroxine was considerably increased.
The differences in thyroxine binding to
albumin variants reported here are unlikely to have
physiological effects, considering the fact that
albumin has mereIy an eXCCS5 thyroxine binding role, and two
more specific carrier proteins occur in serum.
7.3.3. Warfarin Binding
The binding of warfarin to double Albumins
Carlisle and Redhill was compared to that for HSA
(Sigma). Each sample was defatted and the .concentra-
tion measured before loading onto the column. Elution
profiles were constructed at 313 nm to follow the
elution of warfarin and at 280 nm for that of the
protein.
The binding of warfarin to each albumin is
summarised below in Table 7.3.
Table 7.3 The Binding of Warfarin to Albumin Variants
Albumin
Ratio
Warfarin:Albumin
bound
HSA 0.695:1.0
H~ 0.69:1.0
Double Alhumin Redhill 0.532:1.0
Double Albumin Carlisle 1.81:1.0
The results indicate that Albumin Carlisle
binds more warfarin than normal albumin but that
Albumin Redhill binds slightly less. These results
must be viewed with caution, however, and represent
merely initial trends as there are several possible
sources of error:
(i) The absorbance of the baseline is very
large compared to that of the peak,making assessment
of the area of the warfarin-albumin complex difficult.
Further experiments with more albumin would be
required to give more conclusive results.
L6b
(ii) The method makes no allowances for Donnan
effects on the column. Comparison of the Ka values
obtained to those published by Sun, et al., 1984, which
are of the order of 105 to 106 for the primary binding site
and 103_104 for the secondarY,would seem to indicate
that the method used here is approximating the two sites together
or that the primary site is still blocked. It is not
possible to quantitatively study the binding of warfarin
by a single experiment; sufficient points to construct
a Scatchard (1949) plot are needed. However, this was
not possible at the time due to the substantial amount
of pro~ein required for such a study and hence only the
qualitative trends can be reported. Albumin B has
been shown to have increased warfarin binding (Wilding,
et al., 1977) and Albur:linsNaskapi and Mexico to have
reduced binding. In the light of the importance of
warfarin-type drugs in the treatment of thrombosis and
related conditions,a more complete study of the role
of variant albumins in controlling serum levels of
warfarin may well yield important results.
7.3.4 Bilirubin Binding
The quenching of albumin solutions with
bilirubin was followed over a bilirubin:albumin molar
ratio of 0:1 to 1:1. Quenching was completed by
~ 0.6:1.0 molar ratio of bilirubin:albumin. No
improvement in the extent of quenching was achieved,
despite vigorous defatting of the albumin and
purification of the bilirubin (Fog, 1964).
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This may be indicative of some tightly-bound
endogenous ligand still being present. Despite this problem
quench curves for double Albumin Carlisle and albumin A
were compared in several experiments, and it seemed to
be a consistent trend that the initial quenching of
albumin A, proportional to the first mole of bilirubin
binding at the primary binding site, was higher than
for Albumin Carlisle. This seemed to indicate a
tighter binding affinity for normal albumin than
Albumin Carlisle at this site.
The secondary bilirubin sites represented
lower 'down the quench curve also showed some reduced
affinity in samples of Albumin Carlisle (Fig. 7.4).
As it has been thought that the primary bilirubin
site and that of warfarin are equivalent or in close
proximity the results may seem contradictory for those
two ligands, with increased warfarin binding but reduced
bilirubin affinity. However, if the primary bilirubin
site was inaccessible it may be that the binding studies
are revealing the properties of lower affinity sites.
It is possible that other studies using the peroxidase
method (Brodersen, 1974) may be of value in assessing
these results.
7.3.5 Palmitate Binding
Electrophore~is on cellulose acetate was
used to qualitatively assess the binding of palmitate,
labelled with 14C, to the albumin types. Both Albumin
o
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Warwick-l and Albumin Carlisle showed two bands of
equal intensity on autoradiography (Fig. 7.5). This
suggests that both albumin variants have in broad
terms similar fatty acid binding properties to that
of albumin A which is consistent with no mutation
having occurred at the C-terminal fatty acid binding
site.' However, the results are only qualitative and
as there are so many sites for weak fatty acid interactions
(up to 60 (Spector, 1975» a mutation causing a
reduction in one of these sites would not be detected
by this method.
If time had allowed,a quantitative binding
study, such as that described by Spector and
Fletcher (1977), would have been performed to investigate
any such mutation.
7.4 CONCLUSION
The binding properties of Albumin Narwick-l
recorded here are consistent with its assignment as
a non-N-terminal albumin variant with essentially
normal NiII/cuII and fatty acid binding. The thyroxine
binding, although nearly twice that of no~mal albumin,
would probably be of little physiological consequence,
as the role of albumin is only as an over-flow carrier
for this ligand. The results obtained for other Indian
variants have failed to show any gross ligand-binding
deficiencies and this is also true for Albumin Warwick-I,
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and so its inclusion with them as an Indian albumin
variant seems justifiable.
The binding of metal ions to Albumin Redhill,
initially shown to be defective by Brand (1983), has
been confirmed in these studies. The ligand binding
to double albumin has been reduced to ~ 50% of the
normal and this is consistent with metal ion binding
to Albumin Redhill being largely deficient. However,
less specific divalent metal binding sites exist
and it may well be that although the N-terminal
binding site is disrupted these lower affinity
sites still do bind some cuII/NiII, and may explain
why affinity chromatography on immobilised NiII
was unable to separate the variant and normal
albwnins.
The sequence data (Chapter 6) lends
considerable support to the hypothesis that the
primary metal ion binding site is non-functional
in Albumin Redhill. The incorporation of a positively
charged N-terminal residue would disrupt not only
the configuration but also the charge interactions in
such a site.
Thyroxine binding in Albumin Redhill is
elevated although the molecular explanation of this
result must await further evaluation. The increased
binding is not of the order noticed in the variants
reported by Lalloz, et at. (1983, 1985) and
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presumably has little if any physiological effect.
~he binding of warfarin to Albumin Redhill
may be slightly reduced from gel filtration experimental
results and both this and the thyroxine binding
differences may be a consequence of the second mutation
site proposed by Brand (1983) in the c-terminal half
of the molecule and thought to be a possible region
of peptide duplication. As no molecular evidence
for such a mutation exists any comments on the
reason for these ligand binding changes must be purely
speculative. It may be that as thyroxine is a
hydrophobic ligand, an increase in the leng~h of a
hydrophobic pocket in the albumin molecule could
increase its binding. Similarly, if a duplication
of sequence has occurred it may have altered the
conformation or environment at the warfarin binding
site and so disrupted binding of this ligand.
Alrumin Carlisle appears to bind metal
ions normally, and to have qualitatively similar
palmitate binding to normal albumin. A slightly
decreased bilirubin binding but increased affinity
for warfarin compared to normal albumin have also
been shown. Albumin Yanomama-2 and possibly other
polymorphic variants display reduced affinity for
bilirubin, as does AlbumimRedhill and Warwick-2
(Brand, 1983). Therefore, little evidence may be
obtained for the classification of Albumin Carlisle
from this result. The increased binding of warfarin
noticed for Albumin Carlisle may be more informative.
Wilding, et aZ. (1977) have shown that albumin B
has increased warfarin binding but that Albumins
Naskapi and Mexico show reduced affinity. Thus in
this respect Albumin Carlisle shows some similarity
to albumin B. The evidence of Chapter 5,describing
the probable site of mutation in Albumin Carlisle,
may suggest a similar area of Mutation to that in
albumin B. However, further studies are necessary
to locate the precise site of the mutation in
Albumin Carlisle before it can be considered to be
analogous to the variant described by Winter, et aZ.
(1972), especially in the light of the electrophoretic
heterogeneity occurring within the group of variants
classed as albunin B by Ott, et al. (1975).
'2'/6
APPENDIX
Special equipment and chemicals were purchased
from the suppliers listed below. All other reagents
were readily available.
Chromatographic Materials
Sephadex gel filtration, chromatofocusing,
ion-exchange and affinity column materials were
purchased from Pharmacia Ltd., Milton Keynes, U.K.
FPLC equipment was also from Pharmacia. Chelex-IOO
and hydroxyapatite HTP were from Bio Rad Laboratories
Ltd., Watford, Herts, U.K. Filter papers, DE52
cellulose anion exchange media and the Partisil SAX
anion exchange HPLC column were from l-lhatman
Laboratory Sales Ltd., Maidstone, Kent, U.K.
HPLC grade solvents were purchased from
Fisons plc, Loughborough, U.K. Filters for HPLC
solvents were from Millipore UK Ltd., Harrow,
Middlesex, U.K., and filtration/degassing apparatus
from Whatman. The LKB HPLC system was from LKB
Instruments Ltd., Hartford, Cheshire, U.K.
Polyamide t.l.c. plates were prepared by the
Cheng Chin Trading Co and obtained through BDH
Chemicals Ltd., poole, Dorset, U.K. Avicell
microcrystalline cellulose and pre-made silica G60
'1. OJ 0;
t.l.c. plates were made by Merck and were also
obtained through BOH.
Electrophoretic Materials
Acrylamide, N,N'-methylene bisacrylamide
and sodium dodecyl sulphate were of Electron grade
and were purchased from BDH. IEF pre-cast PAG-plates
were from LKB and an LKB Multiphor apparatus and
power supply were used. The IEF pI standards kit and
Pharmalyte were from Pharmacia and the molecular
weight markers for SDS-PAGE were from BDH. Cellulose
acetate strips were purchased from Sartorious
Instruments Ltd., Belmont, Surrey, U.K.
Reagents and Miscellaneous Equipment
HSA was purchased from Sigma Fine Chemicals
Ltd., Poole, Dorset, U.K. TPCK-treated trypsin,
papain, a-chymotrypsin, and pepsin were also from
Sigma as were the cyanogen bromide and o-iodosobenzoic
acid. Carboxypeptidases and additional pepsin
were obtained from Worthington Diagnostic Systems
Inc., Freehold, New Jersey, U.S.A., BNPS-skatole
was purchased from Fluka, Fluorochem Ltd., Glossop,
Derbyshire, U.K. and N-chloro-succinimide from
Aldrich Fine Chemicals, poole, Dorset, U.K. Rabbit
anti-human albumin anti-serum was purchased from
Miles Laboratories Ltd., Slough, U.K.
1..'/8
Radio-labelled ligands ('see Chapter Seven) were
obtained from Amersham International pIc, Amersham,
Bucks., U.K. Centricon micro-concentration apparatus
was supplied by Amicon Ltd., Stonehouse, Gloucs., U.K.
Atomic absorbance readings were made using a Varian
Techtron atomic absorbance spectrophotometer.
Photographic chemicals were obtained from Kodak Ltd.,
Kirkby, Liverpool, U.K.
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